[House Report 109-315]
[From the U.S. Government Publishing Office]



109th Congress                                            Rept. 109-315
                        HOUSE OF REPRESENTATIVES
 2d Session                                                      Part 3

======================================================================



 
   OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION ACT OF 2005

                                _______
                                

                 March 3, 2006.--Ordered to be printed

                                _______
                                

 Mr. Sensenbrenner, from the Committee on the Judiciary, submitted the 
                               following

                              R E P O R T

                        [To accompany H.R. 2829]

      [Including cost estimate of the Congressional Budget Office]

  The Committee on the Judiciary, to whom was referred the bill 
(H.R. 2829) to reauthorize the Office of National Drug Control 
Policy Act, having considered the same, report favorably 
thereon with an amendment and recommend that the bill as 
amended do pass.
  The amendment is as follows:
  Strike all after the enacting clause and insert the 
following:

SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

  (a) Short Title.--This Act may be cited as the ``Office of National 
Drug Control Policy Reauthorization Act of 2005''.
  (b) Table of Contents.--The table of contents for this Act is as 
follows:

Sec. 1. Short title; table of contents.
Sec. 2. Amendment of Office of National Drug Control Policy 
Reauthorization Act of 1998.
Sec. 3. Repeal of termination provision.
Sec. 4. Amendments to definitions.
Sec. 5. Amendments relating to establishment of Office of National Drug 
Control Policy and designation of officers.
Sec. 6. Amendments relating to appointment and duties of Director and 
Deputy Director.
Sec. 7. Amendments relating to coordination with other agencies.
Sec. 8. Development, submission, implementation, and assessment of 
National Drug Control Strategy.
Sec. 9. High Intensity Drug Trafficking Areas Program.
Sec. 10. Funding for certain High Intensity Drug Trafficking Areas.
Sec. 11. Amendments relating to Counter-Drug Technology Assessment 
Center.
Sec. 12. National youth antidrug media campaign.
Sec. 13. Drug interdiction.
Sec. 14. Awards for demonstration programs by local partnerships to 
shut down illicit drug market hot-spots by deterring drug dealers or 
altering the dynamic of drug sales.
Sec. 15. Awards for demonstration programs by local partnerships to 
coerce abstinence in chronic hard-drug users under community 
supervision through the use of drug testing and sanctions.
Sec. 16. Authorization of appropriations.
Sec. 17. Technical amendments and repeal.
Sec. 18. Requirement for disclosure of Federal sponsorship of all 
Federal advertising or other communication materials.
Sec. 19. Policy relating to syringe exchange programs.

SEC. 2. AMENDMENT OF OFFICE OF NATIONAL DRUG CONTROL POLICY 
                    REAUTHORIZATION ACT OF 1998.

  Except as otherwise expressly provided, whenever in this Act an 
amendment or repeal is expressed in terms of an amendment to, or repeal 
of, a section or other provision, the reference shall be considered to 
be made to a section or other provision of the Office of National Drug 
Control Policy Reauthorization Act of 1998 (Public Law 105-277; 21 
U.S.C. 1701 et seq.).

SEC. 3. REPEAL OF TERMINATION PROVISION.

  Section 715 (21 U.S.C. 1712) is repealed, and the law shall read as 
if such section was never in effect.

SEC. 4. AMENDMENTS TO DEFINITIONS.

  (a) Amendments to Definitions.--Section 702 (21 U.S.C. 1701) is 
amended--
          (1) in paragraph (1)--
                  (A) by striking ``and'' at the end of subparagraph 
                (F);
                  (B) by striking the period at the end of subparagraph 
                (G) and inserting ``, including the testing of 
                employees;''; and
                  (C) by adding at the end the following:
                  ``(H) interventions for drug abuse and dependence; 
                and
                  ``(I) international drug control coordination and 
                cooperation with respect to activities described in 
                this paragraph.'';
          (2) in paragraph (6), by adding before the period at the end: 
        ``, including any activities involving supply reduction, demand 
        reduction, or State and local affairs'';
          (3) in paragraph (7)--
                  (A) by striking ``Agency'' and inserting ``agency'';
                  (B) by striking ``National Foreign Intelligence 
                Program,'' and inserting ``National Intelligence 
                Program,''; and
                  (C) by inserting a comma before ``or Tactical'';
          (4) in paragraph (9), by striking ``implicates'' and 
        inserting ``indicates'';
          (5) in paragraph (10)--
                  (A) by adding ``National Drug Control Program 
                agencies and'' after ``among'' in subparagraph (B);
                  (B) by striking ``and'' at the end of subparagraph 
                (B);
                  (C) by striking the period at the end of subparagraph 
                (C) and inserting a semicolon; and
                  (D) by adding at the end the following:
                  ``(D) domestic drug law enforcement, including 
                domestic drug interdiction and law enforcement directed 
                at drug users; and
                  ``(E) coordination and enhancement of Federal, State, 
                and local law enforcement initiatives to gather, 
                analyze, and disseminate information and intelligence 
                relating to drug control among domestic law enforcement 
                agencies.'';
          (6) in paragraph (11)--
                  (A) by inserting before the semicolon in subparagraph 
                (A) the following: ``, including--
                          ``(i) law enforcement outside the United 
                        States; and
                          ``(ii) source country programs, including 
                        economic development programs primarily 
                        intended to reduce the production or 
                        trafficking of illicit drugs'';
                  (B) by striking subparagraph (B) and inserting the 
                following:
                  ``(B) facilitating and enhancing the sharing of 
                foreign and domestic information and law enforcement 
                intelligence relating to drug production and 
                trafficking among National Drug Control Program 
                agencies, and between those agencies and foreign law 
                enforcement agencies; and'';
                  (C) by striking ``; and'' at the end of subparagraph 
                (C) and inserting a period; and
                  (D) by striking subparagraph (D); and
          (7) by adding at the end the following:
          ``(12) Appropriate congressional committees.--Except where 
        otherwise provided, the term `appropriate congressional 
        committees' means the Committee on the Judiciary, the Committee 
        on Appropriations, and the Caucus on International Narcotics 
        Control of the Senate and the Committee on Government Reform, 
        the Committee on the Judiciary, and the Committee on 
        Appropriations of the House of Representatives.
          ``(13) Law enforcement.--The term `law enforcement' or `drug 
        law enforcement' means all efforts by a Federal, State, or 
        local government agency to enforce the drug laws of the United 
        States or any State, including investigation, arrest, 
        prosecution, and incarceration or other punishments or 
        penalties.''.
  (b) Conforming Amendments.--Section 703(b)(3) (21 U.S.C. 1702(b)(3)) 
is amended--
          (1) in subparagraph (A), by striking ``(G)'' and inserting 
        ``(I)''; and
          (2) in subparagraph (C)--
                  (A) by striking ``through (C)'' and inserting 
                ``through (E)'';
                  (B) by striking ``and subparagraph (D) of section 
                702(11)''; and
                  (C) by adding before the period at the end the 
                following: ``, and sections 707 and 708 of this Act''.

SEC. 5. AMENDMENTS RELATING TO ESTABLISHMENT OF OFFICE OF NATIONAL DRUG 
                    CONTROL POLICY AND DESIGNATION OF OFFICERS.

  (a) Responsibilities.--Paragraph (4) of section 703(a) (21 U.S.C. 
1702(a)) is amended to read as follows:
          ``(4) evaluate the effectiveness of the national drug control 
        policy and the National Drug Control Program agencies' 
        programs, by developing and applying specific goals and 
        performance measurements.''.
  (b) Rank of Director.--Section 703(b) (21 U.S.C. 1702(b)) is amended 
in paragraph (1) by adding before the period the following: ``, who 
shall hold the same rank and status as the head of an executive 
department listed in section 101 of title 5, United States Code''.
  (c) Deputy Directors.--Section 703(b) (21 U.S.C. 1702(b)) is amended 
in paragraph (3)--
          (1) by striking ``Office--'' and inserting ``Office the 
        following additional Deputy Directors--''; and
          (2) in subparagraph (B), by striking ``who shall'' and 
        inserting the following: ``who shall have substantial 
        experience and expertise in drug interdiction operations and 
        other supply reduction activities, and who shall serve as the 
        United States Interdiction Coordinator and''.

SEC. 6. AMENDMENTS RELATING TO APPOINTMENT AND DUTIES OF DIRECTOR AND 
                    DEPUTY DIRECTOR.

  (a) Designation of Other Officers.--Section 704(a)(3) (21 U.S.C. 
1703(a)(3)) is amended--
          (1) by striking ``permanent employee'' and inserting 
        ``officer or employee''; and
          (2) by striking ``serve as the Director'' and inserting 
        ``serve as the acting Director''.
  (b) Responsibilities of Director.--Section 704(b) (21 U.S.C. 1703(b)) 
is amended--
          (1) in paragraph (4), by striking ``Federal departments and 
        agencies engaged in drug enforcement,'' and inserting 
        ``National Drug Control Program agencies,'';
          (2) in paragraph (7), by inserting after ``President'' the 
        following: ``and the appropriate congressional committees'';
          (3) in paragraph (13), by striking ``(beginning in 1999)'';
          (4) in paragraph (14)--
                  (A) by striking ``Appropriations'' and all that 
                follows through ``Senate'' and inserting ``appropriate 
                congressional committees''; and
                  (B) by striking ``and'' after the semicolon at the 
                end;
          (5) in paragraph (15), by striking subparagraph (C) and 
        inserting the following:
                  ``(C) supporting the substance abuse information 
                clearinghouse administered by the Administrator of the 
                Substance Abuse and Mental Health Services 
                Administration and established in section 501(d)(16) of 
                the Public Health Service Act by--
                          ``(i) encouraging all National Drug Control 
                        Program agencies to provide all appropriate and 
                        relevant information; and
                          ``(ii) supporting the dissemination of 
                        information to all interested entities;''; and
          (6) by inserting at the end the following:
          ``(16) shall coordinate with the private sector to promote 
        private research and development of medications to treat 
        addiction;
          ``(17) shall seek the support and commitment of State and 
        local officials in the formulation and implementation of the 
        National Drug Control Strategy;
          ``(18) shall monitor and evaluate the allocation of resources 
        among Federal law enforcement agencies in response to 
        significant local and regional drug trafficking and production 
        threats;
          ``(19) shall submit an annual report to Congress detailing 
        how the Office of National Drug Control Policy has consulted 
        with and assisted State and local governments with respect to 
        the formulation and implementation of the National Drug Control 
        Strategy and other relevant issues; and
          ``(20) shall, within one year after the date of the enactment 
        of the Office of National Drug Control Policy Reauthorization 
        Act of 2005, report to Congress on the impact of each Federal 
        drug reduction strategy upon the availability, addiction rate, 
        use rate, and other harms of illegal drugs.''.
  (c) Submission of Drug Control Budget Requests.--Section 704(c)(1) is 
amended by adding at the end the following:
                  ``(C) Content of drug control budget requests.--A 
                drug control budget request submitted by a department, 
                agency, or program under this paragraph shall include 
                all requests for funds for any drug control activity 
                undertaken by that department, agency, or program, 
                including demand reduction, supply reduction, and State 
                and local affairs, including any drug law enforcement 
                activities. If an activity has both drug control and 
                nondrug control purposes or applications, the 
                department, agency, or program shall estimate by a 
                documented calculation the total funds requested for 
                that activity that would be used for drug control, and 
                shall set forth in its request the basis and method for 
                making the estimate.''.
  (d) National Drug Control Budget Proposal.--Section 704(c)(2) is 
amended in subparagraph (A) by inserting before the semicolon: ``and to 
inform Congress and the public about the total amount proposed to be 
spent on all supply reduction, demand reduction, State and local 
affairs, including any drug law enforcement, and other drug control 
activities by the Federal Government, which shall conform to the 
content requirements set forth in subparagraph (C) of paragraph (1) of 
this subsection''.
  (e) Review and Certification of National Drug Control Program 
Budget.--Section 704(c)(3) (21 U.S.C. 1703(c)(3)) is amended--
          (1) by redesignating subparagraphs (C) and (D) as 
        subparagraphs (D) and (E), respectively;
          (2) by inserting after subparagraph (B) the following new 
        subparagraph:
                  ``(C) Specific requests.--The Director shall not 
                confirm the adequacy of any budget request that--
                          ``(i) requests funding for Federal law 
                        enforcement activities that do not adequately 
                        compensate for transfers of drug enforcement 
                        resources and personnel to law enforcement and 
                        investigation activities not related to drug 
                        enforcement as determined by the Director;
                          ``(ii) requests funding for law enforcement 
                        activities on the borders of the United States 
                        that do not adequately direct resources to drug 
                        interdiction and enforcement as determined by 
                        the Director;
                          ``(iii) requests funding for drug treatment 
                        activities that do not provide adequate result 
                        and accountability measures as determined by 
                        the Director;
                          ``(iv) requests funding for any activities of 
                        the Safe and Drug Free Schools Program that do 
                        not include a clear antidrug message or purpose 
                        intended to reduce drug use;
                          ``(v) requests funding to enforce section 
                        484(r)(1) of the Higher Education Act of 1965 
                        (20 U.S.C. 1091(r)(1)) with respect to 
                        convictions for drug-related offenses not 
                        occurring during a period of enrollment for 
                        which the student was receiving any Federal 
                        grant, loan, or work assistance;
                          ``(vi) requests funding for drug treatment 
                        activities that do not adequately support and 
                        enhance Federal drug treatment programs and 
                        capacity, as determined by the Director;
                          ``(vii) requests funding for fiscal year 2007 
                        for activities of the Department of Education, 
                        unless it is accompanied by a report setting 
                        forth a plan for providing expedited 
                        consideration of student loan applications for 
                        all individuals who submitted an application 
                        for any Federal grant, loan, or work assistance 
                        that was rejected or denied pursuant to 
                        484(r)(1) of the Higher Education Act of 1965 
                        (20 U.S.C. 1091(r)(1)) by reason of a 
                        conviction for a drug-related offense not 
                        occurring during a period of enrollment for 
                        which the individual was receiving any Federal 
                        grant, loan, or work assistance; and
                          ``(viii) requests funding for the operations 
                        and management of the Department of Homeland 
                        Security that does not include a specific 
                        request for funds for the Office of 
                        Counternarcotics Enforcement to carry out its 
                        responsibilities under section 878 of the 
                        Homeland Security Act of 2002 (6 U.S.C. 
                        458).'';
          (3) in subparagraph (D)(iii), as so redesignated, by 
        inserting ``and the appropriate congressional committees'' 
        after ``House of Representatives''; and
          (4) in subparagraph (E)(ii)(II)(bb), as so redesignated, by 
        inserting ``and the appropriate congressional committees'' 
        after ``House of Representatives''.
  (f) Reprogramming and Transfer Requests.--Section 704(c)(4)(A) (21 
U.S.C. 1703(c)(4)(A)) is amended by striking ``$5,000,000'' and 
inserting ``$1,000,000''.
  (g) Powers of Director.--Section 704(d) (21 U.S.C. 1703(d)) is 
amended--
          (1) in paragraph (8)(D), by striking ``have been authorized 
        by Congress;'' and inserting ``authorized by law;'';
          (2) in paragraph (9)--
                  (A) by inserting ``notwithstanding any other 
                provision of law,'' after ``(9)''; and
                  (B) by striking ``Strategy; and'' and inserting 
                ``Strategy and notify the appropriate congressional 
                committees of any fund control notice issued;'';
          (3) in paragraph (10), by striking ``(22 U.S.C. 2291j).'' and 
        inserting ``(22 U.S.C. 2291j) and section 706 of the Foreign 
        Relations Authorization Act, Fiscal Year 2003 (22 U.S.C. 2291j-
        1); and''; and
          (4) by adding at the end the following new paragraph:
          ``(11) not later than August 1 of each year, submit to the 
        President a report, and transmit copies of the report to the 
        Secretary of State and the appropriate congressional 
        committees, that--
                  ``(A) provides the Director's assessment of which 
                countries are major drug transit countries or major 
                illicit drug producing countries as defined in section 
                481(e) of the Foreign Assistance Act of 1961 (22 U.S.C. 
                2291(e));
                  ``(B) provides the Director's assessment of whether 
                each country identified under subparagraph (A) has 
                cooperated fully with the United States or has taken 
                adequate steps on its own to achieve full compliance 
                with the goals and objectives established by the United 
                Nations Convention Against Illicit Traffic in Narcotic 
                Drugs and Psychotropic Substances and otherwise has 
                assisted in reducing the supply of illicit drugs to the 
                United States; and
                  ``(C) provides the Director's assessment of whether 
                application of procedures set forth in section 490 of 
                the Foreign Assistance Act of 1961 (22 U.S.C. 2291j), 
                as provided in section 706 of the Foreign Relations 
                Authorization Act, Fiscal Year 2003 (22 U.S.C. 2291j-
                1), is warranted with respect to countries the Director 
                assesses have not cooperated fully.''.
  (g) Fund Control Notices.--Section 704(f) (21 U.S.C. 1703(f)) is 
amended by adding at the end the following:
          ``(4) Congressional notice.--A copy of each fund control 
        notice shall be transmitted to the appropriate congressional 
        committees.
          ``(5) Restrictions.--The Director shall not issue a fund 
        control notice to direct that all or part of an amount 
        appropriated to the National Drug Control Program agency 
        account be obligated, modified, or altered in any manner 
        contrary, in whole or in part, to a specific appropriation or 
        statute.''.
  (h) Technical Amendments.--Section 704 (21 U.S.C. 1703) is amended--
          (1) in subsection (g)--
                  (A) by striking ``National Foreign Intelligence 
                Program'' and inserting ``National Intelligence 
                Program''; and
                  (B) by inserting a comma before ``and Tactical''; and
          (2) in subsection (h), by striking ``Director of Central 
        Intelligence'' and inserting ``Director of National 
        Intelligence or the Director of the Central Intelligence 
        Agency''.
  (i) Requirement for South American Heroin Strategy.--
          (1) In general.--Not later than 90 days after the date of the 
        enactment of this Act, the Director of National Drug Control 
        Policy shall submit to the Congress a comprehensive strategy 
        that addresses the increased threat from South American heroin, 
        and in particular Colombian heroin and the emerging threat from 
        opium poppy grown in Peru and often intended for transit to 
        Columbia for processing into heroin.
          (2) Contents.--The strategy shall include--
                  (A) opium eradication efforts to eliminate the 
                problem at the source to prevent heroin from entering 
                the stream of commerce;
                  (B) interdiction and precursor chemical controls;
                  (C) demand reduction and treatment;
                  (D) alternative development programs, including 
                direct assistance to regional governments to demobilize 
                and provide alternative livelihoods to former members 
                of insurgent or other groups engaged in heroin, coca, 
                or other illicit drug production or trafficking;
                  (E) efforts to inform and involve local citizens in 
                the programs described in subparagraphs (A) through 
                (D), such as through leaflets advertising rewards for 
                information;
                  (F) provisions that ensure the maintenance at current 
                levels of efforts to eradicate coca in Colombia; and
                  (G) assessment of the specific level of funding and 
                resources necessary to simultaneously address the 
                threat from South American heroin and the threat from 
                Colombian and Peruvian coca.
          (3) Treatment of classified or law enforcement sensitive 
        information.--Any content of the strategy that involves 
        information classified under criteria established by an 
        Executive order, or whose public disclosure, as determined by 
        the Director or the head of any relevant Federal agency, would 
        be detrimental to the law enforcement or national security 
        activities of any Federal, foreign, or international agency, 
        shall be presented to Congress separately from the rest of the 
        strategy.
  (j) Requirement for Afghan Heroin Strategy.--
          (1) In general.--Not later than 90 days after the date of the 
        enactment of this Act, the Director of the Office of National 
        Drug Control Policy shall submit to the Congress a 
        comprehensive strategy that addresses the increased threat from 
        Afghan heroin.
          (2) Contents.--The strategy shall include--
                  (A) opium crop eradication efforts to eliminate the 
                problem at the source to prevent heroin from entering 
                the stream of commerce;
                  (B) destruction or other direct elimination of 
                stockpiles of heroin and raw opium, and heroin 
                production and storage facilities;
                  (C) interdiction and precursor chemical controls;
                  (D) demand reduction and treatment;
                  (E) alternative development programs;
                  (F) measures to improve cooperation and coordination 
                between Federal Government agencies, and between such 
                agencies, agencies of foreign governments, and 
                international organizations with responsibility for the 
                prevention of heroin production in, or trafficking out 
                of, Afghanistan; and
                  (G) an assessment of the specific level of funding 
                and resources necessary significantly to reduce the 
                production and trafficking of heroin.
          (3) Treatment of classified or law enforcement sensitive 
        information.--Any content of the strategy that involves 
        information classified under criteria established by an 
        Executive order, or whose public disclosure, as determined by 
        the Director or the head of any relevant Federal agency, would 
        be detrimental to the law enforcement or national security 
        activities of any Federal, foreign, or international agency, 
        shall be presented to Congress separately from the rest of the 
        strategy.
  (k) Requirement for General Counterdrug Intelligence Plan.--
          (1) In general.--Not later than 120 days after the date of 
        enactment of this Act, and not later than every two years 
        thereafter, the Director of the Office of National Drug Control 
        Policy, with the concurrence of the Director of National 
        Intelligence, shall submit to the appropriate congressional 
        committees, a general counterdrug intelligence plan to improve 
        coordination, and eliminate unnecessary duplication, among the 
        counterdrug intelligence centers and information sharing 
        systems, and counterdrug activities of the Federal Government, 
        including the centers, systems, and activities of the following 
        departments and agencies:
                  (A) The Department of Defense, including the Defense 
                Intelligence Agency, and the joint interagency task 
                forces.
                  (B) The Department of the Treasury, including the 
                Financial Crimes Enforcement Network (FinCEN).
                  (C) The Central Intelligence Agency.
                  (D) The National Security Agency.
                  (E) The Department of Homeland Security, including 
                the United States Coast Guard, the bureau of Customs 
                and Border Protection, and the bureau of Immigration 
                and Customs Enforcement.
                  (F) The Department of Justice, including the National 
                Drug Intelligence Center (NDIC); the Drug Enforcement 
                Administration, including the El Paso Intelligence 
                Center (EPIC); the Federal Bureau of Investigation; the 
                Organized Crime Drug Enforcement Task Force; and the 
                Regional Information Sharing System.
                  (G) The Office of National Drug Control Policy, 
                including the High Intensity Drug Trafficking Areas 
                Program.
                  (H) The Counterdrug Intelligence Executive 
                Secretariat.
          (2) Purpose.--The purpose of the plan under paragraph (1) is 
        to maximize the effectiveness of the centers and activities 
        referred to in that paragraph in achieving the objectives of 
        the National Drug Control Strategy promulgated under 21 U.S.C. 
        1705. In order to maximize such effectiveness, the plan shall--
                  (A) articulate clear and specific mission statements 
                (including purpose and scope of activity) for each 
                counterdrug intelligence center, system, and activity, 
                including the manner in which responsibility for 
                counterdrug intelligence activities will be allocated 
                among the counterdrug intelligence centers and systems;
                  (B) specify each government agency (whether Federal, 
                State, or local) that participates in each such center, 
                system, and activity, including a description of the 
                extent and nature of that participation;
                  (C) specify the relationship between such centers, 
                systems, and activities;
                  (D) specify the means by which proper oversight of 
                such centers, systems, and activities will be assured;
                  (E) specify the means by which counterdrug 
                intelligence and information will be forwarded 
                effectively to all levels of officials responsible for 
                United States counterdrug policy; and
                  (F) specify mechanisms to ensure that State and local 
                law enforcement agencies are apprised of counterdrug 
                intelligence and information acquired by Federal law 
                enforcement agencies in a manner which--
                          (i) facilitates effective counterdrug 
                        activities by State and local law enforcement 
                        agencies; and
                          (ii) provides such State and local law 
                        enforcement agencies with the information 
                        relating to the safety of officials involved in 
                        their counterdrug activities.
          (3) Definitions.--As used in this subsection--
                  (A) the term ``center'' refers to any center, office, 
                task force, or other coordinating organization engaged 
                in counterdrug intelligence or information analyzing or 
                sharing activities;
                  (B) the term ``system'' refers to any computerized 
                database or other electronic system used for 
                counterdrug intelligence or information analyzing or 
                sharing activities; and
                  (C) the term ``appropriate congressional committees'' 
                means the following:
                          (i) The Committee on Appropriations, the 
                        Committee on Foreign Relations, the Committee 
                        on the Judiciary, the Committee on Homeland 
                        Security and Governmental Affairs, the Caucus 
                        on International Narcotics Control, and the 
                        Select Committee on Intelligence of the Senate.
                          (ii) The Committee on Appropriations, the 
                        Committee on International Relations, the 
                        Committee on the Judiciary, the Committee on 
                        Government Reform, the Committee on Homeland 
                        Security, and the Permanent Select Committee on 
                        Intelligence of the House of Representatives.
          (4) Limitation.--The general counterdrug intelligence plan 
        shall not--
                  (A) change existing agency authorities or the laws 
                governing interagency relationships, but may include 
                recommendations about changes to such authorities or 
                laws; or
                  (B) include any information about specific methods of 
                obtaining, or sources of, intelligence or information, 
                or any information about specific individuals, cases, 
                investigations, or operations.
          (5) Classified or law enforcement sensitive information.--Any 
        content of the general counterdrug intelligence plan that 
        involves information classified under criteria established by 
        an Executive order, or whose public disclosure, as determined 
        by the Director of the Office of National Drug Control Policy, 
        the Director of National Intelligence, or the head of any 
        Federal Government agency whose activities are described in the 
        plan, would be detrimental to the law enforcement or national 
        security activities of any Federal, State, or local agency, 
        shall be presented to Congress separately from the rest of the 
        report.
  (l) Requirement for Southwest Border Counternarcotics Strategy.--
          (1) In general.--Not later than 120 days after the date of 
        enactment of this Act, and every two years thereafter, the 
        Director of National Drug Control Policy shall submit to the 
        Congress a Southwest Border Counternarcotics Strategy.
          (2) Purposes.--The Southwest Border Counternarcotics Strategy 
        shall--
                  (A) set forth the Government's strategy for 
                preventing the illegal trafficking of drugs across the 
                international border between the United States and 
                Mexico, including through ports of entry and between 
                ports of entry on that border;
                  (B) state the specific roles and responsibilities of 
                the relevant National Drug Control Program agencies (as 
                defined in section 702 of the Office of National Drug 
                Control Policy Reauthorization Act of 1998 (21 U.S.C. 
                1701)) for implementing that strategy; and
                  (C) identify the specific resources required to 
                enable the relevant National Drug Control Program 
                agencies to implement that strategy.
          (3) Consultation with other agencies.--The Director shall 
        issue the Southwest Border Counternarcotics Strategy in 
        consultation with the heads of the relevant National Drug 
        Control Program agencies.
          (4) Limitation.--The Southwest Border Counternarcotics 
        Strategy shall not change existing agency authorities or the 
        laws governing interagency relationships, but may include 
        recommendations about changes to such authorities or laws.
          (5) Report to congress.--The Director shall provide a copy of 
        the Southwest Border Counternarcotics Strategy to the 
        appropriate congressional committees (as defined in section 702 
        of the Office of National Drug Control Policy Reauthorization 
        Act of 1998 (21 U.S.C. 1701)), and to the Committee on Armed 
        Services and the Committee on Homeland Security of the House of 
        Representatives, and the Committee on Homeland Security and 
        Governmental Affairs and the Committee on Armed Services of the 
        Senate.
          (6) Treatment of classified or law enforcement sensitive 
        information.--Any content of the Southwest Border 
        Counternarcotics Strategy that involves information classified 
        under criteria established by an Executive order, or whose 
        public disclosure, as determined by the Director or the head of 
        any relevant National Drug Control Program agency, would be 
        detrimental to the law enforcement or national security 
        activities of any Federal, State, or local agency, shall be 
        presented to Congress separately from the rest of the strategy.
  (m) Requirement for Scientific Study of Mycoherbicide in Illicit Drug 
Crop Eradication.--Not later than 90 days after the date of enactment 
of this Act, the Director of the Office of National Drug Control Policy 
shall submit to the Congress a report that includes a plan to conduct, 
on an expedited basis, a scientific study of the use of mycoherbicide 
as a means of illicit drug crop elimination by an appropriate 
Government scientific research entity, including a complete and 
thorough scientific peer review. The study shall include an evaluation 
of the likely human health and environmental impacts of such use. The 
report shall also include a plan to conduct controlled scientific 
testing in a major drug producing nation of mycoherbicide naturally 
existing in the producing nation.

SEC. 7. AMENDMENTS RELATING TO COORDINATION WITH OTHER AGENCIES.

  Section 705 (21 U.S.C. 1704) is amended--
          (1) in subsection (a)(1)(A), by striking ``abuse'';
          (2) in subsection (a)(2)(A), by striking ``Director of 
        Central Intelligence'' and inserting ``Director of National 
        Intelligence'';
          (3) in subsection (a)(2)(B), by striking ``Director of 
        Central Intelligence'' and inserting ``Director of National 
        Intelligence and the Director of the Central Intelligence 
        Agency'';
          (4) by amending paragraph (3) of subsection (a) to read as 
        follows:
          ``(3) Required reports.--
                  ``(A) Secretaries of the interior and agriculture.--
                The Secretaries of Agriculture and Interior shall, by 
                July 1 of each year, jointly submit to the Director, 
                the appropriate congressional committees, the Committee 
                on Agriculture and the Committee on Resources of the 
                House of Representatives, and the Committee on 
                Agriculture and the Committee on Energy and Natural 
                Resources of the Senate, an assessment of the quantity 
                of illegal drug cultivation and manufacturing in the 
                United States on lands owned or under the jurisdiction 
                of the Federal Government for the preceding year.
                  ``(B) Attorney general.--The Attorney General shall, 
                by July 1 of each year, submit to the Director and the 
                appropriate congressional committees information for 
                the preceding year regarding the number and type of--
                          ``(i) arrests for drug violations;
                          ``(ii) prosecutions for drug violations by 
                        United States Attorneys; and
                          ``(iii) seizures of drugs by each component 
                        of the Department of Justice seizing drugs, as 
                        well as statistical information on the 
                        geographic areas of such seizures.
                  ``(C) Secretary of homeland security.--The Secretary 
                of Homeland Security shall, by July 1 of each year, 
                submit to the Director, the appropriate congressional 
                committees, and the Committee on Homeland Security of 
                the House of Representatives, and the Committee on 
                Homeland Security and Governmental Affairs of the 
                Senate, information for the preceding year regarding--
                          ``(i) the number and type of seizures of 
                        drugs by each component of the Department of 
                        Homeland Security seizing drugs, as well as 
                        statistical information on the geographic areas 
                        of such seizures; and
                          ``(ii) the number of air and maritime patrol 
                        hours undertaken by each component of that 
                        Department primarily dedicated to drug supply 
                        reduction missions.
                  ``(D) Secretary of defense.--The Secretary of Defense 
                shall, by July 1 of each year, submit to the Director, 
                the appropriate congressional committees, the Committee 
                on Armed Services of the House of Representatives, and 
                the Committee on Armed Services of the Senate, 
                information for the preceding year regarding the number 
                of air and maritime patrol hours primarily dedicated to 
                drug supply reduction missions undertaken by each 
                component of the Department of Defense.'';
          (5) in subsection (b)(2)(B), by striking ``Program.'' and 
        inserting ``Strategy.''; and
          (6) in subsection (c), by striking ``in'' and inserting 
        ``on''.

SEC. 8. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
                    NATIONAL DRUG CONTROL STRATEGY.

  Section 706 (21 U.S.C. 1705) is amended to read as follows:

``SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
                    NATIONAL DRUG CONTROL STRATEGY.

  ``(a) Timing, Contents, and Process for Development and Submission of 
National Drug Control Strategy.--
          ``(1) In general.--Not later than February 1 of each year, 
        the President shall submit to Congress a National Drug Control 
        Strategy, which shall set forth a comprehensive plan for 
        reducing illicit drug use and the consequences of illicit drug 
        use in the United States by reducing the demand for illegal 
        drugs, limiting the availability of illegal drugs, and 
        conducting law enforcement activities with respect to illegal 
        drugs.
          ``(2) Contents.--
                  ``(A) In general.--The National Drug Control Strategy 
                submitted under paragraph (1) shall include the 
                following:
                          ``(i) Comprehensive, research-based, long-
                        range, and quantifiable goals for reducing 
                        illicit drug use and the consequences of 
                        illicit drug use in the United States.
                          ``(ii) Annual quantifiable objectives for 
                        demand reduction, supply reduction, and law 
                        enforcement activities, specific targets to 
                        accomplish long-range quantifiable reduction in 
                        illicit drug use as determined by the Director, 
                        and specific measurements to evaluate progress 
                        toward the targets and strategic goals.
                          ``(iii) A strategy to reduce the availability 
                        and purity of illegal drugs and the level of 
                        drug-related crime in the United States.
                          ``(iv) An assessment of Federal effectiveness 
                        in achieving the National Drug Control Strategy 
                        for the previous year, including a specific 
                        evaluation of whether the objectives and 
                        targets for reducing illicit drug use for the 
                        previous year were met and reasons for the 
                        success or failure of the previous year's 
                        Strategy.
                          ``(v) A general review of the status of, and 
                        trends in, international, State, and local drug 
                        control activities to ensure that the United 
                        States pursues well-coordinated and effective 
                        drug control at all levels of government.
                          ``(vi) A general review of the status of, and 
                        trends in, demand reduction activities by 
                        private sector entities and community-based 
                        organizations, including faith-based 
                        organizations, to determine their effectiveness 
                        and the extent of cooperation, coordination, 
                        and mutual support between such entities and 
                        organizations and Federal, State, and local 
                        government agencies.
                          ``(vii) An assessment of current illicit drug 
                        use (including inhalants and steroids) and 
                        availability, impact of illicit drug use, and 
                        treatment availability, which assessment shall 
                        include--
                                  ``(I) estimates of drug prevalence 
                                and frequency of use as measured by 
                                national, State, and local surveys of 
                                illicit drug use and by other special 
                                studies of nondependent and dependent 
                                illicit drug use;
                                  ``(II) illicit drug use in the 
                                workplace and the productivity lost by 
                                such use; and
                                  ``(III) illicit drug use by 
                                arrestees, probationers, and parolees.
                          ``(viii) An assessment of the reduction of 
                        illicit drug availability, as measured by--
                                  ``(I) the quantities of cocaine, 
                                heroin, marijuana, methamphetamine, 
                                ecstasy, and other drugs available for 
                                consumption in the United States;
                                  ``(II) the amount of marijuana, 
                                cocaine, heroin, methamphetamine, 
                                ecstasy, and precursor chemicals and 
                                other drugs entering the United States;
                                  ``(III) the number of illicit drug 
                                manufacturing laboratories seized and 
                                destroyed and the number of hectares of 
                                marijuana, poppy, and coca cultivated 
                                and destroyed domestically and in other 
                                countries;
                                  ``(IV) the number of metric tons of 
                                marijuana, heroin, cocaine, and 
                                methamphetamine seized and other drugs; 
                                and
                                  ``(V) changes in the price and purity 
                                of heroin, methamphetamine, and 
                                cocaine, changes in the price of 
                                ecstasy, and changes in 
                                tetrahydrocannabinol level of marijuana 
                                and other drugs.
                          ``(ix) An assessment of the reduction of the 
                        consequences of illicit drug use and 
                        availability, which shall include--
                                  ``(I) the burden illicit drug users 
                                place on hospital emergency departments 
                                in the United States, such as the 
                                quantity of illicit drug-related 
                                services provided;
                                  ``(II) the annual national health 
                                care cost of illicit drug use; and
                                  ``(III) the extent of illicit drug-
                                related crime and criminal activity.
                          ``(x) A general review of the status of, and 
                        trends in, of drug treatment in the United 
                        States, by assessing--
                                  ``(I) public and private treatment 
                                utilization; and
                                  ``(II) the number of illicit drug 
                                users the Director estimates meet 
                                diagnostic criteria for treatment.
                          ``(xi) A review of the research agenda of the 
                        Counterdrug Technology Assessment Center to 
                        reduce the availability and abuse of drugs.
                          ``(xii) A summary of the efforts made by 
                        Federal agencies to coordinate with private 
                        sector entities to conduct private research and 
                        development of medications to treat addiction 
                        by--
                                  ``(I) screening chemicals for 
                                potential therapeutic value;
                                  ``(II) developing promising 
                                compounds;
                                  ``(III) conducting clinical trials;
                                  ``(IV) seeking, where appropriate, 
                                Food and Drug Administration approval 
                                for drugs to treat addiction;
                                  ``(V) marketing, where appropriate, 
                                the drug for the treatment of 
                                addiction;
                                  ``(VI) urging physicians, where 
                                appropriate, to use the drug in the 
                                treatment of addiction; and
                                  ``(VII) encouraging, where 
                                appropriate, insurance companies to 
                                reimburse the cost of the drug for the 
                                treatment of addiction.
                          ``(xiii) Such additional statistical data and 
                        information as the Director considers 
                        appropriate to demonstrate and assess trends 
                        relating to illicit drug use, the effects and 
                        consequences of illicit drug use, supply 
                        reduction, demand reduction, drug-related law 
                        enforcement, and the implementation of the 
                        National Drug Control Strategy.
                          ``(xiv) A supplement reviewing the activities 
                        of each individual National Drug Control 
                        Program agency during the previous year with 
                        respect to the National Drug Control Strategy 
                        and the Director's assessment of the progress 
                        of each National Drug Control Program agency in 
                        meeting its responsibilities under the National 
                        Drug Control Strategy.
                  ``(B) Classified information.--Any contents of the 
                National Drug Control Strategy that involve information 
                properly classified under criteria established by an 
                Executive order shall be presented to Congress 
                separately from the rest of the National Drug Control 
                Strategy.
                  ``(C) Selection of data and information.--In 
                selecting data and information for inclusion under 
                subparagraph (A), the Director shall ensure--
                          ``(i) the inclusion of data and information 
                        that will permit analysis of current trends 
                        against previously compiled data and 
                        information where the Director believes such 
                        analysis enhances long-term assessment of the 
                        National Drug Control Strategy; and
                          ``(ii) the inclusion of data and information 
                        to permit a standardized and uniform assessment 
                        of the effectiveness of drug treatment programs 
                        in the United States.
          ``(3) Process for development and submission.--
                  ``(A) Consultation.--In developing and effectively 
                implementing the National Drug Control Strategy, the 
                Director--
                          ``(i) shall consult with--
                                  ``(I) the heads of the National Drug 
                                Control Program agencies;
                                  ``(II) Congress;
                                  ``(III) State and local officials;
                                  ``(IV) private citizens and 
                                organizations, including community- and 
                                faith-based organizations, with 
                                experience and expertise in demand 
                                reduction;
                                  ``(V) private citizens and 
                                organizations with experience and 
                                expertise in supply reduction;
                                  ``(VI) private citizens and 
                                organizations with experience and 
                                expertise in law enforcement; and
                                  ``(VII) appropriate representatives 
                                of foreign governments;
                          ``(ii) with the concurrence of the Attorney 
                        General, may require the El Paso Intelligence 
                        Center to undertake specific tasks or projects 
                        to implement the National Drug Control 
                        Strategy;
                          ``(iii) with the concurrence of the Director 
                        of National Intelligence and the Attorney 
                        General, may request that the National Drug 
                        Intelligence Center undertake specific tasks or 
                        projects to implement the National Drug Control 
                        Strategy; and
                          ``(iv) may make recommendations to the 
                        Secretary of Health and Human Services on 
                        research that supports or advances the National 
                        Drug Control Strategy.
                  ``(B) Commitment to support strategy.--In satisfying 
                the requirements of subparagraph (A)(i), the Director 
                shall ensure, to the maximum extent possible, that 
                State and local officials and relevant private 
                organizations commit to support and take steps to 
                achieve the goals and objectives of the National Drug 
                Control Strategy.
                  ``(C) Recommendations.--Recommendations under 
                subparagraph (A)(iv) may include recommendations of 
                research to be performed at the National Institutes of 
                Health, including the National Institute on Drug Abuse, 
                or any other appropriate agency within the Department 
                of Health and Human Services.
                  ``(D) Inclusion in strategy.--The National Drug 
                Control Strategy under this subsection shall include a 
                list of each entity consulted under subparagraph 
                (A)(i).
          ``(4) Submission of revised strategy.--The President may 
        submit to Congress a revised National Drug Control Strategy 
        that meets the requirements of this section--
                  ``(A) at any time, upon a determination by the 
                President, in consultation with the Director, that the 
                National Drug Control Strategy in effect is not 
                sufficiently effective; or
                  ``(B) if a new President or Director takes office.
  ``(b) Performance Measurement System.--Not later than February 1 of 
each year, the Director shall submit to Congress, as part of the 
National Drug Control Strategy, a description of a national drug 
control performance measurement system that--
          ``(1) develops 2-year and 5-year performance measures and 
        targets for each National Drug Control Strategy goal and 
        objective established for reducing drug use, drug availability, 
        and the consequences of drug use;
          ``(2) describes the sources of information and data that will 
        be used for each performance measure incorporated into the 
        performance measurement system;
          ``(3) identifies major programs and activities of the 
        National Drug Control Program agencies that support the goals 
        and annual objectives of the National Drug Control Strategy;
          ``(4) evaluates the contribution of demand reduction and 
        supply reduction activities implemented by each National Drug 
        Control Program agency in support of the National Drug Control 
        Strategy;
          ``(5) monitors consistency of drug-related goals and 
        objectives among the National Drug Control Program agencies and 
        ensures that each agency's goals, objectives, and budgets 
        support and are fully consistent with the National Drug Control 
        Strategy; and
          ``(6) coordinates the development and implementation of 
        national drug control data collection and reporting systems to 
        support policy formulation and performance measurement, 
        including an assessment of--
                  ``(A) the quality of current drug use measurement 
                instruments and techniques to measure supply reduction 
                and demand reduction activities;
                  ``(B) the adequacy of the coverage of existing 
                national drug use measurement instruments and 
                techniques to measure the illicit drug user population, 
                and groups that are at risk for illicit drug use; and
                  ``(C) the adequacy of the coverage of existing 
                national treatment outcome monitoring systems to 
                measure the effectiveness of drug abuse treatment in 
                reducing illicit drug use and criminal behavior during 
                and after the completion of substance abuse treatment; 
                and
          ``(7) identifies the actions the Director shall take to 
        correct any inadequacies, deficiencies, or limitations 
        identified in the assessment described in paragraph (6).
  ``(c) Modifications.--A description of any modifications made during 
the preceding year to the national drug performance measurement system 
described in subsection (b) shall be included in each report submitted 
under subsection (a).''.

SEC. 9. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

  Section 707 (21 U.S.C. 1706) is amended to read as follows:

``SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

  ``(a) Establishment.--
          ``(1) In general.--There is established in the Office a 
        program to be known as the High Intensity Drug Trafficking 
        Areas Program (in this section referred to as the `Program').
          ``(2) Purpose.--The purpose of the Program is to reduce drug 
        trafficking and drug production in the United States by--
                  ``(A) facilitating cooperation among Federal, State, 
                and local law enforcement agencies to share information 
                and implement coordinated enforcement activities;
                  ``(B) enhancing intelligence sharing among Federal, 
                State, and local law enforcement agencies;
                  ``(C) providing reliable intelligence to law 
                enforcement agencies needed to design effective 
                enforcement strategies and operations; and
                  ``(D) supporting coordinated law enforcement 
                strategies which maximize use of available resources to 
                reduce the supply of illegal drugs in designated areas 
                and in the United States as a whole.
  ``(b) Designation.--The Director, upon consultation with the Attorney 
General, the Secretary of the Treasury, the Secretary of Homeland 
Security, heads of the National Drug Control Program agencies, and the 
Governor of each applicable State, may designate any specified area of 
the United States as a high intensity drug trafficking area. After 
making such a designation and in order to provide Federal assistance to 
the area so designated, the Director may--
          ``(1) obligate such sums as are appropriated for the Program;
          ``(2) direct the temporary reassignment of Federal personnel 
        to such area, subject to the approval of the head of the 
        department or agency that employs such personnel;
          ``(3) take any other action authorized under section 704 to 
        provide increased Federal assistance to those areas; and
          ``(4) coordinate activities under this section (specifically 
        administrative, recordkeeping, and funds management activities) 
        with State and local officials.
  ``(c) Petitions for Designation.--The Director shall establish 
regulations under which a coalition of interested law enforcement 
agencies from an area may petition for designation as a high intensity 
drug trafficking area. Such regulations shall provide for a regular 
review by the Director of the petition, including a recommendation 
regarding the merit of the petition to the Director by a panel of 
qualified, independent experts.
  ``(d) Factors for Consideration.--In considering whether to designate 
an area under this section as a high intensity drug trafficking area, 
the Director shall consider, in addition to such other criteria as the 
Director considers to be appropriate, the extent to which--
          ``(1) the area is a significant center of illegal drug 
        production, manufacturing, importation, or distribution;
          ``(2) State and local law enforcement agencies have committed 
        resources to respond to the drug trafficking problem in the 
        area, thereby indicating a determination to respond 
        aggressively to the problem;
          ``(3) drug-related activities in the area are having a 
        significant harmful impact in the area, and in other areas of 
        the country; and
          ``(4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-related 
        activities in the area.
  ``(e) Organization of High Intensity Drug Trafficking Areas.--
          ``(1) Executive board and officers.--To be eligible for funds 
        appropriated under this section, each high intensity drug 
        trafficking area shall be governed by an Executive Board. The 
        Executive Board shall designate a chairman, vice chairman, and 
        any other officers to the Executive Board that it determines 
        are necessary.
          ``(2) Responsibilities.--The Executive Board of a high 
        intensity drug trafficking area shall be responsible for--
                  ``(A) providing direction and oversight in 
                establishing and achieving the goals of the high 
                intensity drug trafficking area;
                  ``(B) managing the funds of the high intensity drug 
                trafficking area;
                  ``(C) reviewing and approving all funding proposals 
                consistent with the overall objective of the high 
                intensity drug trafficking area; and
                  ``(D) reviewing and approving all reports to the 
                Director on the activities of the high intensity drug 
                trafficking area.
          ``(3) Board representation.--None of the funds appropriated 
        under this section may be expended for any high intensity drug 
        trafficking area, or for a partnership or region of a high 
        intensity drug trafficking area, if that area's, region's or 
        partnership's Executive Board does not apportion an equal 
        number of votes between representatives of participating 
        Federal agencies and representatives of participating State and 
        local agencies. Where it is impractical for a equal number of 
        representatives of Federal agencies and State and local 
        agencies to attend a meeting of an Executive Board in person, 
        the Executive Board may use a system of proxy votes or weighted 
        votes to achieve the voting balance required by this paragraph.
          ``(4) No agency relationship.--The eligibility requirements 
        of this section are intended to ensure the responsible use of 
        Federal funds. Nothing in this section is intended to create an 
        agency relationship between individual high intensity drug 
        trafficking areas and the Federal Government.
  ``(f) Use of Funds.--The Director shall ensure that no Federal funds 
appropriated for the Program are expended for the establishment or 
expansion of drug treatment programs, and shall ensure that not more 
than five percent of the Federal funds appropriated for the Program are 
expended for the establishment of drug prevention programs.
  ``(g) Counterterrorism Activities.--
          ``(1) Assistance authorized.--The Director may authorize use 
        of resources available for the Program to assist Federal, 
        State, and local law enforcement agencies in investigations and 
        activities related to terrorism and prevention of terrorism, 
        especially but not exclusively with respect to such 
        investigations and activities that are also related to drug 
        trafficking.
          ``(2) Limitation.--The Director shall ensure--
                  ``(A) that assistance provided under paragraph (1) 
                remains incidental to the purpose of the Program to 
                reduce drug availability and carry out drug-related law 
                enforcement activities; and
                  ``(B) that significant resources of the Program are 
                not redirected to activities exclusively related to 
                terrorism, except on a temporary basis under 
                extraordinary circumstances, as determined by the 
                Director.
  ``(h) Role of Drug Enforcement Administration.--The Director, in 
consultation with the Attorney General, shall ensure that a 
representative of the Drug Enforcement Administration is included in 
the Intelligence Support Center for each high intensity drug 
trafficking area.
  ``(i) Annual HIDTA Program Budget Submissions.--As part of the 
documentation that supports the President's annual budget request for 
the Office, the Director shall submit to Congress a budget 
justification that includes the following:
          ``(1) The amount requested for each high intensity drug 
        trafficking area with supporting narrative descriptions and 
        rationale for each request.
          ``(2) A detailed justification for each funding request that 
        explains the reasons for the requested funding level, how such 
        funding level was determined based on a current assessment of 
        the drug trafficking threat in each high intensity drug 
        trafficking area, how such funding will ensure that the goals 
        and objectives of each such area will be achieved, and how such 
        funding supports the National Drug Control Strategy.
  ``(j) Emerging Threat Response Fund.--
          ``(1) In general.--The Director may expend up to 10 percent 
        of the amounts appropriated under this section on a 
        discretionary basis, to respond to any emerging drug 
        trafficking threat in an existing high intensity drug 
        trafficking area, or to establish a new high intensity drug 
        trafficking area or expand an existing high intensity drug 
        trafficking area, in accordance with the criteria established 
        under paragraph (2).
          ``(2) Consideration of impact.--In allocating funds under 
        this subsection, the Director shall consider--
                  ``(A) the impact of activities funded on reducing 
                overall drug traffic in the United States, or 
                minimizing the probability that an emerging drug 
                trafficking threat will spread to other areas of the 
                United States; and
                  ``(B) such other criteria as the Director considers 
                appropriate.
  ``(k) Evaluation.--
          ``(1) Initial report.--Not later than 90 days after the date 
        of the enactment of this subsection, the Director shall, after 
        consulting with the Executive Boards of each designated high 
        intensity drug trafficking area, submit a report to Congress 
        that describes, for each designated high intensity drug 
        trafficking area--
                  ``(A) the specific purposes for the high intensity 
                drug trafficking area;
                  ``(B) the specific long-term and short-term goals and 
                objectives for the high intensity drug trafficking 
                area;
                  ``(C) the measurements that will be used to evaluate 
                the performance of the high intensity drug trafficking 
                area in achieving the long-term and short-term goals; 
                and
                  ``(D) the reporting requirements needed to evaluate 
                the performance of the high intensity drug trafficking 
                area in achieving the long-term and short-term goals.
          ``(2) Evaluation of hidta program as part of national drug 
        control strategy.--For each designated high intensity drug 
        trafficking area, the Director shall submit, as part of the 
        annual National Drug Control Strategy report, a report that--
                  ``(A) describes--
                          ``(i) the specific purposes for the high 
                        intensity drug trafficking area; and
                          ``(ii) the specific long-term and short-term 
                        goals and objectives for the high intensity 
                        drug trafficking area; and
                  ``(B) includes an evaluation of the performance of 
                the high intensity drug trafficking area in 
                accomplishing the specific long-term and short-term 
                goals and objectives identified under paragraph (1)(B).
  ``(l) Assessment of Drug Enforcement Task Forces in High Intensity 
Drug Trafficking Areas.--Not later than 180 days after the date of 
enactment of this subsection, and as part of each subsequent annual 
National Drug Control Strategy report, the Director shall submit to 
Congress a report--
          ``(1) assessing the number and operation of all federally 
        funded drug enforcement task forces within each high intensity 
        drug trafficking area; and
          ``(2) describing--
                  ``(A) each Federal, State, and local drug enforcement 
                task force operating in the high intensity drug 
                trafficking area;
                  ``(B) how such task forces coordinate with each 
                other, with any high intensity drug trafficking area 
                task force, and with investigations receiving funds 
                from the Organized Crime and Drug Enforcement Task 
                Force;
                  ``(C) what steps, if any, each such task force takes 
                to share information regarding drug trafficking and 
                drug production with other federally funded drug 
                enforcement task forces in the high intensity drug 
                trafficking area;
                  ``(D) the role of the high intensity drug trafficking 
                area in coordinating the sharing of such information 
                among task forces;
                  ``(E) the nature and extent of cooperation by each 
                Federal, State, and local participant in ensuring that 
                such information is shared among law enforcement 
                agencies and with the high intensity drug trafficking 
                area;
                  ``(F) the nature and extent to which information 
                sharing and enforcement activities are coordinated with 
                joint terrorism task forces in the high intensity drug 
                trafficking area; and
                  ``(G) any recommendations for measures needed to 
                ensure that task force resources are utilized 
                efficiently and effectively to reduce the availability 
                of illegal drugs in the high intensity drug trafficking 
                areas.
  ``(m) Assessment of Intelligence Sharing in High Intensity Drug 
Trafficking Areas--program.--Not later than 180 days after the date of 
the enactment of this subsection, and as part of each subsequent annual 
National Drug Control Strategy report, the Director shall submit to 
Congress a report--
          ``(1) evaluating existing and planned intelligence systems 
        supported by each high intensity drug trafficking area, or 
        utilized by task forces receiving any funding under the 
        Program, including the extent to which such systems ensure 
        access and availability of intelligence to Federal, State, and 
        local law enforcement agencies within the high intensity drug 
        trafficking area and outside of it;
          ``(2) the extent to which Federal, State, and local law 
        enforcement agencies participating in each high intensity drug 
        trafficking area are sharing intelligence information to assess 
        current drug trafficking threats and design appropriate 
        enforcement strategies; and
          ``(3) the measures needed to improve effective sharing of 
        information and intelligence regarding drug trafficking and 
        drug production among Federal, State, and local law enforcement 
        participating in a high intensity drug trafficking area, and 
        between such agencies and similar agencies outside the high 
        intensity drug trafficking area.
  ``(n) Coordination of Intelligence Sharing With Organized Crime Drug 
Enforcement Task Force Program.--The Director, in consultation with the 
Attorney General, shall ensure that any drug enforcement intelligence 
obtained by the Intelligence Support Center for each high intensity 
drug trafficking area is shared, on a timely basis, with the drug 
intelligence fusion center operated by the Organized Crime Drug 
Enforcement Task Force of the Department of Justice.
  ``(o) Use of Funds to Combat Methamphetamine Trafficking.--
          ``(1) In general.--
                  ``(A) Requirement.--The Director shall ensure that, 
                of the amounts appropriated for a fiscal year for the 
                Program, at least $15,000,000 is allocated to combat 
                the trafficking of methamphetamine in areas designated 
                by the Director as high intensity drug trafficking 
                areas.
                  ``(B) Activities.--In meeting the requirement in 
                subparagraph (A), the Director shall transfer funds to 
                appropriate Federal, State, and local governmental 
                agencies for employing additional Federal law 
                enforcement personnel, or facilitating the employment 
                of additional State and local law enforcement 
                personnel, including agents, investigators, 
                prosecutors, laboratory technicians, chemists, 
                investigative assistants, and drug prevention 
                specialists.
          ``(2) Apportionment of funds.--
                  ``(A) Factors in apportionment.--The Director shall 
                apportion amounts allocated under paragraph (1) among 
                areas designated by the Director as high intensity drug 
                trafficking areas based on the following factors:
                          ``(i) The number of methamphetamine 
                        manufacturing facilities discovered by Federal, 
                        State, or local law enforcement officials in 
                        the area during the previous fiscal year.
                          ``(ii) The number of methamphetamine 
                        prosecutions in Federal, State, or local courts 
                        in the area during the previous fiscal year.
                          ``(iii) The number of methamphetamine arrests 
                        by Federal, State, or local law enforcement 
                        officials in the area during the previous 
                        fiscal year.
                          ``(iv) The amounts of methamphetamine or 
                        listed chemicals (as that term is defined in 
                        section 102(33) of the Controlled Substances 
                        Act (21 U.S.C. 802(33)) seized by Federal, 
                        State, or local law enforcement officials in 
                        the area during the previous fiscal year.
                          ``(v) Intelligence and predictive data from 
                        the Drug Enforcement Administration showing 
                        patterns and trends in abuse, trafficking, and 
                        transportation in methamphetamine and listed 
                        chemicals (as that term is so defined).
                  ``(B) Certification.--Before the Director apportions 
                any funds under this paragraph to a high intensity drug 
                trafficking area, the Director shall certify that the 
                law enforcement entities responsible for clandestine 
                methamphetamine laboratory seizures in that area are 
                providing laboratory seizure data to the national 
                clandestine laboratory database at the El Paso 
                Intelligence Center.
  ``(p) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office of National Drug Control Policy to carry out 
this section--
          ``(1) $280,000,000 for fiscal year 2007;
          ``(2) $290,000,000 for each of fiscal years 2008 and 2009; 
        and
          ``(3) $300,000,000 for each of fiscal years 2010 and 2011.''.

SEC. 10. FUNDING FOR CERTAIN HIGH INTENSITY DRUG TRAFFICKING AREAS.

  (a) Short Title.--This section may be cited as the ``Dawson Family 
Community Protection Act''.
  (b) Findings.--Congress finds the following:
          (1) In the early morning hours of October 16, 2002, the home 
        of Carnell and Angela Dawson was firebombed in apparent 
        retaliation for Mrs. Dawson's notification of police about 
        persistent drug distribution activity in their East Baltimore 
        City neighborhood.
          (2) The arson claimed the lives of Mr. and Mrs. Dawson and 
        their 5 young children, aged 9 to 14.
          (3) The horrific murder of the Dawson family is a stark 
        example of domestic narco-terrorism.
          (4) In all phases of counter-narcotics law enforcement--from 
        prevention to investigation to prosecution to reentry--the 
        voluntary cooperation of ordinary citizens is a critical 
        component.
          (5) Voluntary cooperation is difficult for law enforcement 
        officials to obtain when citizens feel that cooperation carries 
        the risk of violent retaliation by illegal drug trafficking 
        organizations and their affiliates.
          (6) Public confidence that law enforcement is doing all it 
        can to make communities safe is a prerequisite for voluntary 
        cooperation among people who may be subject to intimidation or 
        reprisal (or both).
          (7) Witness protection programs are insufficient on their own 
        to provide security because many individuals and families who 
        strive every day to make distressed neighborhoods livable for 
        their children, other relatives, and neighbors will resist or 
        refuse offers of relocation by local, State, and Federal 
        prosecutorial agencies and because, moreover, the continued 
        presence of strong individuals and families is critical to 
        preserving and strengthening the social fabric in such 
        communities.
          (8) Where (as in certain sections of Baltimore City) 
        interstate trafficking of illegal drugs has severe ancillary 
        local consequences within areas designated as high intensity 
        drug trafficking areas, it is important that supplementary High 
        Intensity Drug Trafficking Areas Program funds be committed to 
        support initiatives aimed at making the affected communities 
        safe for the residents of those communities and encouraging 
        their cooperation with local, State, and Federal law 
        enforcement efforts to combat illegal drug trafficking.
  (c) Funding for Certain High Intensity Drug Trafficking Areas.--
Section 707 (21 U.S.C. 1706), as amended by section 9, is further 
amended by adding at the end the following new subsection:
  ``(q) Specific Purposes.--
          ``(1) In general.--The Director shall ensure that, of the 
        amounts appropriated for a fiscal year for the Program, at 
        least $7,000,000 is used in high intensity drug trafficking 
        areas with severe neighborhood safety and illegal drug 
        distribution problems.
          ``(2) Required uses.--The funds used under paragraph (1) 
        shall be used--
                  ``(A) to ensure the safety of neighborhoods and the 
                protection of communities, including the prevention of 
                the intimidation of potential witnesses of illegal drug 
                distribution and related activities; and
                  ``(B) to combat illegal drug trafficking through such 
                methods as the Director considers appropriate, such as 
                establishing or operating (or both) a toll-free 
                telephone hotline for use by the public to provide 
                information about illegal drug-related activities.''.

SEC. 11. AMENDMENTS RELATING TO COUNTER-DRUG TECHNOLOGY ASSESSMENT 
                    CENTER.

  (a) Chief Scientist.--Section 708(b) (21 U.S.C. 1707(b)) is amended--
          (1) in the heading by striking ``Director of Technology.--'' 
        and inserting ``Chief Scientist.--''; and
          (2) by striking ``Director of Technology,'' and inserting 
        ``Chief Scientist,''.
  (b) Additional Responsibilities of Director.--Section 708(c) (21 
U.S.C. 1707(c)) is amended to read as follows:
  ``(c) Additional Responsibilities of the Director of National Drug 
Control Policy.--
          ``(1) In general.--The Director, acting through the Chief 
        Scientist shall--
                  ``(A) identify and define the short-, medium-, and 
                long-term scientific and technological needs of 
                Federal, State, and local law enforcement agencies 
                relating to drug enforcement, including--
                          ``(i) advanced surveillance, tracking, and 
                        radar imaging;
                          ``(ii) electronic support measures;
                          ``(iii) communications;
                          ``(iv) data fusion, advanced computer 
                        systems, and artificial intelligence; and
                          ``(v) chemical, biological, radiological 
                        (including neutron, electron, and graviton), 
                        and other means of detection;
                  ``(B) identify demand reduction (including drug 
                prevention) basic and applied research needs and 
                initiatives, in consultation with affected National 
                Drug Control Program agencies, including--
                          ``(i) improving treatment through 
                        neuroscientific advances;
                          ``(ii) improving the transfer of biomedical 
                        research to the clinical setting; and
                          ``(iii) in consultation with the National 
                        Institute on Drug Abuse and the Substance Abuse 
                        and Mental Health Services Administration, and 
                        through interagency agreements or grants, 
                        examining addiction and rehabilitation research 
                        and the application of technology to expanding 
                        the effectiveness or availability of drug 
                        treatment;
                  ``(C) make a priority ranking of such needs 
                identified in subparagraphs (A) and (B) according to 
                fiscal and technological feasibility, as part of a 
                National Counterdrug Research and Development Program;
                  ``(D) oversee and coordinate counterdrug technology 
                initiatives with related activities of other Federal 
                civilian and military departments;
                  ``(E) provide support to the development and 
                implementation of the national drug control performance 
                measurement system established under subsection (b) of 
                section 706;
                  ``(F) with the advice and counsel of experts from 
                State and local law enforcement agencies, oversee and 
                coordinate a technology transfer program for the 
                transfer of technology to State and local law 
                enforcement agencies; and
                  ``(G) pursuant to the authority of the Director of 
                National Drug Control Policy under section 704, submit 
                requests to Congress for the reprogramming or transfer 
                of funds appropriated for counterdrug technology 
                research and development.
          ``(2) Priorities in transferring technology.--
                  ``(A) In general.--The Chief Scientist shall give 
                priority, in transferring technology under paragraph 
                (1)(F), based on the following criteria:
                          ``(i) the need of potential recipients for 
                        such technology;
                          ``(ii) the effectiveness of the technology to 
                        enhance current counterdrug activities of 
                        potential recipients; and
                          ``(iii) the ability and willingness of 
                        potential recipients to evaluate transferred 
                        technology.
                  ``(B) Interdiction and border drug law enforcement 
                technologies.--The Chief Scientist shall give priority, 
                in transferring technologies most likely to assist in 
                drug interdiction and border drug law enforcement, to 
                State, local, and tribal law enforcement agencies in 
                southwest border areas and northern border areas with 
                significant traffic in illicit drugs.
          ``(3) Limitation on authority.--The authority granted to the 
        Director under this subsection shall not extend to the direct 
        management of individual projects or other operational 
        activities.
          ``(4) Report.--On or before July 1 of each year, the Director 
        shall submit a report to the appropriate congressional 
        committees that addresses the following:
                  ``(A) The number of requests received during the 
                previous 12 months, including the identity of each 
                requesting agency and the type of technology requested.
                  ``(B) The number of requests fulfilled during the 
                previous 12 months, including the identity of each 
                recipient agency and the type of technology 
                transferred.
                  ``(C) A summary of the criteria used in making the 
                determination on what requests were funded and what 
                requests were not funded, except that such summary 
                shall not include specific information on any 
                individual requests.
                  ``(D) A general assessment of the future needs of the 
                program, based on expected changes in threats, expected 
                technologies, and likely need from potential 
                recipients.
                  ``(E) An assessment of the effectiveness of the 
                technologies transferred, based in part on the 
                evaluations provided by the recipients, with a 
                recommendation whether the technology should continue 
                to be offered through the program.''.
  (c) Assistance From Secretary of Homeland Security.--Section 708(d) 
(21 U.S.C. 1707(d)) is amended by inserting ``, the Secretary of 
Homeland Security,'' after ``The Secretary of Defense''.

SEC. 12. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN.

  (a) In General.--Section 709 (21 U.S.C. 1708) is amended to read as 
follows:

``SEC. 709. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN.

  ``(a) In General.--The Director shall conduct a national youth anti-
drug media campaign (referred to in this subtitle as the `national 
media campaign') in accordance with this section for the purposes of--
          ``(1) preventing drug abuse among young people in the United 
        States;
          ``(2) increasing awareness of adults of the impact of drug 
        abuse on young people; and
          ``(3) encouraging parents and other interested adults to 
        discuss with young people the dangers of illegal drug use.
  ``(b) Use of Funds.--
          ``(1) In general.--Amounts made available to carry out this 
        section for the national media campaign may only be used for 
        the following:
                  ``(A) The purchase of media time and space, including 
                the strategic planning for, and accounting of, such 
                purchases.
                  ``(B) Creative and talent costs, consistent with 
                paragraph (2)(A).
                  ``(C) Advertising production costs.
                  ``(D) Testing and evaluation of advertising.
                  ``(E) Evaluation of the effectiveness of the national 
                media campaign.
                  ``(F) The negotiated fees for the winning bidder on 
                requests for proposals issued either by the Office or 
                its designee to enter into contracts to carry out 
                activities authorized by this section.
                  ``(G) Partnerships with professional and civic 
                groups, community-based organizations, including faith-
                based organizations, and government organizations 
                related to the national media campaign.
                  ``(H) Entertainment industry outreach, interactive 
                outreach, media projects and activities, public 
                information, news media outreach, and corporate 
                sponsorship and participation.
                  ``(I) Operational and management expenses.
          ``(2) Specific requirements.--
                  ``(A) Creative services.--
                          ``(i) In using amounts for creative and 
                        talent costs under paragraph (1)(B), the 
                        Director shall use creative services donated at 
                        no cost to the Government (including creative 
                        services provided by the Partnership for a 
                        Drug-Free America) wherever feasible and may 
                        only procure creative services for 
                        advertising--
                                  ``(I) responding to high-priority or 
                                emergent campaign needs that cannot 
                                timely be obtained at no cost; or
                                  ``(II) intended to reach a minority, 
                                ethnic, or other special audience that 
                                cannot reasonably be obtained at no 
                                cost; or
                                  ``(III) the Director determines that 
                                the Partnership for a Drug-Free America 
                                is unable to provide, pursuant to 
                                subsection (d)(2)(B).
                          ``(ii) No more than $1,500,000 may be 
                        expended under this section each fiscal year on 
                        creative services, except that the Director may 
                        expend up to $2,000,000 in a fiscal year on 
                        creative services to meet urgent needs of the 
                        national media campaign with advance approval 
                        from the Committee on Appropriations of the 
                        House of Representatives and of the Senate upon 
                        a showing of the circumstances causing such 
                        urgent needs of the national media campaign.
                  ``(B) Testing and evaluation of advertising.--In 
                using amounts for testing and evaluation of advertising 
                under paragraph (1)(D), the Director shall test all 
                advertisements prior to use in the national media 
                campaign to ensure that the advertisements are 
                effective and meet industry-accepted standards. The 
                Director may waive this requirement for advertisements 
                using no more than 10 percent of the purchase of 
                advertising time purchased under this section in a 
                fiscal year and no more than 10 percent of the 
                advertising space purchased under this section in a 
                fiscal year, if the advertisements respond to emergent 
                and time-sensitive campaign needs or the advertisements 
                will not be widely utilized in the national media 
                campaign.
                  ``(C) Evaluation of effectiveness of media 
                campaign.--In using amounts for the evaluation of the 
                effectiveness of the national media campaign under 
                paragraph (1)(E), the Director shall--
                          ``(i) designate an independent entity to 
                        evaluate annually the effectiveness of the 
                        national media campaign based on data from--
                                  ``(I) the Monitoring the Future Study 
                                published by the Department of Health 
                                and Human Services;
                                  ``(II) the Attitude Tracking Study 
                                published by the Partnership for a Drug 
                                Free America;
                                  ``(III) the National Household Survey 
                                on Drug Abuse; and
                                  ``(IV) other relevant studies or 
                                publications, as determined by the 
                                Director, including tracking and 
                                evaluation data collected according to 
                                marketing and advertising industry 
                                standards; and
                          ``(ii) ensure that the effectiveness of the 
                        national media campaign is evaluated in a 
                        manner that enables consideration of whether 
                        the national media campaign has contributed to 
                        reduction of illicit drug use among youth and 
                        such other measures of evaluation as the 
                        Director determines are appropriate.
          ``(3) Purchase of advertising time and space.--For each 
        fiscal year, not less than 77 percent of the amounts 
        appropriated under this section shall be used for the purchase 
        of advertising time and space for the national media campaign, 
        subject to the following exceptions:
                  ``(A) In any fiscal year for which less than 
                $125,000,000 is appropriated for the national media 
                campaign, not less than 82 percent of the amounts 
                appropriated under this section shall be used for the 
                purchase of advertising time and space for the national 
                media campaign.
                  ``(B) In any fiscal year for which more than 
                $195,000,000 is appropriated under this section, not 
                less than 72 percent shall be used for advertising 
                production costs and the purchase of advertising time 
                and space for the national media campaign.
  ``(c) Advertising.--In carrying out this section, the Director shall 
ensure that sufficient funds are allocated to meet the stated goals of 
the national media campaign.
  ``(d) Division of Responsibilities and Functions Under the Program.--
          ``(1) In general.--The Director, in consultation with the 
        Partnership for a Drug-Free America, shall determine the 
        overall purposes and strategy of the national media campaign.
          ``(2) Responsibilities.--
                  ``(A) Director.--The Director shall be responsible 
                for implementing a focused national media campaign to 
                meet the purposes set forth in subsection (a), and 
                shall approve--
                          ``(i) the strategy of the national media 
                        campaign;
                          ``(ii) all advertising and promotional 
                        material used in the national media campaign; 
                        and
                          ``(iii) the plan for the purchase of 
                        advertising time and space for the national 
                        media campaign.
                  ``(B) The partnership for a drug-free america.--The 
                Director shall request that the Partnership for a Drug-
                Free America--
                          ``(i) develop and recommend strategies to 
                        achieve the goals of the national media 
                        campaign, including addressing national and 
                        local drug threats in specific regions or 
                        States, such as methamphetamine and ecstasy;
                          ``(ii) create all advertising to be used in 
                        the national media campaign, except 
                        advertisements that are--
                                  ``(I) provided by other nonprofit 
                                entities pursuant to subsection (f);
                                  ``(II) intended to respond to high-
                                priority or emergent campaign needs 
                                that cannot timely be obtained at no 
                                cost (not including production costs 
                                and talent reuse payments), provided 
                                that any such advertising material is 
                                reviewed by the Partnership for a Drug-
                                Free America;
                                  ``(III) intended to reach a minority, 
                                ethnic, or other special audience that 
                                cannot be obtained at no cost (not 
                                including production costs and talent 
                                reuse payments), provided that any such 
                                advertising material is reviewed by the 
                                Partnership for a Drug-Free America; or
                                  ``(IV) any other advertisements that 
                                the Director determines that the 
                                Partnership for a Drug-Free America is 
                                unable to provide.
                  ``(C) Media buying contractor.--The Director shall 
                enter into a contract with a media buying contractor to 
                plan and purchase advertising time and space for the 
                national media campaign. The media buying contractor 
                shall not provide any other service or material, or 
                conduct any other function or activity which the 
                Director determines should be provided by the 
                Partnership for a Drug-Free America.
  ``(e) Prohibitions.--None of the amounts made available under 
subsection (b) may be obligated or expended for any of the following:
          ``(1) To supplant current antidrug community-based 
        coalitions.
          ``(2) To supplant pro bono public service time donated by 
        national and local broadcasting networks for other public 
        service campaigns.
          ``(3) For partisan political purposes, or express advocacy in 
        support of or to defeat any clearly identified candidate, 
        clearly identified ballot initiative, or clearly identified 
        legislative or regulatory proposal.
          ``(4) To fund advertising that features any elected 
        officials, persons seeking elected office, cabinet level 
        officials, or other Federal officials employed pursuant to 
        section 213 of Schedule C of title 5, Code of Federal 
        Regulations.
          ``(5) To fund advertising that does not contain a primary 
        message intended to reduce or prevent illicit drug use.
          ``(6) To fund advertising containing a primary message 
        intended to promote support for the media campaign or private 
        sector contributions to the media campaign.
  ``(f) Matching Requirement.--
          ``(1) In general.--Amounts made available under subsection 
        (b) for media time and space shall be matched by an equal 
        amount of non-Federal funds for the national media campaign, or 
        be matched with in-kind contributions of the same value.
          ``(2) No-cost match advertising direct relationship 
        requirement.--The Director shall ensure that at least 70 
        percent of no-cost match advertising provided directly relates 
        to substance abuse prevention consistent with the specific 
        purposes of the national media campaign, except that in any 
        fiscal year in which less than $125,000,000 is appropriated to 
        the national media campaign, the Director shall ensure that at 
        least 85 percent of no-cost match advertising directly relates 
        to substance abuse prevention consistent with the specific 
        purposes of the national media campaign.
          ``(3) No-cost match advertising not directly related.--The 
        Director shall ensure that no-cost match advertising that does 
        not directly relate to substance abuse prevention consistent 
        with the purposes of the national media campaign includes a 
        clear antidrug message. Such message is not required to be the 
        primary message of the match advertising.
  ``(g) Financial and Performance Accountability.--The Director shall 
cause to be performed--
          ``(1) audits and reviews of costs of the national media 
        campaign pursuant to section 304C of the Federal Property and 
        Administrative Services Act of 1949 (41 U.S.C. 254d); and
          ``(2) an audit to determine whether the costs of the national 
        media campaign are allowable under section 306 of such Act (41 
        U.S.C. 256).
  ``(h) Report to Congress.--The Director shall submit on an annual 
basis a report to Congress that describes--
          ``(1) the strategy of the national media campaign and whether 
        specific objectives of the media campaign were accomplished;
          ``(2) steps taken to ensure that the national media campaign 
        operates in an effective and efficient manner consistent with 
        the overall strategy and focus of the national media campaign;
          ``(3) plans to purchase advertising time and space;
          ``(4) policies and practices implemented to ensure that 
        Federal funds are used responsibly to purchase advertising time 
        and space and eliminate the potential for waste, fraud, and 
        abuse; and
          ``(5) all contracts entered into with a corporation, 
        partnership, or individual working on behalf of the national 
        media campaign.
  ``(i) Local Target Requirement.--The Director shall, to the maximum 
extent feasible, use amounts made available under this section for 
media that focuses on, or includes specific information on, prevention 
or treatment resources for consumers within specific local areas.
  ``(j) Prevention of Marijuana Use.--
          ``(1) Findings.--The Congress finds the following:
                  ``(A) 60 percent of adolescent admissions for drug 
                treatment are based on marijuana use.
                  ``(B) Potency levels of contemporary marijuana, 
                particularly hydroponically grown marijuana, are 
                significantly higher than in the past, rising from 
                under 1 percent of THC in the mid-1970s to as high as 
                30 percent today.
                  ``(C) Contemporary research has demonstrated that 
                youths smoking marijuana early in life may be up to 
                five times more likely to use hard drugs.
                  ``(D) Contemporary research has demonstrated clear 
                detrimental effects in adolescent educational 
                achievement resulting from marijuana use.
                  ``(E) Contemporary research has demonstrated clear 
                detrimental effects in adolescent brain development 
                resulting from marijuana use.
                  ``(F) An estimated 9,000,000 Americans a year drive 
                while under the influence of illegal drugs, including 
                marijuana.
                  ``(G) Marijuana smoke contains 50 to 70 percent more 
                of certain cancer causing chemicals than tobacco smoke.
                  ``(H) Teens who use marijuana are up to four times 
                more likely to have a teen pregnancy than teens who 
                have not.
                  ``(I) Federal law enforcement agencies have 
                identified clear links suggesting that trade in 
                hydroponic marijuana facilitates trade by criminal 
                organizations in hard drugs, including heroin.
                  ``(J) Federal law enforcement agencies have 
                identified possible links between trade in cannabis 
                products and financing for terrorist organizations.
          ``(2) Emphasis on prevention of youth marijuana use.--In 
        conducting advertising and activities otherwise authorized 
        under this section, the Director may emphasize prevention of 
        youth marijuana use.
  ``(k) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office to carry out this section, $195,000,000 for 
each of fiscal years 2007 and 2008 and $210,000,000 for each of fiscal 
years 2009 through 2011.''.
  (b) Repeal of Superseded Provisions.--The Drug-Free Media Campaign 
Act of 1998 (21 U.S.C. 1801 et seq.) is repealed.

SEC. 13. DRUG INTERDICTION.

  (a) In General.--Subsections (a) and (b) of section 711 (21 U.S.C. 
1710) are amended to read as follows:
  ``(a) United States Interdiction Coordinator.--
          ``(1) In general.--The Deputy Director for Supply Reduction 
        in the Office shall serve as the United States Interdiction 
        Coordinator, and shall perform the duties of that position 
        described in paragraph (2) and such other duties as may be 
        determined by the Director with respect to coordination of 
        efforts to interdict illicit drugs from entering the United 
        States.
          ``(2) Responsibilities.--The United States Interdiction 
        Coordinator shall be responsible to the Director for--
                  ``(A) coordinating the interdiction activities of the 
                National Drug Control Program agencies to ensure 
                consistency with the National Drug Control Strategy;
                  ``(B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and in 
                accordance with paragraph (3), a National Interdiction 
                Command and Control Plan to ensure the coordination and 
                consistency described in subparagraph (A);
                  ``(C) assessing the sufficiency of assets committed 
                to illicit drug interdiction by the relevant National 
                Drug Control Program agencies; and
                  ``(D) advising the Director on the efforts of each 
                National Drug Control Program agency to implement the 
                National Interdiction Command and Control Plan.
          ``(3) Staff.--The Director shall assign such permanent staff 
        of the Office as he considers appropriate to assist the United 
        States Interdiction Coordinator to carry out the 
        responsibilities described in paragraph (2), and may also, at 
        his discretion, request that appropriate National Drug Control 
        Program agencies detail or assign staff to the Office of Supply 
        Reduction for that purpose.
          ``(4) National interdiction command and control plan.--
                  ``(A) Purposes.--The National Interdiction Command 
                and Control Plan shall--
                          ``(i) set forth the Government's strategy for 
                        drug interdiction;
                          ``(ii) state the specific roles and 
                        responsibilities of the relevant National Drug 
                        Control Program agencies for implementing that 
                        strategy; and
                          ``(iii) identify the specific resources 
                        required to enable the relevant National Drug 
                        Control Program agencies to implement that 
                        strategy.
                  ``(B) Consultation with other agencies.--The United 
                States Interdiction Coordinator shall issue the 
                National Interdiction Command and Control Plan in 
                consultation with the other members of the Interdiction 
                Committee described in subsection (b).
                  ``(C) Limitation.--The National Interdiction Command 
                and Control Plan shall not change existing agency 
                authorities or the laws governing interagency 
                relationships, but may include recommendations about 
                changes to such authorities or laws.
                  ``(D) Report to congress.--On or before March 1 of 
                each year, the United States Interdiction Coordinator 
                shall provide a report on behalf of the Director to the 
                appropriate congressional committees, to the Committee 
                on Armed Services and the Committee on Homeland 
                Security of the House of Representatives, and to the 
                Committee on Homeland Security and Governmental Affairs 
                and the Committee on Armed Services of the Senate, 
                which shall include--
                          ``(i) a copy of that year's National 
                        Interdiction Command and Control Plan;
                          ``(ii) information for the previous 10 years 
                        regarding the number and type of seizures of 
                        drugs by each National Drug Control Program 
                        agency conducting drug interdiction activities, 
                        as well as statistical information on the 
                        geographic areas of such seizures; and
                          ``(iii) information for the previous 10 years 
                        regarding the number of air and maritime patrol 
                        hours undertaken by each National Drug Control 
                        Program agency conducting drug interdiction 
                        activities, as well as statistical information 
                        on the geographic areas in which such patrol 
                        hours took place.
                  ``(E) Treatment of classified or law enforcement 
                sensitive information.--Any content of the report 
                described in subparagraph (D) that involves information 
                classified under criteria established by an Executive 
                order, or the public disclosure of which, as determined 
                by the United States Interdiction Coordinator or the 
                head of any relevant National Drug Control Program 
                agency, would be detrimental to the law enforcement or 
                national security activities of any Federal, State, or 
                local agency, shall be presented to Congress separately 
                from the rest of the plan.
  ``(b) Interdiction Committee.--
          ``(1) In general.--The Interdiction Committee shall meet to--
                  ``(A) discuss and resolve issues related to the 
                coordination, oversight and integration of 
                international, border, and domestic drug interdiction 
                efforts in support of the National Drug Control 
                Strategy;
                  ``(B) review the annual National Interdiction Command 
                and Control Plan, and provide advice to the Director 
                and the United States Interdiction Coordinator 
                concerning that plan; and
                  ``(C) provide such other advice to the Director 
                concerning drug interdiction strategy and policies as 
                the committee determines is appropriate.
          ``(2) Membership.--The membership of the Interdiction 
        Committee shall consist of--
                  ``(A) the Commissioner of the bureau of Customs and 
                Border Protection at the Department of Homeland 
                Security;
                  ``(B) the Assistant Secretary of the bureau of 
                Immigration and Customs Enforcement at the Department 
                of Homeland Security;
                  ``(C) the Commandant of the United States Coast 
                Guard;
                  ``(D) the Director of the Office of Counternarcotics 
                Enforcement at the Department of Homeland Security;
                  ``(E) the Administrator of the Drug Enforcement 
                Administration;
                  ``(F) the Assistant Secretary of State for 
                International Narcotics and Law Enforcement Affairs;
                  ``(G) the Assistant Secretary of Defense for Special 
                Operations and Low Intensity Conflict;
                  ``(H) the Deputy Director for Supply Reduction of the 
                Office of National Drug Control Policy, acting in his 
                role as the United States Interdiction Coordinator;
                  ``(I) the director of the Crime and Narcotics Center 
                of the Central Intelligence Agency;
                  ``(J) the Deputy Director for State and Local Affairs 
                of the Office of National Drug Control Policy;
                  ``(K) the Chief of the National Guard Bureau's 
                Counterdrug Program; and
                  ``(L) such additional persons as may be determined by 
                the Director.
          ``(3) Chairman.--The Director shall designate one of the 
        members of the Interdiction Committee to serve as chairman.
          ``(4) Meetings.--The members of the Interdiction Committee 
        shall meet, in person and not through any delegate or 
        representative, at least once per calendar year, prior to March 
        1. At the call of either the Director or the current chairman, 
        the Interdiction Committee may hold additional meetings, which 
        shall be attended by the members either in person, or through 
        such delegates or representatives as they may choose.
          ``(5) Report.--Not later than September 30 of each year, the 
        chairman of the Interdiction Committee shall submit a report to 
        the Director and to the appropriate congressional committees 
        describing the results of the meetings and any significant 
        findings of the Committee during the previous 12 months. Any 
        content of such a report that involves information classified 
        under criteria established by an Executive order, or whose 
        public disclosure, as determined by the Director, the chairman, 
        or any member, would be detrimental to the law enforcement or 
        national security activities of any Federal, State, or local 
        agency, shall be presented to Congress separately from the rest 
        of the report.''.
  (b) Conforming Amendment to Homeland Security Act of 2002.--Section 
878 of the Homeland Security Act of 2002 (6 U.S.C. 458) is amended--
          (1) in subsection (c), by striking ``Except as provided in 
        subsection (d), the'' and inserting ``The''; and
          (2) by striking subsection (d) and redesignating subsections 
        (e), (f), and (g) as subsections (d), (e), and (f), 
        respectively.

SEC. 14. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
                    SHUT DOWN ILLICIT DRUG MARKET HOT-SPOTS BY 
                    DETERRING DRUG DEALERS OR ALTERING THE DYNAMIC OF 
                    DRUG SALES.

  Sections 713 and 714 (21 U.S.C. 1711) are redesignated as sections 
715 and 716, respectively, and after section 712 (21 U.S.C. 1710) 
insert the following new section:

``SEC. 713. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
                    SHUT DOWN ILLICIT DRUG MARKET HOT-SPOTS BY 
                    DETERRING DRUG DEALERS OR ALTERING THE DYNAMIC OF 
                    DRUG SALES.

  ``(a) Awards Required.--The Director shall make competitive awards 
for demonstration programs by eligible partnerships for the purpose of 
shutting down local illicit drug market hot-spots and reducing drug-
related crime through evidence-based, strategic problem-solving 
interventions that deter drug dealers or alter the dynamic of drug 
sales.
  ``(b) Use of Award Amounts.--Award amounts received under this 
section shall be used--
          ``(1) to support the efforts of the agencies, organizations, 
        and researchers included in the eligible partnership;
          ``(2) to develop and field a directed and credible deterrent 
        threat; and
          ``(3) to strengthen rehabilitation efforts through such means 
        as job training, drug treatment, or other services.
  ``(c) Eligible Partnership Defined.--In this section, the term 
`eligible partnership' means a working group whose application to the 
Director--
          ``(1) identifies the roles played, and certifies the 
        involvement of, three or more agencies or organizations, which 
        may include--
                  ``(A) State or local agencies (such as those carrying 
                out police, probation, prosecution, courts, 
                corrections, parole, or treatment functions);
                  ``(B) Federal agencies (such as the Drug Enforcement 
                Agency, the Bureau of Alcohol, Tobacco, Firearms, and 
                Explosives, and United States Attorney offices); and
                  ``(C) community-based organizations;
          ``(2) includes a qualified researcher;
          ``(3) includes a plan for identifying the impact players in, 
        and assessing the nature and dynamic of, the local drug market 
        and its related crime through information gathering and 
        analysis;
          ``(4) includes a plan for developing an evidence-based 
        strategic intervention aimed at quickly and sustainably 
        eradicating the local drug market by deterring drug dealers or 
        altering the dynamic of drug sales; and
          ``(5) includes a plan that describes the methodology and 
        outcome measures proposed for evaluating the impact of that 
        strategic intervention on drug sales, neighborhood disorder, 
        and crime.
  ``(d) Reports to Congress.--
          ``(1) Interim report.--Not later than June 1, 2009, the 
        Director shall submit to Congress a report that identifies the 
        best practices in drug market eradication, including the best 
        practices identified through the activities funded under this 
        section.
          ``(2) Final report.--Not later than June 1, 2010, the 
        Director shall submit to Congress a report on the demonstration 
        programs funded under this section, including on the matters 
        specified in paragraph (1).
  ``(e) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $10,000,000 for each of fiscal 
years 2007 through 2009.''.

SEC. 15. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
                    COERCE ABSTINENCE IN CHRONIC HARD-DRUG USERS UNDER 
                    COMMUNITY SUPERVISION THROUGH THE USE OF DRUG 
                    TESTING AND SANCTIONS.

  After section 713, as inserted by section 14 of this Act, insert the 
following new section:

``SEC. 714. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
                    COERCE ABSTINENCE IN CHRONIC HARD-DRUG USERS UNDER 
                    COMMUNITY SUPERVISION THROUGH THE USE OF DRUG 
                    TESTING AND SANCTIONS.

  ``(a) Awards Required.--The Director shall make competitive awards to 
fund demonstration programs by eligible partnerships for the purpose of 
reducing the use of illicit drugs by chronic hard-drug users living in 
the community while under the supervision of the criminal justice 
system.
  ``(b) Use of Award Amounts.--Award amounts received under this 
section shall be used--
          ``(1) to support the efforts of the agencies, organizations, 
        and researchers included in the eligible partnership;
          ``(2) to develop and field a drug testing and graduated 
        sanctions program for chronic hard-drug users living in the 
        community under criminal justice supervision; and
          ``(3) to assist individuals described in subsection (a) by 
        strengthening rehabilitation efforts through such means as job 
        training, drug treatment, or other services.
  ``(c) Eligible Partnership Defined.--In this section, the term 
`eligible partnership' means a working group whose application to the 
Director--
          ``(1) identifies the roles played, and certifies the 
        involvement of, two or more agencies or organizations, which 
        may include--
                  ``(A) State or local agencies (such as those carrying 
                out police, probation, prosecution, courts, 
                corrections, parole, or treatment functions);
                  ``(B) Federal agencies (such as the Drug Enforcement 
                Agency, the Bureau of Alcohol, Tobacco, Firearms, and 
                Explosives, and United States Attorney offices); and
                  ``(C) community-based organizations;
          ``(2) includes a qualified researcher;
          ``(3) includes a plan for using judicial or other criminal 
        justice authority to administer drug tests to individuals 
        described in subsection (a) at least twice a week, and to 
        swiftly and certainly impose a known set of graduated sanctions 
        for non-compliance with community-release provisions relating 
        to drug abstinence (whether imposed as a pre-trial, probation, 
        or parole condition or otherwise);
          ``(4) includes a strategy for responding to a range of 
        substance use and abuse problems and a range of criminal 
        histories;
          ``(5) includes a plan for integrating data infrastructure 
        among the agencies and organizations included in the eligible 
        partnership to enable seamless, real-time tracking of 
        individuals described in subsection (a);
          ``(6) includes a plan to monitor and measure the progress 
        toward reducing the percentage of the population of individuals 
        described in subsection (a) who, upon being summoned for a drug 
        test, either fail to show up or who test positive for drugs.
  ``(d) Reports to Congress.--
          ``(1) Interim report.--Not later than June 1, 2009, the 
        Director shall submit to Congress a report that identifies the 
        best practices in reducing the use of illicit drugs by chronic 
        hard-drug users, including the best practices identified 
        through the activities funded under this section.
          ``(2) Final report.--Not later than June 1, 2010, the 
        Director shall submit to Congress a report on the demonstration 
        programs funded under this section, including on the matters 
        specified in paragraph (1).
  ``(e) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $10,000,000 for each of fiscal 
years 2007 through 2009.''.

SEC. 16. AUTHORIZATION OF APPROPRIATIONS.

  Section 716 (21 U.S.C. 1711), as redesignated by section 14 of this 
Act, is amended--
          (1) by striking ``title,'' and inserting ``title, except 
        activities for which amounts are otherwise specifically 
        authorized by this title,''; and
          (2) by striking ``1999 through 2003'' and inserting ``2007 
        through 2011''.

SEC. 17. TECHNICAL AMENDMENTS AND REPEAL.

  (a) Amendment to Public Health Service Act to Replace Obsolete 
References.--Section 464P(c) of the Public Health Service Act (42 
U.S.C. 285o-4(c)) is amended--
          (1) in paragraph (1), by striking ``under section 1002 of the 
        Anti-Drug Abuse Act of 1988 (21 U.S.C. 1501)'' and inserting 
        ``under section 703 of the Office of National Drug Control 
        Policy Reauthorization Act of 1998 (21 U.S.C. 1702)''; and
          (2) in paragraph (2), by striking ``under section 1005 of the 
        Anti-Drug Abuse Act of 1988 (21 U.S.C. 1504)'' and inserting 
        ``under section 706 of the Office of National Drug Control 
        Policy Reauthorization Act of 1998 (21 U.S.C. 1705)''.
  (b) Repeal of Special Forfeiture Fund.--Section 6073 of the Asset 
Forfeiture Amendments Act of 1988 (21 U.S.C. 1509) is repealed.

SEC. 18. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP OF ALL 
                    FEDERAL ADVERTISING OR OTHER COMMUNICATION 
                    MATERIALS.

  Section 712 is amended to read as follows:

``SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP OF ALL 
                    FEDERAL ADVERTISING OR OTHER COMMUNICATION 
                    MATERIALS.

  ``(a) Requirement.--Each advertisement or other communication paid 
for by the Office, either directly or through a contract awarded by the 
Office, shall include a prominent notice informing the target audience 
that the advertisement or other communication is paid for by the 
Office.
  ``(b) Advertisement or Other Communication.--In this section, the 
term `advertisement or other communication' includes--
          ``(1) an advertisement disseminated in any form, including 
        print or by any electronic means; and
          ``(2) a communication by an individual in any form, including 
        speech, print, or by any electronic means.''.

SEC. 19. POLICY RELATING TO SYRINGE EXCHANGE PROGRAMS.

  Section 703(a) (21 U.S.C. 1702(a)) is amended by adding at the end 
the following:
``When developing the national drug control policy, any policy of the 
Director relating to syringe exchange programs for intravenous drug 
users shall be based on the best available medical and scientific 
evidence regarding their effectiveness in promoting individual health 
and preventing the spread of infectious disease, and their impact on 
drug addiction and use. In making any policy relating to syringe 
exchange programs, the Director shall consult with the National 
Institutes of Health and the National Academy of Sciences.''.

                          Purpose and Summary

    The purpose of H.R. 2829, the ``Office of National Drug 
Control Policy Reauthorization Act of 2005,'' is to reauthorize 
the Office of National Drug Control Policy (ONDCP) within the 
Executive Office of the President for five years, through the 
end of Fiscal Year (FY) 2010. It also renews congressional 
authorization for national programs administered by ONDCP, 
including the National Youth Anti-Drug Media Campaign and the 
High Intensity Drug Trafficking Areas (HIDTA) program. The 
office was originally created in 1988 and serves as the 
President's principal advisor with respect to drug control 
policy development and program oversight. ONDCP's current 
statutory mission is to guide the Nation's efforts to both 
reduce the use, manufacturing, and trafficking of illicit 
drugs, and to reduce the associated crime, violence, and health 
consequences of illegal drug use.
    H.R. 2829 was referred to the House Committees on 
Government Reform, Intelligence, Energy and Commerce, and the 
Judiciary on June 9th, 2005. This legislation was reported as 
amended by the Committee on Government Reform on November 18th, 
2005 (H.R. Rept. No. 109-315, Part I). The Committees on the 
Judiciary, Intelligence, and Energy and Commerce received 
extensions on the referral to March 3rd, 2006.

                Background and Need for the Legislation

    Since Congress established ONDCP in 1988, the office has 
been the cornerstone of Federal drug policy in the United 
States, improving the lives of all Americans by reducing the 
impact of drugs and the consequences of their abuse in our 
society and communities. The ONDCP Director advises the 
President on national and international drug control policies 
and strategies, formulates the National Drug Control Strategy, 
reviews and certifies the budgets of National Drug Control 
Program Agencies, and works to ensure the effective 
coordination of drug programs by the National Drug Control 
Program agencies.
    The last authorization for the Office of National Drug 
Control Policy (ONDCP) expired on September 30, 2003. ONDCP's 
statutory mission is to guide the Nation's efforts to reduce 
the use, manufacturing, and trafficking of illicit drugs, and 
to reduce the associated crime, violence, and health 
consequences of illegal drug use. Its Director serves as the 
principal advisor to the President on drug control policy 
development and program oversight. Congress established ONDCP 
through the Anti-Drug Abuse Act of 1988, and reauthorized it in 
1993 and 1998. During the 108th Congress, the Committee 
approved, and the House subsequently passed, a reauthorization 
bill (H.R. 2086) in 2003. However, the Senate did not act on 
this legislation. Despite the lack of statutory authorization, 
Congress has continued to appropriate funds for ONDCP and its 
programs.
    The Director reviews the annual budget requests for each 
Federal department and agency charged with implementing a 
Federal drug control program and is empowered to require 
funding levels and initiatives the Director believes are 
sufficient to accomplish those goals. Additionally, the 
National Drug Control Strategy is submitted to Congress 
annually to coordinate the Nation's anti-drug efforts and 
establish programs, budgets, and guidelines for cooperation 
among Federal, State, and local entities. This document 
contains a number of mandated statistics and assessments 
related to drug policy and serves as a strategic review of 
Federal programs by evaluating their coordination and 
effectiveness.
    ONDCP also administers approximately $500 million in 
programs, including: the High Intensity Drug Trafficking Areas 
(HIDTA) program, which provides assistance for State and local 
law enforcement to coordinate with Federal agencies to assist 
in the prevention of drug trafficking in critical areas of the 
country that have an impact on the national drug market; the 
National Youth Anti-Drug Media Campaign, which supports the 
airing of anti-drug television and print ads; the Drug-Free 
Communities grant program; and the Counter Drug Technology 
Assessment Center (CTAC).
    To assist in these responsibilities at a senior level, 
ONDCP also authorizes a Deputy Director of National Drug 
Control Policy and Deputy Directors for Demand Reduction, 
Supply Reduction, and State and Local Affairs, all of whom are 
appointed by the President with the advice and consent of the 
Senate. ONDCP has a total staff of approximately 110 employees 
and an overall budget of approximately $520 million.

                                Hearings

    The House Committee on the Judiciary held no hearings on 
H.R. 2829.

                        Committee Consideration

    On June 9, 2005, the House Committee on the Judiciary 
received a referral of H.R. 2829. On March 2, 2006, the 
Committee met in open session and ordered favorably reported 
the bill H.R. 2829, as amended, by voice vote, a quorum being 
present.

                         Vote of the Committee

    In compliance with clause 3(b) of rule XIII of the Rules of 
the House of Representatives, the Committee notes that there 
were no recorded votes during the Committee consideration of 
H.R. 2829.

                      Committee Oversight Findings

    In compliance with clause 3(c)(1) of rule XIII of the Rules 
of the House of Representatives, the Committee reports that the 
findings and recommendations of the Committee, based on 
oversight activities under clause 2(b)(1) of rule X of the 
Rules of the House of Representatives, are incorporated in the 
descriptive portions of this report.

               New Budget Authority and Tax Expenditures

    Clause 3(c)(2) of rule XIII of the Rules of the House of 
Representatives is inapplicable because this legislation does 
not provide new budgetary authority or increased tax 
expenditures.

               Congressional Budget Office Cost Estimate

    In compliance with clause 3(c)(3) of rule XIII of the Rules 
of the House of Representatives, the Committee sets forth, with 
respect to the bill, H.R. 2859, the following estimate and 
comparison prepared by the Director of the Congressional Budget 
Office under section 402 of the Congressional Budget Act of 
1974.
                                                     March 3, 2006.
Hon. F. James Sensenbrenner, Jr.,
Chairman, Committee on the Judiciary
U.S. House of Representatives, Washington, DC 20515
    Dear Mr. Chairman: The Congressional Budget Office has 
prepared the enclosed estimate for H.R. 2829, a bill to 
reauthorize the Office of National Drug Control Policy Act.
    If you wish further details on this estimate, we will be 
pleased to provide them. The CBO staff contact is Matthew 
Pickford, who can be reached at 226-2860.
            Sincerely,
                                          Donald B. Marron,
                                                   Acting Director.
    Enclosure.

H.R. 2829--A bill to reauthorize the Office of National Drug Control 
        Policy Act

    Summary: H.R. 2829 would reauthorize operations of the 
Office of National Drug Control Policy (ONDCP) and programs 
administered by that office through 2011. Major programs 
administered by ONDCP include the High-Intensity Drug 
Trafficking Areas program, the National Youth Anti-Drug Media 
Campaign, and the Counterdrug Technology Assessment Center.
    Assuming appropriation of the necessary amounts, CBO 
estimates that implementing H.R. 2829 would cost about $3 
billion over the 2007-2011 period. Of this total, about $2.2 
billion would result from amounts specifically authorized for 
the National Youth Anti-Drug Media Campaign and High-Intensity 
Drug Trafficking Areas.
    By reauthorizing ONDCP's authority to accept and spend 
gifts, enacting H.R. 2829 could affect direct spending and 
revenues, but CBO estimates that any such impact would be 
negligible.
    H.R. 2829 contains no intergovernmental or private-sector 
mandates as defined in the Unfunded Mandates Reform Act (UMRA); 
any costs incurred by state, local, or tribal entities would 
result from participating in a voluntary federal program.
    Estimated Cost to the Federal Government: The estimated 
budgetary impact of H.R. 2829 is shown in the following table. 
The costs of this legislation fall within budget functions 750 
(administration of justice) and 800 (general government).

----------------------------------------------------------------------------------------------------------------
                                                            By fiscal year, in millions of dollars--
                                               -----------------------------------------------------------------
                                                   2006       2007       2008       2009       2010       2011
----------------------------------------------------------------------------------------------------------------
                                        SPENDING SUBJECT TO APPROPRIATION

Spending Under Current Law for ONDCP
    Budget Authority \1\......................        479          0          0          0          0          0
    Estimated Outlays.........................        484        196         36         11          0          0
Proposed Changes:
    High-Intensity Drug Trafficking Areas
        Authorization Level...................          0        280        290        290        300        300
        Estimated Outlays.....................          0         70        241        275        292        299
    National Youth Anti-Drug Media Campaign
        Authorization Level...................          0        195        195        210        210        210
        Estimated Outlays.....................          0        176        195        209        210        210
    Demonstration Programs
        Authorization Level...................          0         20         20         20          0          0
        Estimated Outlays.....................          0         18         20         20          2          0
    Other Federal Drug Control Programs
        Estimated Authorization Level.........          0         97         98        100        102        104
        Estimated Outlays.....................          0         81         94         98        100        101
    Counterdrug Technology Assessment Center
        Estimated Authorization Level.........          0         31         31         32         32         33
        Estimated Outlays.....................          0         29         31         32         32         33
    Office of National Drug Control Policy
        Estimated Authorization Level.........          0         28         29         30         30         31
        Estimated Outlays.....................          0         24         28         30         30         31
    Other Provisions
        Estimated Authorization Level.........          0          7          7          7          7          7
        Estimated Outlays.....................          0          6          7          7          7          7
        Total Proposed Changes
            Estimated Authorization Level.....          0        657        670        689        681        685
            Estimated Outlays.................          0        403        615        669        672        680
Total Spending Under H.R. 2829 for ONDCP
    Estimated Authorization Level \1\.........        479        657        670        689        681        685
    Estimated Outlays.........................        484        599        651        680        672       680
----------------------------------------------------------------------------------------------------------------
Notes: Components may not sum to totals because of rounding.
\1\ The 2006 level is the amount appropriated for that year for programs administered by the Office of National
  Drug Control Policy.

    Basis of Estimate: For this estimate, CBO assumes that the 
bill will be enacted during fiscal year 2006, that the 
necessary amounts will be provided each year, and that spending 
will follow historical patterns for the ONDCP and its programs.

Spending subject to appropriation

    The bill would reauthorize all the programs of ONDCP 
through 2011. The current authorization for ONDCP expired at 
the end of fiscal year 2003 (although the office continued to 
receive funding in 2004, 2005, and 2006). Based on information 
from ONDCP and historical spending patterns of the agency, CBO 
estimates that these authorizations, if funded, would result in 
outlays of $403 million in 2007 and about $3 billion over the 
2007-2011 period.
    High-Intensity Drug Trafficking Areas. Section 9 would 
authorize the appropriation of $280 million in fiscal year 
2007, $290 million for 2008 and 2009, and $300 million a year 
for 2009 and 2010 for the High-Intensity Drug Trafficking Areas 
program. This program coordinates drug-control efforts among 
local, state, and federal law enforcement agencies. Assuming 
appropriation of the specified amounts, CBO estimates that 
implementing this provision would cost $70 million in fiscal 
year 2007 and $1.2 billion over the 2007-2011 period.
    National Youth Anti-Drug Media Campaign. Section 12 would 
authorize the appropriation of $195 million in fiscal years 
2007 and 2008 and $210 million a year for the 2009-2011 period 
for the National Youth Anti-Drug Media Campaign (NYADMC) 
program. NYADMC delivers anti-drug messages through mass 
communications to help prevent and reduce youth drug use. 
Assuming appropriation of the specified amounts, CBO estimates 
that implementing this provision would cost $176 million in 
2007 and about $1 billion over the 2007-2011 period.
    Demonstration Programs. Sections 14 and 15 would authorize 
the appropriation of $20 million annually over the 2007-2009 
period to fund two demonstration projects ($10 million per 
program). The demonstration projects would work to reduce drug 
abuse in the criminal justice system and deter illegal drug 
markets. Assuming appropriation of the specified amounts, CBO 
estimates that implementing these provisions would cost $18 
million in 2007 and $60 million over the 2007-2011 period.
    Other Federal Drug Control Programs. H.R. 2829 would 
authorize the appropriation of such sums as necessary to 
operate other federal drug-control programs (excluding NYADMC) 
through fiscal year 2011. Those include the Drug-Free 
Communities program, National Drug Court Institute, and the 
U.S. Anti-Doping Agency. Based on the level of funding for 
2006, information from ONDCP, and adjusting for anticipated 
inflation, CBO estimates that implementing the programs would 
cost $81 million in 2007 and about $475 million over the 2007-
2011 period.
    Counterdrug Technology Assessment Center. The legislation 
would authorize the appropriation of such sums as necessary to 
operate the Counterdrug Assessment Center. The center 
coordinates counterdrug research and development activities for 
the federal government. Because the bill did not specify 
funding levels, CBO estimated the costs by adjusting 2006 
funding for anticipated inflation. On that basis, we estimate 
that operation of the center would cost $29 million in 2007 and 
$157 million over the 2007-2011 period.
    Office of National Drug Control Policy. H.R. 2829 would 
authorize the appropriation of such sums as necessary for 
ONDCP. The office establishes policies, priorities, and 
objectives for federal drug-control programs. Assuming 
appropriation of the necessary amounts, CBO estimates that 
those activities would cost $24 million in 2007 and $141 
million over the 2007-2011 period. This estimate is based on 
historical spending patterns and assumes that the appropriation 
for 2006 is adjusted for anticipated inflation.
    Other Provisions. Section 6 would require ONDCP to produce 
a biannual plan to increase the coordination among federal 
agencies working to combat illegal drug use. Based on 
information from ONDCP, CBO estimates that completing such 
plans would cost $3 million a year.
    Section 13 would amend the responsibilities and authorities 
of the United States Interdiction Coordinator. Based within the 
ONDCP, the U.S. Interdiction Coordinator would be responsible 
for coordinating efforts to prevent drugs from entering the 
United States. Based on information from ONDCP and the 
Department of Homeland Security, CBO estimates that increased 
staffing levels and new reporting requirements necessary under 
the bill would cost $2 million annually.
    The legislation includes other provisions that would 
establish new reporting requirements and procedures for 
preparing budget requests for ONDCP. CBO estimates that those 
provisions would cost $2 million annually.

Revenues and direct spending

    H.R. 2829 would reauthorize ONDCP to accept donations of 
real and personal property. Gifts are classified in the budget 
as revenues, and spending of such sums would constitute direct 
spending. According to ONDCP, it has not received any gifts in 
recent years and does not expect to receive any under this 
authority. Hence, CBO estimates that additional revenues and 
direct spending under H.R. 2829 would be negligible.
    Intergovernmental and private-sector impact: H.R. 2829 
contains no intergovernmental or private-sector mandates as 
defined in UMRA; any costs incurred by state, local, or tribal 
entities would result from participating in a voluntary federal 
program.
    Previous CBO estimates: On March 2, 2006, CBO transmitted a 
cost estimate for H.R. 2829, as ordered reported by the House 
Committee on Energy and Commerce on February 16, 2006. On 
August 5, 2005, CBO transmitted a cost estimate for H.R. 2829, 
as ordered reported by the House Committee on Government Reform 
on June 16, 2005. On July 7, 2005, CBO transmitted a cost 
estimate for H.R. 2565, a bill to reauthorize the Office of 
National Drug Control Policy Act and to establish minimum drug-
testing standards for major professional sports leagues, as 
ordered reported by the House Committee on Government Reform on 
May 26, 2005.
    H.R. 2829 and H.R. 2565 are similar; all three versions of 
H.R. 2829 and H.R. 2565 would reauthorize ONDCP and programs 
administered through that office. However, each version of 
legislation would authorize varying amounts for various 
activities over different time periods. CBO's cost estimates 
for those bills reflect those differences.
    The version of H.R. 2879 that was ordered reported by the 
House Committee on Government Reform contains two 
intergovernmental mandates as defined in UMRA not contained in 
the Judiciary Committee's version: a preemption of state 
privacy laws and new authority for the Director of ONDCP to 
regulate public institutions of higher education. The mandates 
statements in CBO's estimates reflect this difference. CBO 
found no intergovernmental mandates in either the Energy and 
Commerce version or the Judiciary Committee version of H.R. 
2829.
    The version of H.R. 2829 approved by the House Committee on 
Government Reform on June 16, 2005, also contains private-
sector mandates regarding steroid use in title II. The 
Judiciary version and the Energy and Commerce version do not 
include those mandates.
    Estimate prepared by: Federal Costs: Matthew Pickford and 
Mark Grabowicz; Impact on State, local, and tribal governments: 
Sarah Puro; Impact on the private sector: Craig Cammarata.
    Estimate approved by: Peter H. Fontaine, Deputy Assistant 
Director for Budget Analysis.

                    Performance Goals and Objectives

    In accordance with clause 3(c)(4) of rule XIII of the Rules 
of the House of Representatives, the Committee's performance 
goals and objectives are reflected in the descriptive portions 
of the report.

                   Constitutional Authority Statement

    Pursuant to clause 3(d)(1) of rule XIII of the Rules of the 
House of Representatives, the Committee finds the authority for 
this legislation in art. I, Sec. 8 of the Constitution.

               Section-by-Section Analysis and Discussion

    The following discussion describes the bill as reported by 
the Committee on the Judiciary.

Section 1. Short title

    This section designates the short title of the bill as the 
``Office of National Drug Control Policy Reauthorization Act of 
2005.''

Section 2. Amendment of Office of National Drug Control Policy 
        Reauthorization Act of 1998

    This section notes that the legislation amends and repeals 
in part the Office of National Drug Control Policy 
Reauthorization Act of 1998 (the 1998 Act).

Section 3. Repeal of termination provision

    This section reauthorizes ONDCP and its programs by 
repealing the 1998 Act's sunset provision. The bill still 
limits authorized appropriations to five more fiscal years, 
from 2006 through 2010 in section 114.

Section 4. Amendments to definitions

    This section clarifies the definition of various terms 
related to drug control defined in the Act, which also affect 
the responsibilities of certain Deputy Directors within the 
Office. The definition of ``demand reduction'' activities is 
amended to include drug testing of employees, interventions to 
stop drug addiction, and international efforts to achieve basic 
demand reduction policies (such as treatment and prevention). 
The existing definition of the ``National Drug Control 
Program'' is clarified to ensure that it includes all Federal 
activities involving supply reduction, demand reduction, or 
State and local affairs (as those terms are defined in 21 
U.S.C. Sec. 1701). Such activities are defined as part of the 
National Drug Control Program, even if some of them are not 
exclusively dedicated to drug control.
    The definition of ``State and local affairs'' is amended to 
include both domestic drug enforcement and intelligence. This 
section also classifies facilitating Federal, State, and local 
cooperation as ``State and local affairs,'' and adds the task 
of facilitating drug intelligence sharing among the different 
levels of government. The definition of ``supply reduction'' is 
amended to include law enforcement activities outside the 
United States, as well as other programs in drug source 
countries (including alternative development programs, such as 
those administered by the U.S. Agency for International 
Development (USAID) in Colombia, primarily intended to reduce 
the production and trafficking of illegal drugs). This section 
also defines intelligence sharing among only Federal or foreign 
agencies (as opposed to sharing involving State or local 
agencies), as a supply reduction function.
    Two new definitions are added, one listing the 
Congressional committees that are the primary recipients of 
information from the Office, and another defining ``law 
enforcement'' related to drug control. The latter definition 
clarifies that drug law enforcement includes not simply 
investigation and arrest, but prosecution and incarceration or 
other punishment of drug offenders.
    Subsection (b) makes several conforming amendments to the 
statutory responsibilities of the Deputy Directors, to reflect 
the clarified definitions of supply reduction, demand 
reduction, and State and local affairs. The subsection also 
confirms the existing responsibility of the Deputy Director for 
State and Local Affairs for the High Intensity Drug Trafficking 
Areas (HIDTA) and Counterdrug Technology Assessment Center 
(CTAC) programs.

Section 5. Amendments relating to establishment of Office of National 
        Drug Control Policy and designation of officers

    Section 105 makes specific changes to the appointment and 
responsibilities of the Director of ONDCP and his subordinate 
officers. Subsection (a) clarifies the current responsibility 
of the Director to evaluate the effectiveness of national drug 
control programs, to include the requirement that the Director 
use specific goals and performance measures. Subsection (b) 
provides that the Director shall have the same ``rank and 
status'' as the heads of the executive departments already 
defined by statute. Subsection (c) provides that the Deputy 
Director for Supply Reduction shall have substantial experience 
in drug interdiction operations.

Section 6. Amendments related to appointment and duties of Director and 
        Deputy Director

    Section 106 makes amendments to the specific duties of the 
Director and Deputy Director of National Drug Control Policy. 
These changes apply to budget and drug certification processes 
along with other duties of the Director and Deputy Director. 
Existing law is amended to provide that any ``officer or 
employee'' may serve as the Director in the absence of the 
Director. The change clarifies that politically appointed 
officers may serve as the Acting Director. Additionally, the 
term ``Federal departments and agencies engaged in drug 
enforcement'' is changed to ``national drug control program 
agencies'' to conform to the term already defined in the 
statute.
    Outlined in this section are the duties of the Director 
pertaining to budget certification processes. The Director is 
prohibited from certifying the adequacy of any drug control 
program budget request that (1) fails to adequately compensate 
for transfers of drug enforcement resources to non-drug related 
activities; (2) requests funding for border activities that do 
not adequatelyaddress drug interdiction; (3) requests funding 
for drug treatment activities that do not provide result and 
accountability measures; (4) requests funding for drug treatment 
activities that do not adequately support and enhance Federal drug 
treatment programs and capacity; (5) requests funding for Department of 
Education drug control programs that do not follow reporting 
requirements concerning expedited consideration of student loan 
applications from improperly denied students; or (6) requests funding 
for management and operations of the Department of Homeland Security 
without including a specific request for funding for that Department's 
Office of Counternarcotics Enforcement.
    The bill adds requirements for authorizing committees for 
the Office to receive notification whenever the Director 
exercises certain authorities with respect to Federal drug 
control budgets and funding. Additionally, the Director's 
authority to issue Fund Control Notices is clarified to extend 
to all drug control program agencies. The Director's authority 
to participate in the annual drug certification process is 
clarified to include the recently amended certification 
process. In addition, the Director is required to submit a 
report to the President each year providing an assessment of 
whether major drug transit or production countries are fully 
cooperating with the United States, and whether certain 
procedures provided for in the amended law with respect to 
countries not fully cooperating should be applied. The Director 
is also required to transmit the report to the Secretary of 
State and the authorizing committees for the Office. The 
Director's responsibilities are expanded to include new duties 
relating to treatment research, and coordination of efforts to 
assist State and local efforts against drug trafficking. This 
section adds a new requirement to the drug budget process that 
any drug budget request made by an agency include all drug 
control activities of that agency, including demand reduction, 
supply reduction, and State and local affairs. At present, the 
drug budget process excludes a number of significant drug 
control activities. This section also requires ONDCP, within 90 
days of enactment, to submit to Congress two separate, 
comprehensive strategies to address the threat of heroin from 
South America (in particular Colombia and Peru), and 
Afghanistan. The Director is also required to submit, with the 
concurrence of the Director of National Intelligence, a new 
General Counterdrug Intelligence Plan to improve coordination, 
and eliminate unnecessary duplication, among the counterdrug 
intelligence centers, information sharing systems, and other 
counterdrug activities of the Federal government. The Plan is 
due within 120 days of enactment, and new Plans must be 
submitted every two years thereafter.
    The Director is also required to submit, within 120 days of 
enactment, a comprehensive strategy to address narcotics 
trafficking at the Southwest Border between the United States 
and Mexico. Finally, this section requires ONDCP to submit, 
within 90 days of enactment, a report that includes a plan to 
conduct, on an expedited basis, a scientific study of the use 
of mycoherbicide as a means of illicit drug crop elimination by 
an appropriate government scientific research entity, including 
a complete and thorough scientific peer review. The study shall 
include an evaluation of the likely human health and 
environmental impacts of such use. The report shall also 
include a plan to conduct controlled scientific testing in a 
major drug producing nation of mycoherbicide.

Section 7. Amendments relating to coordination with other agencies

    This section makes technical corrections to the existing 
law, that reflect the creation of the position of Director of 
National Intelligence in 2004. This section also mandates a 
number of reports from Federal departments on drug control 
issues to the Director and authorizing committees for the 
Office.

Section 8. Development, submission, implementation, and assessment of 
        National Drug Control Strategy

    This section revises the process and content for the 
National Drug Control Strategy. The Director is required to 
submit an annual Strategy report, which shall include 
significant information about the nature and impact of drug 
trafficking and abuse in the United States.

Section 9. High Intensity Drug Trafficking Areas Program

    This section addresses the High Intensity Drug Trafficking 
Areas (HIDTA) program, adding several new provisions to the 
existing statutory authorization for the program, which 
contains limited guidance.
    The Secretary of Homeland Security is added as an official 
the Director is required to consult before designating a HIDTA. 
The bill includes a statement of purposes for the program, as 
well as revised criteria for designating HIDTAs. ONDCP is 
directed to establish, by regulation, procedures for areas to 
seek designation as a HIDTA. The bill also sets forth the basic 
guidelines for the executive committees that govern an 
individual HIDTA.
    ONDCP is also directed to submit, as part of each annual 
budget proposal to Congress, a spending plan that indicates the 
specific amount proposed to be spent on each HIDTA. The bill 
restates current law regarding the Director's authority to 
reassign Federal personnel to HIDTAs and otherwise increase 
Federal assistance. The Director is prohibited from expending 
funds to create or expand drug prevention or drug treatment 
programs in any HIDTA, but would be free to continue funding 
existing programs if necessary. The Director is authorized to 
permit HIDTA assistance to investigations related to terrorism, 
but is required to ensure that such assistance remains 
incidental and that significant resources of the program are 
not redirected to activities exclusively related to terrorism. 
A representative of the Drug Enforcement Administration must be 
included in the Intelligence Support Center of each HIDTA. The 
HIDTA program is authorized at $280 million in fiscal year 
2006, $290 million in fiscal years 2007 and 2008, and 
$300,000,000 in fiscal years 2009 and 2010.

Section 10. Funding for certain High Intensity Drug Trafficking Areas

    This section may be referred to as the ``Dawson Family 
Community Protection Act.'' It includes findings expressing the 
sense of Congress regarding the firebombing of the Dawson 
family home in October 2002, the need for cooperation of 
citizens in law enforcement, and the need for initiatives aimed 
at improving community safety and encouraging cooperation to 
counter illegal drug traffic. The Director is directed to 
ensure that at least $5 million in HIDTA funding is used in 
areas with severe neighborhood safety and illegal drug 
distribution problems toensure neighborhood safety and combat 
illegal drug trafficking.

Section 11. Amendments relating to Counter-Drug Technology Assessment 
        Center

    Section 111 contains provisions relating to the Counterdrug 
Technology Assessment Center (CTAC). The title of ``Director of 
Technology'' within ONDCP is changed to ``Chief Scientist.'' 
Explicit authority is added for the Chief Scientist to oversee 
and coordinate a technology transfer program to State and local 
law enforcement. The Chief Scientist is also required to give 
general priority for such grants based on need and potential 
impact on drug trafficking; a specific priority is also 
required for technologies most likely to assist in drug 
interdiction and border enforcement to agencies in southwest 
border areas and northern border areas with significant traffic 
in illegal drugs. The Substance Abuse and Mental Health 
Administration is included in the list of agencies to be 
consulted with respect to technology research related to drug 
treatment.

Section 12. National youth antidrug media campaign

    Section 112 restates some of the existing law authorizing 
the Media Campaign, and makes some amendments. The primary 
purposes of the Campaign are restated and clarified. 
Authorization to use funds for creative and talent costs is 
narrowed so that the Director will use donated creative 
services wherever possible and may only use funds for creative 
services for advertising responding to high-priority or 
emergent campaign needs that cannot timely be obtained at no 
cost, or intended to reach a minority, ethnic or other special 
audience that cannot be obtained at no cost. Funding for 
creative services is limited to $1.5 million per fiscal year, 
unless the Director demonstrates and the Appropriations 
Committees approve increased funding for urgent needs, which 
may not exceed $2 million.
    The Director is required to test all advertisements to 
ensure they are effective and meet industry-accepted standards. 
The requirement can be waived for advertisements making up less 
than 10 percent of the airtime and print space of the Campaign. 
The Director is also required to designate an independent 
entity to evaluate the effectiveness of the Campaign using 
certain specified data. This independent entity is also 
required to ensure the effectiveness of the Media Campaign is 
evaluated in a manner that enables consideration of whether the 
Media Campaign has contributed to reduction of illicit drug use 
by youth and such other measures of evaluation as the Director 
determines are appropriate.
    The bill requires that 77 percent of the amounts 
appropriated for the Media Campaign must be used for the 
purchase of advertising time and space. The limit changes to 82 
percent when less than $125 million is appropriated for the 
program, and 72 percent when more than $195 million is 
appropriated for the program. The bill prohibits funding for 
advertising not containing a primary message intended to 
prevent illicit drug use or intended to promote support for the 
Media Campaign or private sector contributions to the Media 
Campaign. In addition to the existing prohibition on 
expenditure of campaign funds for partisan political activity, 
the bill prohibits express advocacy in support of or to defeat 
any clearly identified candidate, clearly identified ballot 
initiative, or clearly identified legislative or regulatory 
proposal. The appearance of certain elected and politically 
appointed officials in Media Campaign advertising is also 
prohibited.
    The Director is required to ensure that 70 percent of no-
cost match advertising directly relates to substance abuse 
prevention consistent with the specific purposes of the Media 
Campaign. The limit changes to 85 percent in any fiscal year in 
which less than $125 million is appropriated to the Media 
Campaign. In addition, the Director is required to ensure that 
no-cost match advertising that does not directly relate to 
substance abuse prevention include a clear anti-drug message, 
which is not required to be the primary message of the match 
advertising.
    The bill provides that the Partnership for a Drug-Free 
America shall serve as the primary outside strategic advisor to 
the campaign and be responsible for coordinating donations of 
creative and other services to the campaign, except those 
funded under authorities provided elsewhere in the bill. The 
Director shall inform the Partnership of the strategic goals of 
the campaign and consider advice from the Partnership on 
campaign strategy. The bill also restates provision of current 
law requiring certain information on local treatment resources 
to be included in Media Campaign advertising where feasible.
    Congress makes several findings regarding marijuana use by 
America's youth. The Director is authorized to emphasize 
prevention of youth marijuana use in advertising and activities 
otherwise authorized in this section.
    The bill requires an annual report to Congress on the 
performance of the Media Campaign. The Media Campaign is 
authorized at $195 million in Fiscal Years 2006 and 2007, and 
at $210 million in Fiscal Years 2008 through 2010.

Section 13. Drug interdiction

    This section replaces the previously existing law with new 
provisions that establish and define the functions and role of 
the United States Interdiction Coordinator (USIC) and the 
Interdiction Committee (TIC). The Deputy Director for Supply 
Reduction of the Office serves as the USIC, and is responsible 
for: (1) coordinating the interdiction activities of the 
National Drug Control Program agencies to ensure consistency 
with the National Drug Control Strategy; (2) issuing the annual 
National Interdiction Command and Control Plan (NICCP); (3) 
assessing the sufficiency of assets committed to illicit drug 
interdiction by the relevant National Drug Control Program 
agencies; and (4) advising the Director on the efforts of each 
National Drug Control Program agency to implement the NICCP. 
The NICCP is required to: (1) set forth the government's 
strategy for drug interdiction; (2) state the specific roles 
and responsibilities of the relevant National Drug Control 
Program agencies for implementing that strategy; and (3) 
identify the specific resources required to enable the relevant 
National Drug Control Program agencies to implement that 
strategy.
    This section also authorizes the TIC, which is to meet to: 
(1) discuss and resolve issues related to the coordination, 
oversight and integration of international, border, and 
domestic drug interdiction efforts in support of the National 
Drug Control Strategy; (2) review the annualNICCP, and provide 
advice to the Director and the USIC concerning that plan; and (3) 
provide such other advice to the Director concerning drug interdiction 
strategy and policies as the committee determines is appropriate. The 
TIC is required to meet in person at least once per year, with 
additional meetings subject to the call of the Director or the chairman 
of the TIC.
    The section includes a conforming amendment that modifies 
the Homeland Security Act of 2002 (6 U.S.C. 458), to delete the 
reference to the USIC position from the description of the 
position of Director of Counternarcotics Enforcement at the 
Department of Homeland Security.

Section 14. Awards for demonstration programs by local partnerships to 
        shut down illicit drug market hot-spots by deterring drug 
        dealers or altering the dynamic of drug sales.

    Section 114 would authorize funding for demonstration 
programs that fund interagency collaborations with 
representatives from criminal justice, research, social service 
and community-based agencies. The programs would analyze local 
markets to develop strategic interventions that communicate a 
credible threat to a concentrated group of chronic offenders 
and provide rehabilitative services for the non-violent 
offenders. The programs would be responsible for evaluating the 
effectiveness of the strategic intervention. An example of this 
approach was recently applied in High Point, NC, and the drug 
market promptly collapsed with minimal police intervention or 
crime displacement. Within one year of implementation, the drug 
crime rate fell by 34 percent and the violent crime rate was 
cut in half.

Section 15. Awards for demonstration programs by local partnerships to 
        coerce abstinence in chronic hard-drug users under community 
        supervision through the use of drug testing and sanctions

    Section 115 would authorize funding for demonstration 
programs that fund interagency collaborations with 
representatives from criminal justice, research, treatment and 
community-based agencies. The program would develop coerced 
abstinence (testing and graduated sanctions) interventions that 
communicate a credible deterrent threat to a concentrated group 
of chronic offenders, provide rehabilitative services to these 
offenders and evaluate the effectiveness of the strategic 
interventions. An example of this approach is currently being 
applied in Honolulu, Hawaii. Control group defendants had a 
positive drug test rate of 21.9 percent and a missed 
appointment rate of 10 percent, compared with program 
participants who had a positive drug test rate of 3.8 percent 
and a missed appointment rate of 1.3 percent.

Section 16. Authorization of appropriations

    Section 114 authorizes appropriations for ONDCP activities 
through fiscal year 2010. Except for activities otherwise 
specified, such sums as are necessary are authorized to be 
appropriated for fiscal years 2006 through 2010.

Section 17. Technical amendments and repeal

    This section deletes obsolete references elsewhere in the 
United States Code, and repeals the Special Forfeiture Fund.

Section 18. Requirement for disclosure of Federal sponsorship of all 
        Federal advertising or other communication materials

    This section requires that each advertisement or other 
communication paid for by the Office, either directly or 
through a contract awarded by the Office, shall include a 
prominent notice informing the target audience that the 
advertisement or other communication is paid for by the Office.

Section 19. Policy relating to syringe exchange programs

    This section further amends Section 703(a) (21 U.S.C. 
Sec. 1702(a)) by adding a requirement that when developing the 
national drug control policy, any policy of the Director 
relating to syringe exchange programs for intravenous drug 
users shall be based on the best available medical and 
scientific evidence regarding their effectiveness in promoting 
individual health and preventing the spread of infectious 
disease, and their impact on drug addiction and use. The 
Director is required, when making any policy relating to 
syringe exchange programs, to consult with the National 
Institutes of Health and the National Academy of Sciences.

         Changes in Existing Law Made by the Bill, as Reported

  In compliance with clause 3(e) of rule XIII of the Rules of 
the House of Representatives, changes in existing law made by 
the bill, as reported, are shown as follows (existing law 
proposed to be omitted is enclosed in black brackets, new 
matter is printed in italic, existing law in which no change is 
proposed is shown in roman):

   OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION ACT OF 1998


SEC. 701. SHORT TITLE.

  This title may be cited as the ``Office of National Drug 
Control Policy Reauthorization Act of 1998''.

SEC. 702. DEFINITIONS.

  In this title:
          (1) Demand reduction.--The term ``demand reduction'' 
        means any activity conducted by a National Drug Control 
        Program agency, other than an enforcement activity, 
        that is intended to reduce the use of drugs, 
        including--
                  (A) * * *

           *       *       *       *       *       *       *

                  (F) drug-free workplace programs; [and]
                  (G) drug testing[.], including the testing of 
                employees;
                  (H) interventions for drug abuse and 
                dependence; and
                  (I) international drug control coordination 
                and cooperation with respect to activities 
                described in this paragraph.

           *       *       *       *       *       *       *

          (6) National drug control program.--The term 
        ``National Drug Control Program'' means programs, 
        policies, and activities undertaken by National Drug 
        Control Program agencies pursuant to the 
        responsibilities of such agencies under the National 
        Drug Control Strategy, including any activities 
        involving supply reduction, demand reduction, or State 
        and local affairs.
          (7) National drug control program agency.--The term 
        ``National Drug Control Program [Agency] agency'' means 
        any agency that is responsible for implementing any 
        aspect of the National Drug Control Strategy, including 
        any agency that receives Federal funds to implement any 
        aspect of the National Drug Control Strategy, but does 
        not include any agency that receives funds for drug 
        control activity solely under the [National Foreign 
        Intelligence Program,] National Intelligence Program, 
        the Joint Military Intelligence Program, or Tactical 
        Intelligence and Related Activities, unless such agency 
        has been designated--
                  (A) * * *

           *       *       *       *       *       *       *

          (9) Office.--Unless the context clearly [implicates] 
        indicates otherwise, the term ``Office'' means the 
        Office of National Drug Control Policy established 
        under section 703(a).
          (10) State and local affairs.--The term ``State and 
        local affairs'' means domestic activities conducted by 
        a National Drug Control Program agency that are 
        intended to reduce the availability and use of drugs, 
        including--
                  (A) * * *
                  (B) promotion of coordination and cooperation 
                among National Drug Control Program agencies 
                and the drug supply reduction and demand 
                reduction agencies of the various States, 
                territories, and units of local government; 
                [and]
                  (C) such other cooperative governmental 
                activities which promote a comprehensive 
                approach to drug control at the national, 
                State, territory, and local levels[.];
                  (D) domestic drug law enforcement, including 
                domestic drug interdiction and law enforcement 
                directed at drug users; and
                  (E) coordination and enhancement of Federal, 
                State, and local law enforcement initiatives to 
                gather, analyze, and disseminate information 
                and intelligence relating to drug control among 
                domestic law enforcement agencies.
          (11) Supply reduction.--The term ``supply reduction'' 
        means any activity of a program conducted by a National 
        Drug Control Program agency that is intended to reduce 
        the availability or use of drugs in the United States 
        and abroad, including--
                  (A) international drug control, including--
                          (i) law enforcement outside the 
                        United States; and
                          (ii) source country programs, 
                        including economic development programs 
                        primarily intended to reduce the 
                        production or trafficking of illicit 
                        drugs;
                  [(B) foreign and domestic drug intelligence;]
                  (B) facilitating and enhancing the sharing of 
                foreign and domestic information and law 
                enforcement intelligence relating to drug 
                production and trafficking among National Drug 
                Control Program agencies, and between those 
                agencies and foreign law enforcement agencies; 
                and
                  (C) interdiction[; and].
                  [(D) domestic drug law enforcement, including 
                law enforcement directed at drug users.]
          (12) Appropriate congressional committees.--Except 
        where otherwise provided, the term ``appropriate 
        congressional committees'' means the Committee on the 
        Judiciary, the Committee on Appropriations, and the 
        Caucus on International Narcotics Control of the Senate 
        and the Committee on Government Reform, the Committee 
        on the Judiciary, and the Committee on Appropriations 
        of the House of Representatives.
          (13) Law enforcement.--The term ``law enforcement'' 
        or ``drug law enforcement'' means all efforts by a 
        Federal, State, or local government agency to enforce 
        the drug laws of the United States or any State, 
        including investigation, arrest, prosecution, and 
        incarceration or other punishments or penalties.

SEC. 703. OFFICE OF NATIONAL DRUG CONTROL POLICY.

  (a) Establishment of Office.--There is established in the 
Executive Office of the President an Office of National Drug 
Control Policy, which shall--
          (1) * * *

           *       *       *       *       *       *       *

          [(4) evaluate the effectiveness of the national drug 
        control programs.]
          (4) evaluate the effectiveness of the national drug 
        control policy and the National Drug Control Program 
        agencies' programs, by developing and applying specific 
        goals and performance measurements.
When developing the national drug control policy, any policy of 
the Director relating to syringe exchange programs for 
intravenous drug users shall be based on the best available 
medical and scientific evidence regarding their effectiveness 
in promoting individual health and preventing the spread of 
infectious disease, and their impact on drug addiction and use. 
In making any policy relating to syringe exchange programs, the 
Director shall consult with the National Institutes of Health 
and the National Academy of Sciences.
  (b) Director and Deputy Directors.--
          (1) Director.--There shall be at the head of the 
        Office a Director of National Drug Control Policy, who 
        shall hold the same rank and status as the head of an 
        executive department listed in section 101 of title 5, 
        United States Code.

           *       *       *       *       *       *       *

          (3) Other deputy directors.--There shall be in the 
        [Office--] Office the following additional Deputy 
        Directors--
                  (A) a Deputy Director for Demand Reduction, 
                who shall be responsible for the activities 
                described in subparagraphs (A) through [(G)] 
                (I) of section 702(1);
                  (B) a Deputy Director for Supply Reduction, 
                [who shall] who shall have substantial 
                experience and expertise in drug interdiction 
                operations and other supply reduction 
                activities, and who shall serve as the United 
                States Interdiction Coordinator and be 
                responsible for the activities described in 
                subparagraphs (A) through (C) of section 
                702(11); and
                  (C) a Deputy Director for State and Local 
                Affairs, who shall be responsible for the 
                activities described in subparagraphs (A) 
                through [(C)] (E) of section 702(10) [and 
                subparagraph (D) of section 702(11)], and 
                sections 707 and 708 of this Act.

           *       *       *       *       *       *       *


SEC. 704. APPOINTMENT AND DUTIES OF DIRECTOR AND DEPUTY DIRECTORS.

  (a) Appointment.--
          (1) * * *

           *       *       *       *       *       *       *

          (3) Designation of other officers.--In the absence of 
        the Deputy Director, or if the Office of the Deputy 
        Director is vacant, the Director shall designate such 
        other [permanent employee] officer or employee of the 
        Office to serve as the acting Director, if the Director 
        is absent or unable to serve.

           *       *       *       *       *       *       *

  (b) Responsibilities.--The Director--
          (1) * * *

           *       *       *       *       *       *       *

          (4) shall make such recommendations to the President 
        as the Director determines are appropriate regarding 
        changes in the organization, management, and budgets of 
        [Federal departments and agencies engaged in drug 
        enforcement,] National Drug Control Program agencies, 
        and changes in the allocation of personnel to and 
        within those departments and agencies, to implement the 
        policies, goals, priorities, and objectives established 
        under paragraph (1) and the National Drug Control 
        Strategy;

           *       *       *       *       *       *       *

          (7) shall notify any National Drug Control Program 
        agency if its policies are not in compliance with the 
        responsibilities of the agency under the National Drug 
        Control Strategy, transmit a copy of each such 
        notification to the President and the appropriate 
        congressional committees, and maintain a copy of each 
        such notification;

           *       *       *       *       *       *       *

          (13) shall require each National Drug Control Program 
        agency to submit to the Director on an annual basis 
        [(beginning in 1999)] an evaluation of progress by the 
        agency with respect to drug control program goals using 
        the performance measures for the agency developed under 
        section 706(c), including progress with respect to--
                  (A) * * *

           *       *       *       *       *       *       *

          (14) shall submit to the [Appropriations committees 
        and the authorizing committees of jurisdiction of the 
        House of Representatives and the Senate] appropriate 
        congressional committees on an annual basis, not later 
        than 60 days after the date of the last day of the 
        applicable period, a summary of--
                  (A) each of the evaluations received by the 
                Director under paragraph (13); and
                  (B) the progress of each National Drug 
                Control Program agency toward the drug control 
                program goals of the agency using the 
                performance measures for the agency developed 
                under section 706(c); [and]
          (15) shall ensure that drug prevention and drug 
        treatment research and information is effectively 
        disseminated by National Drug Control Program agencies 
        to State and local governments and nongovernmental 
        entities involved in demand reduction by--
                  (A) * * *

           *       *       *       *       *       *       *

                  [(C) developing a single interagency 
                clearinghouse for the dissemination of research 
                and information by such agencies to State and 
                local governments and nongovernmental agencies 
                involved in demand reduction.]
                  (C) supporting the substance abuse 
                information clearinghouse administered by the 
                Administrator of the Substance Abuse and Mental 
                Health Services Administration and established 
                in section 501(d)(16) of the Public Health 
                Service Act by--
                          (i) encouraging all National Drug 
                        Control Program agencies to provide all 
                        appropriate and relevant information; 
                        and
                          (ii) supporting the dissemination of 
                        information to all interested entities;
          (16) shall coordinate with the private sector to 
        promote private research and development of medications 
        to treat addiction;
          (17) shall seek the support and commitment of State 
        and local officials in the formulation and 
        implementation of the National Drug Control Strategy;
          (18) shall monitor and evaluate the allocation of 
        resources among Federal law enforcement agencies in 
        response to significant local and regional drug 
        trafficking and production threats;
          (19) shall submit an annual report to Congress 
        detailing how the Office of National Drug Control 
        Policy has consulted with and assisted State and local 
        governments with respect to the formulation and 
        implementation of the National Drug Control Strategy 
        and other relevant issues; and
          (20) shall, within one year after the date of the 
        enactment of the Office of National Drug Control Policy 
        Reauthorization Act of 2005, report to Congress on the 
        impact of each Federal drug reduction strategy upon the 
        availability, addiction rate, use rate, and other harms 
        of illegal drugs.
  (c) National Drug Control Program Budget.--
          (1) Responsibilities of national drug control program 
        agencies.--
                  (A) * * *

           *       *       *       *       *       *       *

                  (C) Content of drug control budget 
                requests.--A drug control budget request 
                submitted by a department, agency, or program 
                under this paragraph shall include all requests 
                for funds for any drug control activity 
                undertaken by that department, agency, or 
                program, including demand reduction, supply 
                reduction, and State and local affairs, 
                including any drug law enforcement activities. 
                If an activity has both drug control and 
                nondrug control purposes or applications, the 
                department, agency, or program shall estimate 
                by a documented calculation the total funds 
                requested for that activity that would be used 
                for drug control, and shall set forth in its 
                request the basis and method for making the 
                estimate.
          (2) National drug control program budget proposal.--
        For each fiscal year, following the transmission of 
        proposed drug control budget requests to the Director 
        under paragraph (1), the Director shall, in 
        consultation with the head of each National Drug 
        Control Program agency--
                  (A) develop a consolidated National Drug 
                Control Program budget proposal designed to 
                implement the National Drug Control Strategy 
                and to inform Congress and the public about the 
                total amount proposed to be spent on all supply 
                reduction, demand reduction, State and local 
                affairs, including any drug law enforcement, 
                and other drug control activities by the 
                Federal Government, which shall conform to the 
                content requirements set forth in subparagraph 
                (C) of paragraph (1) of this subsection;

           *       *       *       *       *       *       *

          (3) Review and certification of budget requests and 
        budget submissions of national drug control program 
        agencies.--
                  (A) * * *

           *       *       *       *       *       *       *

                  (C) Specific requests.--The Director shall 
                not confirm the adequacy of any budget request 
                that--
                          (i) requests funding for Federal law 
                        enforcement activities that do not 
                        adequately compensate for transfers of 
                        drug enforcement resources and 
                        personnel to law enforcement and 
                        investigation activities not related to 
                        drug enforcement as determined by the 
                        Director;
                          (ii) requests funding for law 
                        enforcement activities on the borders 
                        of the United States that do not 
                        adequately direct resources to drug 
                        interdiction and enforcement as 
                        determined by the Director;
                          (iii) requests funding for drug 
                        treatment activities that do not 
                        provide adequate result and 
                        accountability measures as determined 
                        by the Director;
                          (iv) requests funding for any 
                        activities of the Safe and Drug Free 
                        Schools Program that do not include a 
                        clear antidrug message or purpose 
                        intended to reduce drug use;
                          (v) requests funding to enforce 
                        section 484(r)(1) of the Higher 
                        Education Act of 1965 (20 U.S.C. 
                        1091(r)(1)) with respect to convictions 
                        for drug-related offenses not occurring 
                        during a period of enrollment for which 
                        the student was receiving any Federal 
                        grant, loan, or work assistance;
                          (vi) requests funding for drug 
                        treatment activities that do not 
                        adequately support and enhance Federal 
                        drug treatment programs and capacity, 
                        as determined by the Director;
                          (vii) requests funding for fiscal 
                        year 2007 for activities of the 
                        Department of Education, unless it is 
                        accompanied by a report setting forth a 
                        plan for providing expedited 
                        consideration of student loan 
                        applications for all individuals who 
                        submitted an application for any 
                        Federal grant, loan, or work assistance 
                        that was rejected or denied pursuant to 
                        484(r)(1) of the Higher Education Act 
                        of 1965 (20 U.S.C. 1091(r)(1)) by 
                        reason of a conviction for a drug-
                        related offense not occurring during a 
                        period of enrollment for which the 
                        individual was receiving any Federal 
                        grant, loan, or work assistance; and
                          (viii) requests funding for the 
                        operations and management of the 
                        Department of Homeland Security that 
                        does not include a specific request for 
                        funds for the Office of 
                        Counternarcotics Enforcement to carry 
                        out its responsibilities under section 
                        878 of the Homeland Security Act of 
                        2002 (6 U.S.C. 458).
                  [(C)] (D) Agency response.--
                          (i) * * *

           *       *       *       *       *       *       *

                          (iii) Congressional notification.--
                        The head of a National Drug Control 
                        Program agency shall submit a copy of 
                        any impact statement under clause (ii) 
                        to the Senate and the House of 
                        Representatives and the appropriate 
                        congressional committees at the time 
                        the budget for that agency is submitted 
                        to Congress under section 1105(a) of 
                        title 31, United States Code.
                  [(D)] (E) Certification of budget 
                submissions.--
                          (i) * * *
                          (ii) Certification.--The Director--
                                  (I) * * *
                                  (II) based on the review 
                                under subclause (I), if the 
                                Director concludes that the 
                                budget submission of a National 
                                Drug Control Program agency 
                                does not include the funding 
                                levels and initiatives 
                                described under subparagraph 
                                (B)--
                                          (aa) * * *
                                          (bb) in the case of a 
                                        decertification issued 
                                        under item (aa), shall 
                                        submit to the Senate 
                                        and the House of 
                                        Representatives and the 
                                        appropriate 
                                        congressional 
                                        committees a copy of--
                                                  (aaa) * * *

           *       *       *       *       *       *       *

          (4) Reprogramming and transfer requests.--
                  (A) In general.--No National Drug Control 
                Program agency shall submit to Congress a 
                reprogramming or transfer request with respect 
                to any amount of appropriated funds in an 
                amount exceeding [$5,000,000] $1,000,000 that 
                is included in the National Drug Control 
                Program budget unless the request has been 
                approved by the Director.

           *       *       *       *       *       *       *

  (d) Powers of the Director.--In carrying out subsection (b), 
the Director may--
          (1)  * * *

           *       *       *       *       *       *       *

          (8) transfer funds made available to a National Drug 
        Control Program agency for National Drug Control 
        Strategy programs and activities to another account 
        within such agency or to another National Drug Control 
        Program agency for National Drug Control Strategy 
        programs and activities, except that--
                  (A) * * *

           *       *       *       *       *       *       *

                  (D) funds transferred to an agency under this 
                paragraph may only be used to increase the 
                funding for programs or activities [have been 
                authorized by Congress;] authorized by law; and

           *       *       *       *       *       *       *

          (9) notwithstanding any other provision of law, issue 
        to the head of a National Drug Control Program agency a 
        fund control notice described in subsection (f) to 
        ensure compliance with the National Drug Control 
        Program [Strategy; and] Strategy and notify the 
        appropriate congressional committees of any fund 
        control notice issued;
          (10) participate in the drug certification process 
        pursuant to section 490 of the Foreign Assistance Act 
        of 1961 [(22 U.S.C. 2291j).] (22 U.S.C. 2291j) and 
        section 706 of the Foreign Relations Authorization Act, 
        Fiscal Year 2003 (22 U.S.C. 2291j-1); and
          (11) not later than August 1 of each year, submit to 
        the President a report, and transmit copies of the 
        report to the Secretary of State and the appropriate 
        congressional committees, that--
                  (A) provides the Director's assessment of 
                which countries are major drug transit 
                countries or major illicit drug producing 
                countries as defined in section 481(e) of the 
                Foreign Assistance Act of 1961 (22 U.S.C. 
                2291(e));
                  (B) provides the Director's assessment of 
                whether each country identified under 
                subparagraph (A) has cooperated fully with the 
                United States or has taken adequate steps on 
                its own to achieve full compliance with the 
                goals and objectives established by the United 
                Nations Convention Against Illicit Traffic in 
                Narcotic Drugs and Psychotropic Substances and 
                otherwise has assisted in reducing the supply 
                of illicit drugs to the United States; and
                  (C) provides the Director's assessment of 
                whether application of procedures set forth in 
                section 490 of the Foreign Assistance Act of 
                1961 (22 U.S.C. 2291j), as provided in section 
                706 of the Foreign Relations Authorization Act, 
                Fiscal Year 2003 (22 U.S.C. 2291j-1), is 
                warranted with respect to countries the 
                Director assesses have not cooperated fully.

           *       *       *       *       *       *       *

  (f) Fund Control Notices.--
          (1) * * *

           *       *       *       *       *       *       *

          (4) Congressional notice.--A copy of each fund 
        control notice shall be transmitted to the appropriate 
        congressional committees.
          (5) Restrictions.--The Director shall not issue a 
        fund control notice to direct that all or part of an 
        amount appropriated to the National Drug Control 
        Program agency account be obligated, modified, or 
        altered in any manner contrary, in whole or in part, to 
        a specific appropriation or statute.
  (g) Inapplicability to Certain Programs.--The provisions of 
this section shall not apply to the [National Foreign 
Intelligence Program] National Intelligence Program, the Joint 
Military Intelligence Program, and Tactical Intelligence and 
Related Activities unless the agency that carries out such 
program is designated as a National Drug Control Program agency 
by the President or jointly by the Director and the head of the 
agency.
  (h) Construction.--Nothing in this Act shall be construed as 
derogating the authorities and responsibilities of the 
[Director of Central Intelligence] Director of National 
Intelligence or the Director of the Central Intelligence Agency 
contained in sections 104 and 504 of the National Security Act 
of 1947 or any other law.

SEC. 705. COORDINATION WITH NATIONAL DRUG CONTROL PROGRAM AGENCIES IN 
                    DEMAND REDUCTION, SUPPLY REDUCTION, AND STATE AND 
                    LOCAL AFFAIRS.

  (a) Access to Information.--
          (1) In general.--Upon the request of the Director, 
        the head of any National Drug Control Program agency 
        shall cooperate with and provide to the Director any 
        statistics, studies, reports, and other information 
        prepared or collected by the agency concerning the 
        responsibilities of the agency under the National Drug 
        Control Strategy that relate to--
                  (A) drug [abuse] control; or

           *       *       *       *       *       *       *

          (2) Protection of intelligence information.--
                  (A) In general.--The authorities conferred on 
                the Office and the Director by this title shall 
                be exercised in a manner consistent with 
                provisions of the National Security Act of 1947 
                (50 U.S.C. 401 et seq.). The [Director of 
                Central Intelligence] Director of National 
                Intelligence shall prescribe such regulations 
                as may be necessary to protect information 
                provided pursuant to this title regarding 
                intelligence sources and methods.
                  (B) Duties of director.--The [Director of 
                Central Intelligence] Director of National 
                Intelligence and the Director of the Central 
                Intelligence Agency shall, to the maximum 
                extent practicable in accordance with 
                subparagraph (A), render full assistance and 
                support to the Office and the Director.
          [(3) Illegal drug cultivation.--The Secretary of 
        Agriculture shall annually submit to the Director an 
        assessment of the acreage of illegal drug cultivation 
        in the United States.]
          (3) Required reports.--
                  (A) Secretaries of the interior and 
                agriculture.--The Secretaries of Agriculture 
                and Interior shall, by July 1 of each year, 
                jointly submit to the Director, the appropriate 
                congressional committees, the Committee on 
                Agriculture and the Committee on Resources of 
                the House of Representatives, and the Committee 
                on Agriculture and the Committee on Energy and 
                Natural Resources of the Senate, an assessment 
                of the quantity of illegal drug cultivation and 
                manufacturing in the United States on lands 
                owned or under the jurisdiction of the Federal 
                Government for the preceding year.
                  (B) Attorney general.--The Attorney General 
                shall, by July 1 of each year, submit to the 
                Director and the appropriate congressional 
                committees information for the preceding year 
                regarding the number and type of--
                          (i) arrests for drug violations;
                          (ii) prosecutions for drug violations 
                        by United States Attorneys; and
                          (iii) seizures of drugs by each 
                        component of the Department of Justice 
                        seizing drugs, as well as statistical 
                        information on the geographic areas of 
                        such seizures.
                  (C) Secretary of homeland security.--The 
                Secretary of Homeland Security shall, by July 1 
                of each year, submit to the Director, the 
                appropriate congressional committees, and the 
                Committee on Homeland Security of the House of 
                Representatives, and the Committee on Homeland 
                Security and Governmental Affairs of the 
                Senate, information for the preceding year 
                regarding--
                          (i) the number and type of seizures 
                        of drugs by each component of the 
                        Department of Homeland Security seizing 
                        drugs, as well as statistical 
                        information on the geographic areas of 
                        such seizures; and
                          (ii) the number of air and maritime 
                        patrol hours undertaken by each 
                        component of that Department primarily 
                        dedicated to drug supply reduction 
                        missions.
                  (D) Secretary of defense.--The Secretary of 
                Defense shall, by July 1 of each year, submit 
                to the Director, the appropriate congressional 
                committees, the Committee on Armed Services of 
                the House of Representatives, and the Committee 
                on Armed Services of the Senate, information 
                for the preceding year regarding the number of 
                air and maritime patrol hours primarily 
                dedicated to drug supply reduction missions 
                undertaken by each component of the Department 
                of Defense.
  (b) Certification of Policy Changes to Director.--
          (1) * * *
          (2) Exception.--If prior notice of a proposed change 
        under paragraph (1) is not practicable--
                  (A) * * *
                  (B) upon such notification, the Director 
                shall review the change and certify to the head 
                of that agency in writing whether the change is 
                consistent with the National Drug Control 
                [Program.] Strategy.
  (c) General Services Administration.--The Administrator of 
General Services shall provide to the Director, [in] on a 
reimbursable basis, such administrative support services as the 
Director may request.

           *       *       *       *       *       *       *


[SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
                    NATIONAL DRUG CONTROL STRATEGY.

  [(a) Timing, Contents, and Process for Development and 
Submission of National Drug Control Strategy.--
          [(1) Timing.--Not later than February 1, 1999, the 
        President shall submit to Congress a National Drug 
        Control Strategy, which shall set forth a comprehensive 
        plan, covering a period of not more than 5 years, for 
        reducing drug abuse and the consequences of drug abuse 
        in the United States, by limiting the availability of 
        and reducing the demand for illegal drugs.
          [(2) Contents.--
                  [(A) In general.--The National Drug Control 
                Strategy submitted under paragraph (1) shall 
                include--
                          [(i) comprehensive, research-based, 
                        long-range, quantifiable, goals for 
                        reducing drug abuse and the 
                        consequences of drug abuse in the 
                        United States;
                          [(ii) annual, quantifiable, and 
                        measurable objectives and specific 
                        targets to accomplish long-term 
                        quantifiable goals that the Director 
                        determines may be achieved during each 
                        year of the period beginning on the 
                        date on which the National Drug Control 
                        Strategy is submitted;
                          [(iii) 5-year projections for program 
                        and budget priorities; and
                          [(iv) a review of international, 
                        State, local, and private sector drug 
                        control activities to ensure that the 
                        United States pursues well-coordinated 
                        and effective drug control at all 
                        levels of government.
                  [(B) Classified information.--Any contents of 
                the National Drug Control Strategy that 
                involves information properly classified under 
                criteria established by an Executive order 
                shall be presented to Congress separately from 
                the rest of the National Drug Control Strategy.
          [(3) Process for development and submission.--
                  [(A) Consultation.--In developing and 
                effectively implementing the National Drug 
                Control Strategy, the Director--
                          [(i) shall consult with--
                                  [(I) the heads of the 
                                National Drug Control Program 
                                agencies;
                                  [(II) Congress;
                                  [(III) State and local 
                                officials;
                                  [(IV) private citizens and 
                                organizations with experience 
                                and expertise in demand 
                                reduction;
                                  [(V) private citizens and 
                                organizations with experience 
                                and expertise in supply 
                                reduction; and
                                  [(VI) appropriate 
                                representatives of foreign 
                                governments;
                          [(ii) with the concurrence of the 
                        Attorney General, may require the El 
                        Paso Intelligence Center to undertake 
                        specific tasks or projects to implement 
                        the National Drug Control Strategy; and
                          [(iii) with the concurrence of the 
                        Director of Central Intelligence and 
                        the Attorney General, may request that 
                        the National Drug Intelligence Center 
                        undertake specific tasks or projects to 
                        implement the National Drug Control 
                        Strategy.
                  [(B) Inclusion in strategy.--The National 
                Drug Control Strategy under this subsection, 
                and each report submitted under subsection (b), 
                shall include a list of each entity consulted 
                under subparagraph (A)(i).
          [(4) Specific targets.--The targets in the National 
        Drug Control Strategy shall include the following:
                  [(A) Reduction of unlawful drug use to 3 
                percent of the population of the United States 
                or less by December 31, 2003 (as measured in 
                terms of overall illicit drug use during the 
                past 30 days by the National Household Survey), 
                and achievement of at least 20 percent of such 
                reduction during each of 1999, 2000, 2001, 
                2002, and 2003.
                  [(B) Reduction of adolescent unlawful drug 
                use (as measured in terms of illicit drug use 
                during the past 30 days by the Monitoring the 
                Future Survey of the University of Michigan or 
                the National PRIDE Survey conducted by the 
                National Parents' Resource Institute for Drug 
                Education) to 3 percent of the adolescent 
                population of the United States or less by 
                December 31, 2003, and achievement of at least 
                20 percent of such reduction during each of 
                1999, 2000, 2001, 2002, and 2003st.
                  [(C) Reduction of the availability of 
                cocaine, heroin, marijuana, and methamphetamine 
                in the United States by 80 percent by December 
                31, 2003.
                  [(D) Reduction of the respective nationwide 
                average street purity levels for cocaine, 
                heroin, marijuana, and methamphetamine (as 
                estimated by the interagency drug flows 
                assessment led by the Office of National Drug 
                Control Policy, and based on statistics 
                collected by the Drug Enforcement 
                Administration and other National Drug Control 
                Program agencies identified as relevant by the 
                Director) by 60 percent by December 31, 2003, 
                and achievement of at least 20 percent of each 
                such reduction during each of 1999, 2000, 2001, 
                2002, and 2003.
                  [(E) Reduction of drug-related crime in the 
                United States by 50 percent by December 31, 
                2003, and achievement of at least 20 percent of 
                such reduction during each of 1999, 2000, 2001, 
                2002, and 2003, including--
                          [(i) reduction of State and Federal 
                        unlawful drug trafficking and 
                        distribution;
                          [(ii) reduction of State and Federal 
                        crimes committed by persons under the 
                        influence of unlawful drugs;
                          [(iii) reduction of State and Federal 
                        crimes committed for the purpose of 
                        obtaining unlawful drugs or obtaining 
                        property that is intended to be used 
                        for the purchase of unlawful drugs; and
                          [(iv) reduction of drug-related 
                        emergency room incidents in the United 
                        States (as measured by data of the Drug 
                        Abuse Warning Network on illicit drug 
                        abuse), including incidents involving 
                        gunshot wounds and automobile accidents 
                        in which illicit drugs are identified 
                        in the bloodstream of the victim, by 50 
                        percent by December 31, 2003.
          [(5) Further reductions in drug use, availability, 
        and crime.--Following the submission of a National Drug 
        Control Strategy under this section to achieve the 
        specific targets described in paragraph (4), the 
        Director may formulate a strategy for additional 
        reductions in drug use and availability and drug-
        related crime beyond the 5-year period covered by the 
        National Drug Control Strategy that has been submitted.
  [(b) Annual Strategy Report.--
          [(1) In general.--Not later than February 1, 1999, 
        and on February 1 of each year thereafter, the 
        President shall submit to Congress a report on the 
        progress in implementing the Strategy under subsection 
        (a), which shall include--
                  [(A) an assessment of the Federal 
                effectiveness in achieving the National Drug 
                Control Strategy goals and objectives using the 
                performance measurement system described in 
                subsection (c), including--
                          [(i) an assessment of drug use and 
                        availability in the United States; and
                          [(ii) an estimate of the 
                        effectiveness of interdiction, 
                        treatment, prevention, law enforcement, 
                        and international programs under the 
                        National Drug Control Strategy in 
                        effect during the preceding year, or in 
                        effect as of the date on which the 
                        report is submitted;
                  [(B) any modifications of the National Drug 
                Control Strategy or the performance measurement 
                system described in subsection (c);
                  [(C) an assessment of the manner in which the 
                budget proposal submitted under section 704(c) 
                is intended to implement the National Drug 
                Control Strategy and whether the funding levels 
                contained in such proposal are sufficient to 
                implement such Strategy;
                  [(D) measurable data evaluating the success 
                or failure in achieving the annual measurable 
                objectives described in subsection 
                (a)(2)(A)(ii);
                  [(E) an assessment of current drug use 
                (including inhalants) and availability, impact 
                of drug use, and treatment availability, which 
                assessment shall include--
                          [(i) estimates of drug prevalence and 
                        frequency of use as measured by 
                        national, State, and local surveys of 
                        illicit drug use and by other special 
                        studies of--
                                  [(I) casual and chronic drug 
                                use;
                                  [(II) high-risk populations, 
                                including school dropouts, the 
                                homeless and transient, 
                                arrestees, parolees, 
                                probationers, and juvenile 
                                delinquents; and
                                  [(III) drug use in the 
                                workplace and the productivity 
                                lost by such use;
                          [(ii) an assessment of the reduction 
                        of drug availability against an 
                        ascertained baseline, as measured by--
                                  [(I) the quantities of 
                                cocaine, heroin, marijuana, 
                                methamphetamine, and other 
                                drugs available for consumption 
                                in the United States;
                                  [(II) the amount of 
                                marijuana, cocaine, heroin, and 
                                precursor chemicals entering 
                                the United States;
                                  [(III) the number of hectares 
                                of marijuana, poppy, and coca 
                                cultivated and destroyed 
                                domestically and in other 
                                countries;
                                  [(IV) the number of metric 
                                tons of marijuana, heroin, 
                                cocaine, and methamphetamine 
                                seized;
                                  [(V) the number of cocaine 
                                and methamphetamine processing 
                                laboratories destroyed 
                                domestically and in other 
                                countries;
                                  [(VI) changes in the price 
                                and purity of heroin and 
                                cocaine, changes in the price 
                                of methamphetamine, and changes 
                                in tetrahydrocannabinol level 
                                of marijuana;
                                  [(VII) the amount and type of 
                                controlled substances diverted 
                                from legitimate retail and 
                                wholesale sources; and
                                  [(VIII) the effectiveness of 
                                Federal technology programs at 
                                improving drug detection 
                                capabilities in interdiction, 
                                and at United States ports of 
                                entry;
                          [(iii) an assessment of the reduction 
                        of the consequences of drug use and 
                        availability, which shall include 
                        estimation of--
                                  [(I) the burden drug users 
                                placed on hospital emergency 
                                departments in the United 
                                States, such as the quantity of 
                                drug-related services provided;
                                  [(II) the annual national 
                                health care costs of drug use, 
                                including costs associated with 
                                people becoming infected with 
                                the human immunodeficiency 
                                virus and other infectious 
                                diseases as a result of drug 
                                use;
                                  [(III) the extent of drug-
                                related crime and criminal 
                                activity; and
                                  [(IV) the contribution of 
                                drugs to the underground 
                                economy, as measured by the 
                                retail value of drugs sold in 
                                the United States;
                          [(iv) a determination of the status 
                        of drug treatment in the United States, 
                        by assessing--
                                  [(I) public and private 
                                treatment capacity within each 
                                State, including information on 
                                the treatment capacity 
                                available in relation to the 
                                capacity actually used;
                                  [(II) the extent, within each 
                                State, to which treatment is 
                                available;
                                  [(III) the number of drug 
                                users the Director estimates 
                                could benefit from treatment; 
                                and
                                  [(IV) the specific factors 
                                that restrict the availability 
                                of treatment services to those 
                                seeking it and proposed 
                                administrative or legislative 
                                remedies to make treatment 
                                available to those individuals; 
                                and
                          [(v) a review of the research agenda 
                        of the Counter-Drug Technology 
                        Assessment Center to reduce the 
                        availability and abuse of drugs; and
                  [(F) an assessment of private sector 
                initiatives and cooperative efforts between the 
                Federal Government and State and local 
                governments for drug control.
          [(2) Submission of revised strategy.--The President 
        may submit to Congress a revised National Drug Control 
        Strategy that meets the requirements of this section--
                  [(A) at any time, upon a determination by the 
                President, in consultation with the Director, 
                that the National Drug Control Strategy in 
                effect is not sufficiently effective; and
                  [(B) if a new President or Director takes 
                office.
          [(3) 1999 strategy report.--With respect to the 
        Strategy report required to be submitted by this 
        subsection on February 1, 1999, the President shall 
        prepare the report using such information as is 
        available for the period covered by the report.
  [(c) Performance Measurement System.--
          [(1) Sense of congress.--It is the sense of Congress 
        that--
                  [(A) the targets described in subsection (a) 
                are important to the reduction of overall drug 
                use in the United States;
                  [(B) the President should seek to achieve 
                those targets during the 5 years covered by the 
                National Drug Control Strategy required to be 
                submitted under subsection (a);
                  [(C) the purpose of such targets and the 
                annual reports to Congress on the progress 
                towards achieving the targets is to allow for 
                the annual restructuring of appropriations by 
                the Appropriations Committees and authorizing 
                committees of jurisdiction of Congress to meet 
                the goals described in this Act;
                  [(D) the performance measurement system 
                developed by the Director described in this 
                subsection is central to the National Drug 
                Control Program targets, programs, and budget; 
                and
                  [(E) the Congress strongly endorses the 
                performance measurement system for establishing 
                clear outcomes for reducing drug use nationwide 
                during the next five years, and the linkage of 
                this system to all agency drug control programs 
                and budgets receiving funds scored as drug 
                control agency funding.
          [(2) Submission to congress.--Not later than February 
        1, 1999, the Director shall submit to Congress a 
        description of the national drug control performance 
        measurement system, designed in consultation with 
        affected National Drug Control Program agencies, that--
                  [(A) develops performance objectives, 
                measures, and targets for each National Drug 
                Control Strategy goal and objective;
                  [(B) revises performance objectives, 
                measures, and targets, to conform with National 
                Drug Control Program Agency budgets;
                  [(C) identifies major programs and activities 
                of the National Drug Control Program agencies 
                that support the goals and objectives of the 
                National Drug Control Strategy;
                  [(D) evaluates in detail the implementation 
                by each National Drug Control Program agency of 
                program activities supporting the National Drug 
                Control Strategy;
                  [(E) monitors consistency between the drug-
                related goals and objectives of the National 
                Drug Control Program agencies and ensures that 
                drug control agency goals and budgets support 
                and are fully consistent with the National Drug 
                Control Strategy; and
                  [(F) coordinates the development and 
                implementation of national drug control data 
                collection and reporting systems to support 
                policy formulation and performance measurement, 
                including an assessment of--
                          [(i) the quality of current drug use 
                        measurement instruments and techniques 
                        to measure supply reduction and demand 
                        reduction activities;
                          [(ii) the adequacy of the coverage of 
                        existing national drug use measurement 
                        instruments and techniques to measure 
                        the casual drug user population and 
                        groups that are at risk for drug use; 
                        and
                          [(iii) the actions the Director shall 
                        take to correct any deficiencies and 
                        limitations identified pursuant to 
                        subparagraphs (A) and (B) of subsection 
                        (b)(4).
          [(3) Modifications.--A description of any 
        modifications made during the preceding year to the 
        national drug control performance measurement system 
        described in paragraph (2) shall be included in each 
        report submitted under subsection (b).

[SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

  [(a) Establishment.--There is established in the Office a 
program to be known as the High Intensity Drug Trafficking 
Areas Program.
  [(b) Designation.--The Director, upon consultation with the 
Attorney General, the Secretary of the Treasury, heads of the 
National Drug Control Program agencies, and the Governor of 
each applicable State, may designate any specified area of the 
United States as a high intensity drug trafficking area. After 
making such a designation and in order to provide Federal 
assistance to the area so designated, the Director may--
          [(1) obligate such sums as appropriated for the High 
        Intensity Drug Trafficking Areas Program;
          [(2) direct the temporary reassignment of Federal 
        personnel to such area, subject to the approval of the 
        head of the department or agency that employs such 
        personnel;
          [(3) take any other action authorized under section 
        704 to provide increased Federal assistance to those 
        areas;
          [(4) coordinate activities under this subsection 
        (specifically administrative, recordkeeping, and funds 
        management activities) with State and local officials.
  [(c) Factors for Consideration.--In considering whether to 
designate an area under this section as a high intensity drug 
trafficking area, the Director shall consider, in addition to 
such other criteria as the Director considers to be 
appropriate, the extent to which--
          [(1) the area is a center of illegal drug production, 
        manufacturing, importation, or distribution;
          [(2) State and local law enforcement agencies have 
        committed resources to respond to the drug trafficking 
        problem in the area, thereby indicating a determination 
        to respond aggressively to the problem;
          [(3) drug-related activities in the area are having a 
        harmful impact in other areas of the country; and
          [(4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-
        related activities in the area.
  [(d) Use of Funds.--The Director shall ensure that no Federal 
funds appropriated for the High Intensity Drug Trafficking 
Program are expended for the establishment or expansion of drug 
treatment programs.]

SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
                    NATIONAL DRUG CONTROL STRATEGY.

  (a) Timing, Contents, and Process for Development and 
Submission of National Drug Control Strategy.--
          (1) In general.--Not later than February 1 of each 
        year, the President shall submit to Congress a National 
        Drug Control Strategy, which shall set forth a 
        comprehensive plan for reducing illicit drug use and 
        the consequences of illicit drug use in the United 
        States by reducing the demand for illegal drugs, 
        limiting the availability of illegal drugs, and 
        conducting law enforcement activities with respect to 
        illegal drugs.
          (2) Contents.--
                  (A) In general.--The National Drug Control 
                Strategy submitted under paragraph (1) shall 
                include the following:
                          (i) Comprehensive, research-based, 
                        long-range, and quantifiable goals for 
                        reducing illicit drug use and the 
                        consequences of illicit drug use in the 
                        United States.
                          (ii) Annual quantifiable objectives 
                        for demand reduction, supply reduction, 
                        and law enforcement activities, 
                        specific targets to accomplish long-
                        range quantifiable reduction in illicit 
                        drug use as determined by the Director, 
                        and specific measurements to evaluate 
                        progress toward the targets and 
                        strategic goals.
                          (iii) A strategy to reduce the 
                        availability and purity of illegal 
                        drugs and the level of drug-related 
                        crime in the United States.
                          (iv) An assessment of Federal 
                        effectiveness in achieving the National 
                        Drug Control Strategy for the previous 
                        year, including a specific evaluation 
                        of whether the objectives and targets 
                        for reducing illicit drug use for the 
                        previous year were met and reasons for 
                        the success or failure of the previous 
                        year's Strategy.
                          (v) A general review of the status 
                        of, and trends in, international, 
                        State, and local drug control 
                        activities to ensure that the United 
                        States pursues well-coordinated and 
                        effective drug control at all levels of 
                        government.
                          (vi) A general review of the status 
                        of, and trends in, demand reduction 
                        activities by private sector entities 
                        and community-based organizations, 
                        including faith-based organizations, to 
                        determine their effectiveness and the 
                        extent of cooperation, coordination, 
                        and mutual support between such 
                        entities and organizations and Federal, 
                        State, and local government agencies.
                          (vii) An assessment of current 
                        illicit drug use (including inhalants 
                        and steroids) and availability, impact 
                        of illicit drug use, and treatment 
                        availability, which assessment shall 
                        include--
                                  (I) estimates of drug 
                                prevalence and frequency of use 
                                as measured by national, State, 
                                and local surveys of illicit 
                                drug use and by other special 
                                studies of nondependent and 
                                dependent illicit drug use;
                                  (II) illicit drug use in the 
                                workplace and the productivity 
                                lost by such use; and
                                  (III) illicit drug use by 
                                arrestees, probationers, and 
                                parolees.
                          (viii) An assessment of the reduction 
                        of illicit drug availability, as 
                        measured by--
                                  (I) the quantities of 
                                cocaine, heroin, marijuana, 
                                methamphetamine, ecstasy, and 
                                other drugs available for 
                                consumption in the United 
                                States;
                                  (II) the amount of marijuana, 
                                cocaine, heroin, 
                                methamphetamine, ecstasy, and 
                                precursor chemicals and other 
                                drugs entering the United 
                                States;
                                  (III) the number of illicit 
                                drug manufacturing laboratories 
                                seized and destroyed and the 
                                number of hectares of 
                                marijuana, poppy, and coca 
                                cultivated and destroyed 
                                domestically and in other 
                                countries;
                                  (IV) the number of metric 
                                tons of marijuana, heroin, 
                                cocaine, and methamphetamine 
                                seized and other drugs; and
                                  (V) changes in the price and 
                                purity of heroin, 
                                methamphetamine, and cocaine, 
                                changes in the price of 
                                ecstasy, and changes in 
                                tetrahydrocannabinol level of 
                                marijuana and other drugs.
                          (ix) An assessment of the reduction 
                        of the consequences of illicit drug use 
                        and availability, which shall include--
                                  (I) the burden illicit drug 
                                users place on hospital 
                                emergency departments in the 
                                United States, such as the 
                                quantity of illicit drug-
                                related services provided;
                                  (II) the annual national 
                                health care cost of illicit 
                                drug use; and
                                  (III) the extent of illicit 
                                drug-related crime and criminal 
                                activity.
                          (x) A general review of the status 
                        of, and trends in, of drug treatment in 
                        the United States, by assessing--
                                  (I) public and private 
                                treatment utilization; and
                                  (II) the number of illicit 
                                drug users the Director 
                                estimates meet diagnostic 
                                criteria for treatment.
                          (xi) A review of the research agenda 
                        of the Counterdrug Technology 
                        Assessment Center to reduce the 
                        availability and abuse of drugs.
                          (xii) A summary of the efforts made 
                        by Federal agencies to coordinate with 
                        private sector entities to conduct 
                        private research and development of 
                        medications to treat addiction by--
                                  (I) screening chemicals for 
                                potential therapeutic value;
                                  (II) developing promising 
                                compounds;
                                  (III) conducting clinical 
                                trials;
                                  (IV) seeking, where 
                                appropriate, Food and Drug 
                                Administration approval for 
                                drugs to treat addiction;
                                  (V) marketing, where 
                                appropriate, the drug for the 
                                treatment of addiction;
                                  (VI) urging physicians, where 
                                appropriate, to use the drug in 
                                the treatment of addiction; and
                                  (VII) encouraging, where 
                                appropriate, insurance 
                                companies to reimburse the cost 
                                of the drug for the treatment 
                                of addiction.
                          (xiii) Such additional statistical 
                        data and information as the Director 
                        considers appropriate to demonstrate 
                        and assess trends relating to illicit 
                        drug use, the effects and consequences 
                        of illicit drug use, supply reduction, 
                        demand reduction, drug-related law 
                        enforcement, and the implementation of 
                        the National Drug Control Strategy.
                          (xiv) A supplement reviewing the 
                        activities of each individual National 
                        Drug Control Program agency during the 
                        previous year with respect to the 
                        National Drug Control Strategy and the 
                        Director's assessment of the progress 
                        of each National Drug Control Program 
                        agency in meeting its responsibilities 
                        under the National Drug Control 
                        Strategy.
                  (B) Classified information.--Any contents of 
                the National Drug Control Strategy that involve 
                information properly classified under criteria 
                established by an Executive order shall be 
                presented to Congress separately from the rest 
                of the National Drug Control Strategy.
                  (C) Selection of data and information.--In 
                selecting data and information for inclusion 
                under subparagraph (A), the Director shall 
                ensure--
                          (i) the inclusion of data and 
                        information that will permit analysis 
                        of current trends against previously 
                        compiled data and information where the 
                        Director believes such analysis 
                        enhances long-term assessment of the 
                        National Drug Control Strategy; and
                          (ii) the inclusion of data and 
                        information to permit a standardized 
                        and uniform assessment of the 
                        effectiveness of drug treatment 
                        programs in the United States.
          (3) Process for development and submission.--
                  (A) Consultation.--In developing and 
                effectively implementing the National Drug 
                Control Strategy, the Director--
                          (i) shall consult with--
                                  (I) the heads of the National 
                                Drug Control Program agencies;
                                  (II) Congress;
                                  (III) State and local 
                                officials;
                                  (IV) private citizens and 
                                organizations, including 
                                community- and faith-based 
                                organizations, with experience 
                                and expertise in demand 
                                reduction;
                                  (V) private citizens and 
                                organizations with experience 
                                and expertise in supply 
                                reduction;
                                  (VI) private citizens and 
                                organizations with experience 
                                and expertise in law 
                                enforcement; and
                                  (VII) appropriate 
                                representatives of foreign 
                                governments;
                          (ii) with the concurrence of the 
                        Attorney General, may require the El 
                        Paso Intelligence Center to undertake 
                        specific tasks or projects to implement 
                        the National Drug Control Strategy;
                          (iii) with the concurrence of the 
                        Director of National Intelligence and 
                        the Attorney General, may request that 
                        the National Drug Intelligence Center 
                        undertake specific tasks or projects to 
                        implement the National Drug Control 
                        Strategy; and
                          (iv) may make recommendations to the 
                        Secretary of Health and Human Services 
                        on research that supports or advances 
                        the National Drug Control Strategy.
                  (B) Commitment to support strategy.--In 
                satisfying the requirements of subparagraph 
                (A)(i), the Director shall ensure, to the 
                maximum extent possible, that State and local 
                officials and relevant private organizations 
                commit to support and take steps to achieve the 
                goals and objectives of the National Drug 
                Control Strategy.
                  (C) Recommendations.--Recommendations under 
                subparagraph (A)(iv) may include 
                recommendations of research to be performed at 
                the National Institutes of Health, including 
                the National Institute on Drug Abuse, or any 
                other appropriate agency within the Department 
                of Health and Human Services.
                  (D) Inclusion in strategy.--The National Drug 
                Control Strategy under this subsection shall 
                include a list of each entity consulted under 
                subparagraph (A)(i).
          (4) Submission of revised strategy.--The President 
        may submit to Congress a revised National Drug Control 
        Strategy that meets the requirements of this section--
                  (A) at any time, upon a determination by the 
                President, in consultation with the Director, 
                that the National Drug Control Strategy in 
                effect is not sufficiently effective; or
                  (B) if a new President or Director takes 
                office.
  (b) Performance Measurement System.--Not later than February 
1 of each year, the Director shall submit to Congress, as part 
of the National Drug Control Strategy, a description of a 
national drug control performance measurement system that--
          (1) develops 2-year and 5-year performance measures 
        and targets for each National Drug Control Strategy 
        goal and objective established for reducing drug use, 
        drug availability, and the consequences of drug use;
          (2) describes the sources of information and data 
        that will be used for each performance measure 
        incorporated into the performance measurement system;
          (3) identifies major programs and activities of the 
        National Drug Control Program agencies that support the 
        goals and annual objectives of the National Drug 
        Control Strategy;
          (4) evaluates the contribution of demand reduction 
        and supply reduction activities implemented by each 
        National Drug Control Program agency in support of the 
        National Drug Control Strategy;
          (5) monitors consistency of drug-related goals and 
        objectives among the National Drug Control Program 
        agencies and ensures that each agency's goals, 
        objectives, and budgets support and are fully 
        consistent with the National Drug Control Strategy; and
          (6) coordinates the development and implementation of 
        national drug control data collection and reporting 
        systems to support policy formulation and performance 
        measurement, including an assessment of--
                  (A) the quality of current drug use 
                measurement instruments and techniques to 
                measure supply reduction and demand reduction 
                activities;
                  (B) the adequacy of the coverage of existing 
                national drug use measurement instruments and 
                techniques to measure the illicit drug user 
                population, and groups that are at risk for 
                illicit drug use; and
                  (C) the adequacy of the coverage of existing 
                national treatment outcome monitoring systems 
                to measure the effectiveness of drug abuse 
                treatment in reducing illicit drug use and 
                criminal behavior during and after the 
                completion of substance abuse treatment; and
          (7) identifies the actions the Director shall take to 
        correct any inadequacies, deficiencies, or limitations 
        identified in the assessment described in paragraph 
        (6).
  (c) Modifications.--A description of any modifications made 
during the preceding year to the national drug performance 
measurement system described in subsection (b) shall be 
included in each report submitted under subsection (a).

SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

  (a) Establishment.--
          (1) In general.--There is established in the Office a 
        program to be known as the High Intensity Drug 
        Trafficking Areas Program (in this section referred to 
        as the ``Program'').
          (2) Purpose.--The purpose of the Program is to reduce 
        drug trafficking and drug production in the United 
        States by--
                  (A) facilitating cooperation among Federal, 
                State, and local law enforcement agencies to 
                share information and implement coordinated 
                enforcement activities;
                  (B) enhancing intelligence sharing among 
                Federal, State, and local law enforcement 
                agencies;
                  (C) providing reliable intelligence to law 
                enforcement agencies needed to design effective 
                enforcement strategies and operations; and
                  (D) supporting coordinated law enforcement 
                strategies which maximize use of available 
                resources to reduce the supply of illegal drugs 
                in designated areas and in the United States as 
                a whole.
  (b) Designation.--The Director, upon consultation with the 
Attorney General, the Secretary of the Treasury, the Secretary 
of Homeland Security, heads of the National Drug Control 
Program agencies, and the Governor of each applicable State, 
may designate any specified area of the United States as a high 
intensity drug trafficking area. After making such a 
designation and in order to provide Federal assistance to the 
area so designated, the Director may--
          (1) obligate such sums as are appropriated for the 
        Program;
          (2) direct the temporary reassignment of Federal 
        personnel to such area, subject to the approval of the 
        head of the department or agency that employs such 
        personnel;
          (3) take any other action authorized under section 
        704 to provide increased Federal assistance to those 
        areas; and
          (4) coordinate activities under this section 
        (specifically administrative, recordkeeping, and funds 
        management activities) with State and local officials.
  (c) Petitions for Designation.--The Director shall establish 
regulations under which a coalition of interested law 
enforcement agencies from an area may petition for designation 
as a high intensity drug trafficking area. Such regulations 
shall provide for a regular review by the Director of the 
petition, including a recommendation regarding the merit of the 
petition to the Director by a panel of qualified, independent 
experts.
  (d) Factors for Consideration.--In considering whether to 
designate an area under this section as a high intensity drug 
trafficking area, the Director shall consider, in addition to 
such other criteria as the Director considers to be 
appropriate, the extent to which--
          (1) the area is a significant center of illegal drug 
        production, manufacturing, importation, or 
        distribution;
          (2) State and local law enforcement agencies have 
        committed resources to respond to the drug trafficking 
        problem in the area, thereby indicating a determination 
        to respond aggressively to the problem;
          (3) drug-related activities in the area are having a 
        significant harmful impact in the area, and in other 
        areas of the country; and
          (4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-
        related activities in the area.
  (e) Organization of High Intensity Drug Trafficking Areas.--
          (1) Executive board and officers.--To be eligible for 
        funds appropriated under this section, each high 
        intensity drug trafficking area shall be governed by an 
        Executive Board. The Executive Board shall designate a 
        chairman, vice chairman, and any other officers to the 
        Executive Board that it determines are necessary.
          (2) Responsibilities.--The Executive Board of a high 
        intensity drug trafficking area shall be responsible 
        for--
                  (A) providing direction and oversight in 
                establishing and achieving the goals of the 
                high intensity drug trafficking area;
                  (B) managing the funds of the high intensity 
                drug trafficking area;
                  (C) reviewing and approving all funding 
                proposals consistent with the overall objective 
                of the high intensity drug trafficking area; 
                and
                  (D) reviewing and approving all reports to 
                the Director on the activities of the high 
                intensity drug trafficking area.
          (3) Board representation.--None of the funds 
        appropriated under this section may be expended for any 
        high intensity drug trafficking area, or for a 
        partnership or region of a high intensity drug 
        trafficking area, if that area's, region's or 
        partnership's Executive Board does not apportion an 
        equal number of votes between representatives of 
        participating Federal agencies and representatives of 
        participating State and local agencies. Where it is 
        impractical for a equal number of representatives of 
        Federal agencies and State and local agencies to attend 
        a meeting of an Executive Board in person, the 
        Executive Board may use a system of proxy votes or 
        weighted votes to achieve the voting balance required 
        by this paragraph.
          (4) No agency relationship.--The eligibility 
        requirements of this section are intended to ensure the 
        responsible use of Federal funds. Nothing in this 
        section is intended to create an agency relationship 
        between individual high intensity drug trafficking 
        areas and the Federal Government.
  (f) Use of Funds.--The Director shall ensure that no Federal 
funds appropriated for the Program are expended for the 
establishment or expansion of drug treatment programs, and 
shall ensure that not more than five percent of the Federal 
funds appropriated for the Program are expended for the 
establishment of drug prevention programs.
  (g) Counterterrorism Activities.--
          (1) Assistance authorized.--The Director may 
        authorize use of resources available for the Program to 
        assist Federal, State, and local law enforcement 
        agencies in investigations and activities related to 
        terrorism and prevention of terrorism, especially but 
        not exclusively with respect to such investigations and 
        activities that are also related to drug trafficking.
          (2) Limitation.--The Director shall ensure--
                  (A) that assistance provided under paragraph 
                (1) remains incidental to the purpose of the 
                Program to reduce drug availability and carry 
                out drug-related law enforcement activities; 
                and
                  (B) that significant resources of the Program 
                are not redirected to activities exclusively 
                related to terrorism, except on a temporary 
                basis under extraordinary circumstances, as 
                determined by the Director.
  (h) Role of Drug Enforcement Administration.--The Director, 
in consultation with the Attorney General, shall ensure that a 
representative of the Drug Enforcement Administration is 
included in the Intelligence Support Center for each high 
intensity drug trafficking area.
  (i) Annual HIDTA Program Budget Submissions.--As part of the 
documentation that supports the President's annual budget 
request for the Office, the Director shall submit to Congress a 
budget justification that includes the following:
          (1) The amount requested for each high intensity drug 
        trafficking area with supporting narrative descriptions 
        and rationale for each request.
          (2) A detailed justification for each funding request 
        that explains the reasons for the requested funding 
        level, how such funding level was determined based on a 
        current assessment of the drug trafficking threat in 
        each high intensity drug trafficking area, how such 
        funding will ensure that the goals and objectives of 
        each such area will be achieved, and how such funding 
        supports the National Drug Control Strategy.
  (j) Emerging Threat Response Fund.--
          (1) In general.--The Director may expend up to 10 
        percent of the amounts appropriated under this section 
        on a discretionary basis, to respond to any emerging 
        drug trafficking threat in an existing high intensity 
        drug trafficking area, or to establish a new high 
        intensity drug trafficking area or expand an existing 
        high intensity drug trafficking area, in accordance 
        with the criteria established under paragraph (2).
          (2) Consideration of impact.--In allocating funds 
        under this subsection, the Director shall consider--
                  (A) the impact of activities funded on 
                reducing overall drug traffic in the United 
                States, or minimizing the probability that an 
                emerging drug trafficking threat will spread to 
                other areas of the United States; and
                  (B) such other criteria as the Director 
                considers appropriate.
  (k) Evaluation.--
          (1) Initial report.--Not later than 90 days after the 
        date of the enactment of this subsection, the Director 
        shall, after consulting with the Executive Boards of 
        each designated high intensity drug trafficking area, 
        submit a report to Congress that describes, for each 
        designated high intensity drug trafficking area--
                  (A) the specific purposes for the high 
                intensity drug trafficking area;
                  (B) the specific long-term and short-term 
                goals and objectives for the high intensity 
                drug trafficking area;
                  (C) the measurements that will be used to 
                evaluate the performance of the high intensity 
                drug trafficking area in achieving the long-
                term and short-term goals; and
                  (D) the reporting requirements needed to 
                evaluate the performance of the high intensity 
                drug trafficking area in achieving the long-
                term and short-term goals.
          (2) Evaluation of hidta program as part of national 
        drug control strategy.--For each designated high 
        intensity drug trafficking area, the Director shall 
        submit, as part of the annual National Drug Control 
        Strategy report, a report that--
                  (A) describes--
                          (i) the specific purposes for the 
                        high intensity drug trafficking area; 
                        and
                          (ii) the specific long-term and 
                        short-term goals and objectives for the 
                        high intensity drug trafficking area; 
                        and
                  (B) includes an evaluation of the performance 
                of the high intensity drug trafficking area in 
                accomplishing the specific long-term and short-
                term goals and objectives identified under 
                paragraph (1)(B).
  (l) Assessment of Drug Enforcement Task Forces in High 
Intensity Drug Trafficking Areas.--Not later than 180 days 
after the date of enactment of this subsection, and as part of 
each subsequent annual National Drug Control Strategy report, 
the Director shall submit to Congress a report--
          (1) assessing the number and operation of all 
        federally funded drug enforcement task forces within 
        each high intensity drug trafficking area; and
          (2) describing--
                  (A) each Federal, State, and local drug 
                enforcement task force operating in the high 
                intensity drug trafficking area;
                  (B) how such task forces coordinate with each 
                other, with any high intensity drug trafficking 
                area task force, and with investigations 
                receiving funds from the Organized Crime and 
                Drug Enforcement Task Force;
                  (C) what steps, if any, each such task force 
                takes to share information regarding drug 
                trafficking and drug production with other 
                federally funded drug enforcement task forces 
                in the high intensity drug trafficking area;
                  (D) the role of the high intensity drug 
                trafficking area in coordinating the sharing of 
                such information among task forces;
                  (E) the nature and extent of cooperation by 
                each Federal, State, and local participant in 
                ensuring that such information is shared among 
                law enforcement agencies and with the high 
                intensity drug trafficking area;
                  (F) the nature and extent to which 
                information sharing and enforcement activities 
                are coordinated with joint terrorism task 
                forces in the high intensity drug trafficking 
                area; and
                  (G) any recommendations for measures needed 
                to ensure that task force resources are 
                utilized efficiently and effectively to reduce 
                the availability of illegal drugs in the high 
                intensity drug trafficking areas.
  (m) Assessment of Intelligence Sharing in High Intensity Drug 
Trafficking Areas--program.--Not later than 180 days after the 
date of the enactment of this subsection, and as part of each 
subsequent annual National Drug Control Strategy report, the 
Director shall submit to Congress a report--
          (1) evaluating existing and planned intelligence 
        systems supported by each high intensity drug 
        trafficking area, or utilized by task forces receiving 
        any funding under the Program, including the extent to 
        which such systems ensure access and availability of 
        intelligence to Federal, State, and local law 
        enforcement agencies within the high intensity drug 
        trafficking area and outside of it;
          (2) the extent to which Federal, State, and local law 
        enforcement agencies participating in each high 
        intensity drug trafficking area are sharing 
        intelligence information to assess current drug 
        trafficking threats and design appropriate enforcement 
        strategies; and
          (3) the measures needed to improve effective sharing 
        of information and intelligence regarding drug 
        trafficking and drug production among Federal, State, 
        and local law enforcement participating in a high 
        intensity drug trafficking area, and between such 
        agencies and similar agencies outside the high 
        intensity drug trafficking area.
  (n) Coordination of Intelligence Sharing With Organized Crime 
Drug Enforcement Task Force Program.--The Director, in 
consultation with the Attorney General, shall ensure that any 
drug enforcement intelligence obtained by the Intelligence 
Support Center for each high intensity drug trafficking area is 
shared, on a timely basis, with the drug intelligence fusion 
center operated by the Organized Crime Drug Enforcement Task 
Force of the Department of Justice.
  (o) Use of Funds to Combat Methamphetamine Trafficking.--
          (1) In general.--
                  (A) Requirement.--The Director shall ensure 
                that, of the amounts appropriated for a fiscal 
                year for the Program, at least $15,000,000 is 
                allocated to combat the trafficking of 
                methamphetamine in areas designated by the 
                Director as high intensity drug trafficking 
                areas.
                  (B) Activities.--In meeting the requirement 
                in subparagraph (A), the Director shall 
                transfer funds to appropriate Federal, State, 
                and local governmental agencies for employing 
                additional Federal law enforcement personnel, 
                or facilitating the employment of additional 
                State and local law enforcement personnel, 
                including agents, investigators, prosecutors, 
                laboratory technicians, chemists, investigative 
                assistants, and drug prevention specialists.
          (2) Apportionment of funds.--
                  (A) Factors in apportionment.--The Director 
                shall apportion amounts allocated under 
                paragraph (1) among areas designated by the 
                Director as high intensity drug trafficking 
                areas based on the following factors:
                          (i) The number of methamphetamine 
                        manufacturing facilities discovered by 
                        Federal, State, or local law 
                        enforcement officials in the area 
                        during the previous fiscal year.
                          (ii) The number of methamphetamine 
                        prosecutions in Federal, State, or 
                        local courts in the area during the 
                        previous fiscal year.
                          (iii) The number of methamphetamine 
                        arrests by Federal, State, or local law 
                        enforcement officials in the area 
                        during the previous fiscal year.
                          (iv) The amounts of methamphetamine 
                        or listed chemicals (as that term is 
                        defined in section 102(33) of the 
                        Controlled Substances Act (21 U.S.C. 
                        802(33)) seized by Federal, State, or 
                        local law enforcement officials in the 
                        area during the previous fiscal year.
                          (v) Intelligence and predictive data 
                        from the Drug Enforcement 
                        Administration showing patterns and 
                        trends in abuse, trafficking, and 
                        transportation in methamphetamine and 
                        listed chemicals (as that term is so 
                        defined).
                  (B) Certification.--Before the Director 
                apportions any funds under this paragraph to a 
                high intensity drug trafficking area, the 
                Director shall certify that the law enforcement 
                entities responsible for clandestine 
                methamphetamine laboratory seizures in that 
                area are providing laboratory seizure data to 
                the national clandestine laboratory database at 
                the El Paso Intelligence Center.
  (p) Authorization of Appropriations.--There is authorized to 
be appropriated to the Office of National Drug Control Policy 
to carry out this section--
          (1) $280,000,000 for fiscal year 2007;
          (2) $290,000,000 for each of fiscal years 2008 and 
        2009; and
          (3) $300,000,000 for each of fiscal years 2010 and 
        2011.
  (q) Specific Purposes.--
          (1) In general.--The Director shall ensure that, of 
        the amounts appropriated for a fiscal year for the 
        Program, at least $7,000,000 is used in high intensity 
        drug trafficking areas with severe neighborhood safety 
        and illegal drug distribution problems.
          (2) Required uses.--The funds used under paragraph 
        (1) shall be used--
                  (A) to ensure the safety of neighborhoods and 
                the protection of communities, including the 
                prevention of the intimidation of potential 
                witnesses of illegal drug distribution and 
                related activities; and
                  (B) to combat illegal drug trafficking 
                through such methods as the Director considers 
                appropriate, such as establishing or operating 
                (or both) a toll-free telephone hotline for use 
                by the public to provide information about 
                illegal drug-related activities.

SEC. 708. COUNTER-DRUG TECHNOLOGY ASSESSMENT CENTER.

  (a) * * *
  (b) [Director of Technology.--] Chief Scientist.--There shall 
be at the head of the Center the [Director of Technology,] 
Chief Scientist, who shall be appointed by the Director of 
National Drug Control Policy from among individuals qualified 
and distinguished in the area of science, medicine, 
engineering, or technology.
  [(c) Additional Responsibilities of the Director of National 
Drug Control Policy.--
          [(1) In general.--The Director, acting through the 
        Director of Technology shall--
                  [(A) identify and define the short-, medium-, 
                and long-term scientific and technological 
                needs of Federal, State, and local drug supply 
                reduction agencies, including--
                          [(i) advanced surveillance, tracking, 
                        and radar imaging;
                          [(ii) electronic support measures;
                          [(iii) communications;
                          [(iv) data fusion, advanced computer 
                        systems, and artificial intelligence; 
                        and
                          [(v) chemical, biological, 
                        radiological (including neutron, 
                        electron, and graviton), and other 
                        means of detection;
                  [(B) identify demand reduction basic and 
                applied research needs and initiatives, in 
                consultation with affected National Drug 
                Control Program agencies, including--
                          [(i) improving treatment through 
                        neuroscientific advances;
                          [(ii) improving the transfer of 
                        biomedical research to the clinical 
                        setting; and
                          [(iii) in consultation with the 
                        National Institute on Drug Abuse, and 
                        through interagency agreements or 
                        grants, examining addiction and 
                        rehabilitation research and the 
                        application of technology to expanding 
                        the effectiveness or availability of 
                        drug treatment;
                  [(C) make a priority ranking of such needs 
                identified in subparagraphs (A) and (B) 
                according to fiscal and technological 
                feasibility, as part of a National Counter-Drug 
                Enforcement Research and Development Program;
                  [(D) oversee and coordinate counter-drug 
                technology initiatives with related activities 
                of other Federal civilian and military 
                departments;
                  [(E) provide support to the development and 
                implementation of the national drug control 
                performance measurement system; and
                  [(F) pursuant to the authority of the 
                Director of National Drug Control Policy under 
                section 704, submit requests to Congress for 
                the reprogramming or transfer of funds 
                appropriated for counter-drug technology 
                research and development.
          [(2) Limitation on authority.--The authority granted 
        to the Director under this subsection shall not extend 
        to the award of contracts, management of individual 
        projects, or other operational activities.]
  (c) Additional Responsibilities of the Director of National 
Drug Control Policy.--
          (1) In general.--The Director, acting through the 
        Chief Scientist shall--
                  (A) identify and define the short-, medium-, 
                and long-term scientific and technological 
                needs of Federal, State, and local law 
                enforcement agencies relating to drug 
                enforcement, including--
                          (i) advanced surveillance, tracking, 
                        and radar imaging;
                          (ii) electronic support measures;
                          (iii) communications;
                          (iv) data fusion, advanced computer 
                        systems, and artificial intelligence; 
                        and
                          (v) chemical, biological, 
                        radiological (including neutron, 
                        electron, and graviton), and other 
                        means of detection;
                  (B) identify demand reduction (including drug 
                prevention) basic and applied research needs 
                and initiatives, in consultation with affected 
                National Drug Control Program agencies, 
                including--
                          (i) improving treatment through 
                        neuroscientific advances;
                          (ii) improving the transfer of 
                        biomedical research to the clinical 
                        setting; and
                          (iii) in consultation with the 
                        National Institute on Drug Abuse and 
                        the Substance Abuse and Mental Health 
                        Services Administration, and through 
                        interagency agreements or grants, 
                        examining addiction and rehabilitation 
                        research and the application of 
                        technology to expanding the 
                        effectiveness or availability of drug 
                        treatment;
                  (C) make a priority ranking of such needs 
                identified in subparagraphs (A) and (B) 
                according to fiscal and technological 
                feasibility, as part of a National Counterdrug 
                Research and Development Program;
                  (D) oversee and coordinate counterdrug 
                technology initiatives with related activities 
                of other Federal civilian and military 
                departments;
                  (E) provide support to the development and 
                implementation of the national drug control 
                performance measurement system established 
                under subsection (b) of section 706;
                  (F) with the advice and counsel of experts 
                from State and local law enforcement agencies, 
                oversee and coordinate a technology transfer 
                program for the transfer of technology to State 
                and local law enforcement agencies; and
                  (G) pursuant to the authority of the Director 
                of National Drug Control Policy under section 
                704, submit requests to Congress for the 
                reprogramming or transfer of funds appropriated 
                for counterdrug technology research and 
                development.
          (2) Priorities in transferring technology.--
                  (A) In general.--The Chief Scientist shall 
                give priority, in transferring technology under 
                paragraph (1)(F), based on the following 
                criteria:
                          (i) the need of potential recipients 
                        for such technology;
                          (ii) the effectiveness of the 
                        technology to enhance current 
                        counterdrug activities of potential 
                        recipients; and
                          (iii) the ability and willingness of 
                        potential recipients to evaluate 
                        transferred technology.
                  (B) Interdiction and border drug law 
                enforcement technologies.--The Chief Scientist 
                shall give priority, in transferring 
                technologies most likely to assist in drug 
                interdiction and border drug law enforcement, 
                to State, local, and tribal law enforcement 
                agencies in southwest border areas and northern 
                border areas with significant traffic in 
                illicit drugs.
          (3) Limitation on authority.--The authority granted 
        to the Director under this subsection shall not extend 
        to the direct management of individual projects or 
        other operational activities.
          (4) Report.--On or before July 1 of each year, the 
        Director shall submit a report to the appropriate 
        congressional committees that addresses the following:
                  (A) The number of requests received during 
                the previous 12 months, including the identity 
                of each requesting agency and the type of 
                technology requested.
                  (B) The number of requests fulfilled during 
                the previous 12 months, including the identity 
                of each recipient agency and the type of 
                technology transferred.
                  (C) A summary of the criteria used in making 
                the determination on what requests were funded 
                and what requests were not funded, except that 
                such summary shall not include specific 
                information on any individual requests.
                  (D) A general assessment of the future needs 
                of the program, based on expected changes in 
                threats, expected technologies, and likely need 
                from potential recipients.
                  (E) An assessment of the effectiveness of the 
                technologies transferred, based in part on the 
                evaluations provided by the recipients, with a 
                recommendation whether the technology should 
                continue to be offered through the program.
  (d) Assistance and Support to Office of National Drug Control 
Policy.--The Secretary of Defense, the Secretary of Homeland 
Security, and the Secretary of Health and Human Services shall, 
to the maximum extent practicable, render assistance and 
support to the Office and to the Director in the conduct of 
counter-drug technology assessment.

[SEC. 709. PRESIDENT'S COUNCIL ON COUNTER-NARCOTICS.

  [(a) Establishment.--There is established a council to be 
known as the President's Council on Counter-Narcotics (referred 
to in this section as the ``Council'').
  [(b) Membership.--
          [(1) In general.--Subject to paragraph (2), the 
        Council shall be composed of 18 members, of whom--
                  [(A) 1 shall be the President, who shall 
                serve as Chairman of the Council;
                  [(B) 1 shall be the Vice President;
                  [(C) 1 shall be the Secretary of State;
                  [(D) 1 shall be the Secretary of the 
                Treasury;
                  [(E) 1 shall be the Secretary of Defense;
                  [(F) 1 shall be the Attorney General;
                  [(G) 1 shall be the Secretary of 
                Transportation;
                  [(H) 1 shall be the Secretary of Health and 
                Human Services;
                  [(I) 1 shall be the Secretary of Education;
                  [(J) 1 shall be the Representative of the 
                United States of America to the United Nations;
                  [(K) 1 shall be the Director of the Office of 
                Management and Budget;
                  [(L) 1 shall be the Chief of Staff to the 
                President;
                  [(M) 1 shall be the Director of the Office, 
                who shall serve as the Executive Director of 
                the Council;
                  [(N) 1 shall be the Director of Central 
                Intelligence;
                  [(O) 1 shall be the Assistant to the 
                President for National Security Affairs;
                  [(P) 1 shall be the Counsel to the President;
                  [(Q) 1 shall be the Chairman of the Joint 
                Chiefs of Staff; and
                  [(R) 1 shall be the National Security Adviser 
                to the Vice President.
          [(2) Additional members.--The President may, in the 
        discretion of the President, appoint additional members 
        to the Council.
  [(c) Functions.--The Council shall advise and assist the 
President in--
          [(1) providing direction and oversight for the 
        national drug control strategy, including relating drug 
        control policy to other national security interests and 
        establishing priorities; and
          [(2) ensuring coordination among departments and 
        agencies of the Federal Government concerning 
        implementation of the National Drug Control Strategy.
  [(d) Administration.--
          [(1) In general.--The Council may utilize established 
        or ad hoc committees, task forces, or interagency 
        groups chaired by the Director (or a representative of 
        the Director) in carrying out the functions of the 
        Council under this section.
          [(2) Staff.--The staff of the Office, in coordination 
        with the staffs of the Vice President and the Assistant 
        to the President for National Security Affairs, shall 
        act as staff for the Council.
          [(3) Cooperation from other agencies.--Each 
        department and agency of the executive branch shall--
                  [(A) cooperate with the Council in carrying 
                out the functions of the Council under this 
                section; and
                  [(B) provide such assistance, information, 
                and advice as the Council may request, to the 
                extent permitted by law.]

SEC. 709. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN.

  (a) In General.--The Director shall conduct a national youth 
anti-drug media campaign (referred to in this subtitle as the 
``national media campaign'') in accordance with this section 
for the purposes of--
          (1) preventing drug abuse among young people in the 
        United States;
          (2) increasing awareness of adults of the impact of 
        drug abuse on young people; and
          (3) encouraging parents and other interested adults 
        to discuss with young people the dangers of illegal 
        drug use.
  (b) Use of Funds.--
          (1) In general.--Amounts made available to carry out 
        this section for the national media campaign may only 
        be used for the following:
                  (A) The purchase of media time and space, 
                including the strategic planning for, and 
                accounting of, such purchases.
                  (B) Creative and talent costs, consistent 
                with paragraph (2)(A).
                  (C) Advertising production costs.
                  (D) Testing and evaluation of advertising.
                  (E) Evaluation of the effectiveness of the 
                national media campaign.
                  (F) The negotiated fees for the winning 
                bidder on requests for proposals issued either 
                by the Office or its designee to enter into 
                contracts to carry out activities authorized by 
                this section.
                  (G) Partnerships with professional and civic 
                groups, community-based organizations, 
                including faith-based organizations, and 
                government organizations related to the 
                national media campaign.
                  (H) Entertainment industry outreach, 
                interactive outreach, media projects and 
                activities, public information, news media 
                outreach, and corporate sponsorship and 
                participation.
                  (I) Operational and management expenses.
          (2) Specific requirements.--
                  (A) Creative services.--
                          (i) In using amounts for creative and 
                        talent costs under paragraph (1)(B), 
                        the Director shall use creative 
                        services donated at no cost to the 
                        Government (including creative services 
                        provided by the Partnership for a Drug-
                        Free America) wherever feasible and may 
                        only procure creative services for 
                        advertising--
                                  (I) responding to high-
                                priority or emergent campaign 
                                needs that cannot timely be 
                                obtained at no cost; or
                                  (II) intended to reach a 
                                minority, ethnic, or other 
                                special audience that cannot 
                                reasonably be obtained at no 
                                cost; or
                                  (III) the Director determines 
                                that the Partnership for a 
                                Drug-Free America is unable to 
                                provide, pursuant to subsection 
                                (d)(2)(B).
                          (ii) No more than $1,500,000 may be 
                        expended under this section each fiscal 
                        year on creative services, except that 
                        the Director may expend up to 
                        $2,000,000 in a fiscal year on creative 
                        services to meet urgent needs of the 
                        national media campaign with advance 
                        approval from the Committee on 
                        Appropriations of the House of 
                        Representatives and of the Senate upon 
                        a showing of the circumstances causing 
                        such urgent needs of the national media 
                        campaign.
                  (B) Testing and evaluation of advertising.--
                In using amounts for testing and evaluation of 
                advertising under paragraph (1)(D), the 
                Director shall test all advertisements prior to 
                use in the national media campaign to ensure 
                that the advertisements are effective and meet 
                industry-accepted standards. The Director may 
                waive this requirement for advertisements using 
                no more than 10 percent of the purchase of 
                advertising time purchased under this section 
                in a fiscal year and no more than 10 percent of 
                the advertising space purchased under this 
                section in a fiscal year, if the advertisements 
                respond to emergent and time-sensitive campaign 
                needs or the advertisements will not be widely 
                utilized in the national media campaign.
                  (C) Evaluation of effectiveness of media 
                campaign.--In using amounts for the evaluation 
                of the effectiveness of the national media 
                campaign under paragraph (1)(E), the Director 
                shall--
                          (i) designate an independent entity 
                        to evaluate annually the effectiveness 
                        of the national media campaign based on 
                        data from--
                                  (I) the Monitoring the Future 
                                Study published by the 
                                Department of Health and Human 
                                Services;
                                  (II) the Attitude Tracking 
                                Study published by the 
                                Partnership for a Drug Free 
                                America;
                                  (III) the National Household 
                                Survey on Drug Abuse; and
                                  (IV) other relevant studies 
                                or publications, as determined 
                                by the Director, including 
                                tracking and evaluation data 
                                collected according to 
                                marketing and advertising 
                                industry standards; and
                          (ii) ensure that the effectiveness of 
                        the national media campaign is 
                        evaluated in a manner that enables 
                        consideration of whether the national 
                        media campaign has contributed to 
                        reduction of illicit drug use among 
                        youth and such other measures of 
                        evaluation as the Director determines 
                        are appropriate.
          (3) Purchase of advertising time and space.--For each 
        fiscal year, not less than 77 percent of the amounts 
        appropriated under this section shall be used for the 
        purchase of advertising time and space for the national 
        media campaign, subject to the following exceptions:
                  (A) In any fiscal year for which less than 
                $125,000,000 is appropriated for the national 
                media campaign, not less than 82 percent of the 
                amounts appropriated under this section shall 
                be used for the purchase of advertising time 
                and space for the national media campaign.
                  (B) In any fiscal year for which more than 
                $195,000,000 is appropriated under this 
                section, not less than 72 percent shall be used 
                for advertising production costs and the 
                purchase of advertising time and space for the 
                national media campaign.
  (c) Advertising.--In carrying out this section, the Director 
shall ensure that sufficient funds are allocated to meet the 
stated goals of the national media campaign.
  (d) Division of Responsibilities and Functions Under the 
Program.--
          (1) In general.--The Director, in consultation with 
        the Partnership for a Drug-Free America, shall 
        determine the overall purposes and strategy of the 
        national media campaign.
          (2) Responsibilities.--
                  (A) Director.--The Director shall be 
                responsible for implementing a focused national 
                media campaign to meet the purposes set forth 
                in subsection (a), and shall approve--
                          (i) the strategy of the national 
                        media campaign;
                          (ii) all advertising and promotional 
                        material used in the national media 
                        campaign; and
                          (iii) the plan for the purchase of 
                        advertising time and space for the 
                        national media campaign.
                  (B) The partnership for a drug-free 
                america.--The Director shall request that the 
                Partnership for a Drug-Free America--
                          (i) develop and recommend strategies 
                        to achieve the goals of the national 
                        media campaign, including addressing 
                        national and local drug threats in 
                        specific regions or States, such as 
                        methamphetamine and ecstasy;
                          (ii) create all advertising to be 
                        used in the national media campaign, 
                        except advertisements that are--
                                  (I) provided by other 
                                nonprofit entities pursuant to 
                                subsection (f);
                                  (II) intended to respond to 
                                high-priority or emergent 
                                campaign needs that cannot 
                                timely be obtained at no cost 
                                (not including production costs 
                                and talent reuse payments), 
                                provided that any such 
                                advertising material is 
                                reviewed by the Partnership for 
                                a Drug-Free America;
                                  (III) intended to reach a 
                                minority, ethnic, or other 
                                special audience that cannot be 
                                obtained at no cost (not 
                                including production costs and 
                                talent reuse payments), 
                                provided that any such 
                                advertising material is 
                                reviewed by the Partnership for 
                                a Drug-Free America; or
                                  (IV) any other advertisements 
                                that the Director determines 
                                that the Partnership for a 
                                Drug-Free America is unable to 
                                provide.
                  (C) Media buying contractor.--The Director 
                shall enter into a contract with a media buying 
                contractor to plan and purchase advertising 
                time and space for the national media campaign. 
                The media buying contractor shall not provide 
                any other service or material, or conduct any 
                other function or activity which the Director 
                determines should be provided by the 
                Partnership for a Drug-Free America.
  (e) Prohibitions.--None of the amounts made available under 
subsection (b) may be obligated or expended for any of the 
following:
          (1) To supplant current antidrug community-based 
        coalitions.
          (2) To supplant pro bono public service time donated 
        by national and local broadcasting networks for other 
        public service campaigns.
          (3) For partisan political purposes, or express 
        advocacy in support of or to defeat any clearly 
        identified candidate, clearly identified ballot 
        initiative, or clearly identified legislative or 
        regulatory proposal.
          (4) To fund advertising that features any elected 
        officials, persons seeking elected office, cabinet 
        level officials, or other Federal officials employed 
        pursuant to section 213 of Schedule C of title 5, Code 
        of Federal Regulations.
          (5) To fund advertising that does not contain a 
        primary message intended to reduce or prevent illicit 
        drug use.
          (6) To fund advertising containing a primary message 
        intended to promote support for the media campaign or 
        private sector contributions to the media campaign.
  (f) Matching Requirement.--
          (1) In general.--Amounts made available under 
        subsection (b) for media time and space shall be 
        matched by an equal amount of non-Federal funds for the 
        national media campaign, or be matched with in-kind 
        contributions of the same value.
          (2) No-cost match advertising direct relationship 
        requirement.--The Director shall ensure that at least 
        70 percent of no-cost match advertising provided 
        directly relates to substance abuse prevention 
        consistent with the specific purposes of the national 
        media campaign, except that in any fiscal year in which 
        less than $125,000,000 is appropriated to the national 
        media campaign, the Director shall ensure that at least 
        85 percent of no-cost match advertising directly 
        relates to substance abuse prevention consistent with 
        the specific purposes of the national media campaign.
          (3) No-cost match advertising not directly related.--
        The Director shall ensure that no-cost match 
        advertising that does not directly relate to substance 
        abuse prevention consistent with the purposes of the 
        national media campaign includes a clear antidrug 
        message. Such message is not required to be the primary 
        message of the match advertising.
  (g) Financial and Performance Accountability.--The Director 
shall cause to be performed--
          (1) audits and reviews of costs of the national media 
        campaign pursuant to section 304C of the Federal 
        Property and Administrative Services Act of 1949 (41 
        U.S.C. 254d); and
          (2) an audit to determine whether the costs of the 
        national media campaign are allowable under section 306 
        of such Act (41 U.S.C. 256).
  (h) Report to Congress.--The Director shall submit on an 
annual basis a report to Congress that describes--
          (1) the strategy of the national media campaign and 
        whether specific objectives of the media campaign were 
        accomplished;
          (2) steps taken to ensure that the national media 
        campaign operates in an effective and efficient manner 
        consistent with the overall strategy and focus of the 
        national media campaign;
          (3) plans to purchase advertising time and space;
          (4) policies and practices implemented to ensure that 
        Federal funds are used responsibly to purchase 
        advertising time and space and eliminate the potential 
        for waste, fraud, and abuse; and
          (5) all contracts entered into with a corporation, 
        partnership, or individual working on behalf of the 
        national media campaign.
  (i) Local Target Requirement.--The Director shall, to the 
maximum extent feasible, use amounts made available under this 
section for media that focuses on, or includes specific 
information on, prevention or treatment resources for consumers 
within specific local areas.
  (j) Prevention of Marijuana Use.--
          (1) Findings.--The Congress finds the following:
                  (A) 60 percent of adolescent admissions for 
                drug treatment are based on marijuana use.
                  (B) Potency levels of contemporary marijuana, 
                particularly hydroponically grown marijuana, 
                are significantly higher than in the past, 
                rising from under 1 percent of THC in the mid-
                1970s to as high as 30 percent today.
                  (C) Contemporary research has demonstrated 
                that youths smoking marijuana early in life may 
                be up to five times more likely to use hard 
                drugs.
                  (D) Contemporary research has demonstrated 
                clear detrimental effects in adolescent 
                educational achievement resulting from 
                marijuana use.
                  (E) Contemporary research has demonstrated 
                clear detrimental effects in adolescent brain 
                development resulting from marijuana use.
                  (F) An estimated 9,000,000 Americans a year 
                drive while under the influence of illegal 
                drugs, including marijuana.
                  (G) Marijuana smoke contains 50 to 70 percent 
                more of certain cancer causing chemicals than 
                tobacco smoke.
                  (H) Teens who use marijuana are up to four 
                times more likely to have a teen pregnancy than 
                teens who have not.
                  (I) Federal law enforcement agencies have 
                identified clear links suggesting that trade in 
                hydroponic marijuana facilitates trade by 
                criminal organizations in hard drugs, including 
                heroin.
                  (J) Federal law enforcement agencies have 
                identified possible links between trade in 
                cannabis products and financing for terrorist 
                organizations.
          (2) Emphasis on prevention of youth marijuana use.--
        In conducting advertising and activities otherwise 
        authorized under this section, the Director may 
        emphasize prevention of youth marijuana use.
  (k) Authorization of Appropriations.--There is authorized to 
be appropriated to the Office to carry out this section, 
$195,000,000 for each of fiscal years 2007 and 2008 and 
$210,000,000 for each of fiscal years 2009 through 2011.

           *       *       *       *       *       *       *


SEC. 711. DRUG INTERDICTION.

  [(a) Definition.--In this section, the term ``Federal drug 
control agency'' means--
          [(1) the Office of National Drug Control Policy;
          [(2) the Department of Defense;
          [(3) the Drug Enforcement Administration;
          [(4) the Federal Bureau of Investigation;
          [(5) the Immigration and Naturalization Service;
          [(6) the United States Coast Guard;
          [(7) the United States Customs Service; and
          [(8) any other department or agency of the Federal 
        Government that the Director determines to be relevant.
  [(b) Report.--In order to assist Congress in determining the 
personnel, equipment, funding, and other resources that would 
be required by Federal drug control agencies in order to 
achieve a level of interdiction success at or above the highest 
level achieved before the date of enactment of this title, not 
later than 90 days after the date of enactment of this Act, the 
Director shall submit to Congress and to each Federal drug 
control program agency a report, which shall include--
          [(1) with respect to the southern and western border 
        regions of the United States (including the Pacific 
        coast, the border with Mexico, the Gulf of Mexico 
        coast, and other ports of entry) and in overall totals, 
        data relating to--
                  [(A) the amount of marijuana, heroin, 
                methamphetamine, and cocaine--
                          [(i) seized during the year of 
                        highest recorded seizures for each drug 
                        in each region and during the year of 
                        highest recorded overall seizures; and
                          [(ii) disrupted during the year of 
                        highest recorded disruptions for each 
                        drug in each region and during the year 
                        of highest recorded overall seizures; 
                        and
                  [(B) the number of persons arrested for 
                violations of section 1010(a) of the Controlled 
                Substances Import and Export Act (21 U.S.C. 
                960(a)) and related offenses during the year of 
                the highest number of arrests on record for 
                each region and during the year of highest 
                recorded overall arrests;
          [(2) the price of cocaine, heroin, methamphetamine, 
        and marijuana during the year of highest price on 
        record during the preceding 10-year period, adjusted 
        for purity where possible; and
          [(3) a description of the personnel, equipment, 
        funding, and other resources of the Federal drug 
        control agency devoted to drug interdiction and 
        securing the borders of the United States against drug 
        trafficking for each of the years identified in 
        paragraphs (1) and (2) for each Federal drug control 
        agency.]
  (a) United States Interdiction Coordinator.--
          (1) In general.--The Deputy Director for Supply 
        Reduction in the Office shall serve as the United 
        States Interdiction Coordinator, and shall perform the 
        duties of that position described in paragraph (2) and 
        such other duties as may be determined by the Director 
        with respect to coordination of efforts to interdict 
        illicit drugs from entering the United States.
          (2) Responsibilities.--The United States Interdiction 
        Coordinator shall be responsible to the Director for--
                  (A) coordinating the interdiction activities 
                of the National Drug Control Program agencies 
                to ensure consistency with the National Drug 
                Control Strategy;
                  (B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and 
                in accordance with paragraph (3), a National 
                Interdiction Command and Control Plan to ensure 
                the coordination and consistency described in 
                subparagraph (A);
                  (C) assessing the sufficiency of assets 
                committed to illicit drug interdiction by the 
                relevant National Drug Control Program 
                agencies; and
                  (D) advising the Director on the efforts of 
                each National Drug Control Program agency to 
                implement the National Interdiction Command and 
                Control Plan.
          (3) Staff.--The Director shall assign such permanent 
        staff of the Office as he considers appropriate to 
        assist the United States Interdiction Coordinator to 
        carry out the responsibilities described in paragraph 
        (2), and may also, at his discretion, request that 
        appropriate National Drug Control Program agencies 
        detail or assign staff to the Office of Supply 
        Reduction for that purpose.
          (4) National interdiction command and control plan.--
                  (A) Purposes.--The National Interdiction 
                Command and Control Plan shall--
                          (i) set forth the Government's 
                        strategy for drug interdiction;
                          (ii) state the specific roles and 
                        responsibilities of the relevant 
                        National Drug Control Program agencies 
                        for implementing that strategy; and
                          (iii) identify the specific resources 
                        required to enable the relevant 
                        National Drug Control Program agencies 
                        to implement that strategy.
                  (B) Consultation with other agencies.--The 
                United States Interdiction Coordinator shall 
                issue the National Interdiction Command and 
                Control Plan in consultation with the other 
                members of the Interdiction Committee described 
                in subsection (b).
                  (C) Limitation.--The National Interdiction 
                Command and Control Plan shall not change 
                existing agency authorities or the laws 
                governing interagency relationships, but may 
                include recommendations about changes to such 
                authorities or laws.
                  (D) Report to congress.--On or before March 1 
                of each year, the United States Interdiction 
                Coordinator shall provide a report on behalf of 
                the Director to the appropriate congressional 
                committees, to the Committee on Armed Services 
                and the Committee on Homeland Security of the 
                House of Representatives, and to the Committee 
                on Homeland Security and Governmental Affairs 
                and the Committee on Armed Services of the 
                Senate, which shall include--
                          (i) a copy of that year's National 
                        Interdiction Command and Control Plan;
                          (ii) information for the previous 10 
                        years regarding the number and type of 
                        seizures of drugs by each National Drug 
                        Control Program agency conducting drug 
                        interdiction activities, as well as 
                        statistical information on the 
                        geographic areas of such seizures; and
                          (iii) information for the previous 10 
                        years regarding the number of air and 
                        maritime patrol hours undertaken by 
                        each National Drug Control Program 
                        agency conducting drug interdiction 
                        activities, as well as statistical 
                        information on the geographic areas in 
                        which such patrol hours took place.
                  (E) Treatment of classified or law 
                enforcement sensitive information.--Any content 
                of the report described in subparagraph (D) 
                that involves information classified under 
                criteria established by an Executive order, or 
                the public disclosure of which, as determined 
                by the United States Interdiction Coordinator 
                or the head of any relevant National Drug 
                Control Program agency, would be detrimental to 
                the law enforcement or national security 
                activities of any Federal, State, or local 
                agency, shall be presented to Congress 
                separately from the rest of the plan.
  (b) Interdiction Committee.--
          (1) In general.--The Interdiction Committee shall 
        meet to--
                  (A) discuss and resolve issues related to the 
                coordination, oversight and integration of 
                international, border, and domestic drug 
                interdiction efforts in support of the National 
                Drug Control Strategy;
                  (B) review the annual National Interdiction 
                Command and Control Plan, and provide advice to 
                the Director and the United States Interdiction 
                Coordinator concerning that plan; and
                  (C) provide such other advice to the Director 
                concerning drug interdiction strategy and 
                policies as the committee determines is 
                appropriate.
          (2) Membership.--The membership of the Interdiction 
        Committee shall consist of--
                  (A) the Commissioner of the bureau of Customs 
                and Border Protection at the Department of 
                Homeland Security;
                  (B) the Assistant Secretary of the bureau of 
                Immigration and Customs Enforcement at the 
                Department of Homeland Security;
                  (C) the Commandant of the United States Coast 
                Guard;
                  (D) the Director of the Office of 
                Counternarcotics Enforcement at the Department 
                of Homeland Security;
                  (E) the Administrator of the Drug Enforcement 
                Administration;
                  (F) the Assistant Secretary of State for 
                International Narcotics and Law Enforcement 
                Affairs;
                  (G) the Assistant Secretary of Defense for 
                Special Operations and Low Intensity Conflict;
                  (H) the Deputy Director for Supply Reduction 
                of the Office of National Drug Control Policy, 
                acting in his role as the United States 
                Interdiction Coordinator;
                  (I) the director of the Crime and Narcotics 
                Center of the Central Intelligence Agency;
                  (J) the Deputy Director for State and Local 
                Affairs of the Office of National Drug Control 
                Policy;
                  (K) the Chief of the National Guard Bureau's 
                Counterdrug Program; and
                  (L) such additional persons as may be 
                determined by the Director.
          (3) Chairman.--The Director shall designate one of 
        the members of the Interdiction Committee to serve as 
        chairman.
          (4) Meetings.--The members of the Interdiction 
        Committee shall meet, in person and not through any 
        delegate or representative, at least once per calendar 
        year, prior to March 1. At the call of either the 
        Director or the current chairman, the Interdiction 
        Committee may hold additional meetings, which shall be 
        attended by the members either in person, or through 
        such delegates or representatives as they may choose.
          (5) Report.--Not later than September 30 of each 
        year, the chairman of the Interdiction Committee shall 
        submit a report to the Director and to the appropriate 
        congressional committees describing the results of the 
        meetings and any significant findings of the Committee 
        during the previous 12 months. Any content of such a 
        report that involves information classified under 
        criteria established by an Executive order, or whose 
        public disclosure, as determined by the Director, the 
        chairman, or any member, would be detrimental to the 
        law enforcement or national security activities of any 
        Federal, State, or local agency, shall be presented to 
        Congress separately from the rest of the report.

           *       *       *       *       *       *       *


[SEC. 712. ESTABLISHMENT OF SPECIAL FORFEITURE FUND.

  [Section 6073 of the Asset Forfeiture Amendments Act of 1988 
(21 U.S.C. 1509) is amended--
          [(1) in subsection (b)--
                  [(A) by striking ``section 524(c)(9)'' and 
                inserting ``section 524(c)(8)''; and
                  [(B) by striking ``section 9307(g)'' and 
                inserting ``section 9703(g)''; and
          [(2) in subsection (e), by striking ``strategy'' and 
        inserting ``Strategy''.]

SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP OF ALL 
                    FEDERAL ADVERTISING OR OTHER COMMUNICATION 
                    MATERIALS.

  (a) Requirement.--Each advertisement or other communication 
paid for by the Office, either directly or through a contract 
awarded by the Office, shall include a prominent notice 
informing the target audience that the advertisement or other 
communication is paid for by the Office.
  (b) Advertisement or Other Communication.--In this section, 
the term ``advertisement or other communication'' includes--
          (1) an advertisement disseminated in any form, 
        including print or by any electronic means; and
          (2) a communication by an individual in any form, 
        including speech, print, or by any electronic means.

SEC. 713 AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
                    SHUT DOWN ILLICIT DRUG MARKET HOT-SPOTS BY 
                    DETERRING DRUG DEALERS OR ALTERING THE DYNAMIC OF 
                    DRUG SALES.

  (a) Awards Required.--The Director shall make competitive 
awards for demonstration programs by eligible partnerships for 
the purpose of shutting down local illicit drug market hot-
spots and reducing drug-related crime through evidence-based, 
strategic problem-solving interventions that deter drug dealers 
or alter the dynamic of drug sales.
  (b) Use of Award Amounts.--Award amounts received under this 
section shall be used--
          (1) to support the efforts of the agencies, 
        organizations, and researchers included in the eligible 
        partnership;
          (2) to develop and field a directed and credible 
        deterrent threat; and
          (3) to strengthen rehabilitation efforts through such 
        means as job training, drug treatment, or other 
        services.
  (c) Eligible Partnership Defined.--In this section, the term 
``eligible partnership'' means a working group whose 
application to the Director--
          (1) identifies the roles played, and certifies the 
        involvement of, three or more agencies or 
        organizations, which may include--
                  (A) State or local agencies (such as those 
                carrying out police, probation, prosecution, 
                courts, corrections, parole, or treatment 
                functions);
                  (B) Federal agencies (such as the Drug 
                Enforcement Agency, the Bureau of Alcohol, 
                Tobacco, Firearms, and Explosives, and United 
                States Attorney offices); and
                  (C) community-based organizations;
          (2) includes a qualified researcher;
          (3) includes a plan for identifying the impact 
        players in, and assessing the nature and dynamic of, 
        the local drug market and its related crime through 
        information gathering and analysis;
          (4) includes a plan for developing an evidence-based 
        strategic intervention aimed at quickly and sustainably 
        eradicating the local drug market by deterring drug 
        dealers or altering the dynamic of drug sales; and
          (5) includes a plan that describes the methodology 
        and outcome measures proposed for evaluating the impact 
        of that strategic intervention on drug sales, 
        neighborhood disorder, and crime.
  (d) Reports to Congress.--
          (1) Interim report.--Not later than June 1, 2009, the 
        Director shall submit to Congress a report that 
        identifies the best practices in drug market 
        eradication, including the best practices identified 
        through the activities funded under this section.
          (2) Final report.--Not later than June 1, 2010, the 
        Director shall submit to Congress a report on the 
        demonstration programs funded under this section, 
        including on the matters specified in paragraph (1).
  (e) Authorization of Appropriations.--There is authorized to 
be appropriated to carry out this section $10,000,000 for each 
of fiscal years 2007 through 2009.

SEC. 714. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
                    COERCE ABSTINENCE IN CHRONIC HARD-DRUG USERS UNDER 
                    COMMUNITY SUPERVISION THROUGH THE USE OF DRUG 
                    TESTING AND SANCTIONS.

  (a) Awards Required.--The Director shall make competitive 
awards to fund demonstration programs by eligible partnerships 
for the purpose of reducing the use of illicit drugs by chronic 
hard-drug users living in the community while under the 
supervision of the criminal justice system.
  (b) Use of Award Amounts.--Award amounts received under this 
section shall be used--
          (1) to support the efforts of the agencies, 
        organizations, and researchers included in the eligible 
        partnership;
          (2) to develop and field a drug testing and graduated 
        sanctions program for chronic hard-drug users living in 
        the community under criminal justice supervision; and
          (3) to assist individuals described in subsection (a) 
        by strengthening rehabilitation efforts through such 
        means as job training, drug treatment, or other 
        services.
  (c) Eligible Partnership Defined.--In this section, the term 
``eligible partnership'' means a working group whose 
application to the Director--
          (1) identifies the roles played, and certifies the 
        involvement of, two or more agencies or organizations, 
        which may include--
                  (A) State or local agencies (such as those 
                carrying out police, probation, prosecution, 
                courts, corrections, parole, or treatment 
                functions);
                  (B) Federal agencies (such as the Drug 
                Enforcement Agency, the Bureau of Alcohol, 
                Tobacco, Firearms, and Explosives, and United 
                States Attorney offices); and
                  (C) community-based organizations;
          (2) includes a qualified researcher;
          (3) includes a plan for using judicial or other 
        criminal justice authority to administer drug tests to 
        individuals described in subsection (a) at least twice 
        a week, and to swiftly and certainly impose a known set 
        of graduated sanctions for non-compliance with 
        community-release provisions relating to drug 
        abstinence (whether imposed as a pre-trial, probation, 
        or parole condition or otherwise);
          (4) includes a strategy for responding to a range of 
        substance use and abuse problems and a range of 
        criminal histories;
          (5) includes a plan for integrating data 
        infrastructure among the agencies and organizations 
        included in the eligible partnership to enable 
        seamless, real-time tracking of individuals described 
        in subsection (a);
          (6) includes a plan to monitor and measure the 
        progress toward reducing the percentage of the 
        population of individuals described in subsection (a) 
        who, upon being summoned for a drug test, either fail 
        to show up or who test positive for drugs.
  (d) Reports to Congress.--
          (1) Interim report.--Not later than June 1, 2009, the 
        Director shall submit to Congress a report that 
        identifies the best practices in reducing the use of 
        illicit drugs by chronic hard-drug users, including the 
        best practices identified through the activities funded 
        under this section.
          (2) Final report.--Not later than June 1, 2010, the 
        Director shall submit to Congress a report on the 
        demonstration programs funded under this section, 
        including on the matters specified in paragraph (1).
  (e) Authorization of Appropriations.--There is authorized to 
be appropriated to carry out this section $10,000,000 for each 
of fiscal years 2007 through 2009.

SEC. [713.] 715. TECHNICAL AND CONFORMING AMENDMENTS.

  (a) Title 5, United States Code.--Chapter 53 of title 5, 
United States Code, is amended--
          (1) * * *

           *       *       *       *       *       *       *


SEC. [714.] 716. AUTHORIZATION OF APPROPRIATIONS.

  There are authorized to be appropriated to carry out this 
[title,] title, except activities for which amounts are 
otherwise specifically authorized by this title, to remain 
available until expended, such sums as may be necessary for 
each of fiscal years [1999 through 2003] 2007 through 2011.

[SEC. 715. TERMINATION OF OFFICE OF NATIONAL DRUG CONTROL POLICY.

  [(a) In General.--Except as provided in subsection (b), 
effective on September 30, 2003, this title and the amendments 
made by this title are repealed.
  [(b) Exception.--Subsection (a) does not apply to section 713 
or the amendments made by that section.]

           *       *       *       *       *       *       *

                              ----------                              


                  DRUG-FREE MEDIA CAMPAIGN ACT OF 1998

  TITLE I--TARGETED SUBSTANCE ABUSE PREVENTION AND TREATMENT PROGRAMS

          [Subtitle A--National Youth Anti-Drug Media Campaign

[SEC. 101. SHORT TITLE.

  [This subtitle may be cited as the ``Drug-Free Media Campaign 
Act of 1998''.

[SEC. 102. REQUIREMENT TO CONDUCT NATIONAL MEDIA CAMPAIGN.

  [(a) In General.--The Director of the Office of National Drug 
Control Policy (in this subtitle referred to as the 
``Director'') shall conduct a national media campaign in 
accordance with this subtitle for the purpose of reducing and 
preventing drug abuse among young people in the United States.
  [(b) Local Target Requirement.--The Director shall, to the 
maximum extent feasible, use amounts made available to carry 
out this subtitle under section 105 for media that focuses on, 
or includes specific information on, prevention or treatment 
resources for consumers within specific local areas.

[SEC. 103. USE OF FUNDS.

  [(a) Authorized Uses.--
          [(1) In general.--Amounts made available to carry out 
        this subtitle for the support of the national media 
        campaign may only be used for--
                  [(A) the purchase of media time and space;
                  [(B) talent reuse payments;
                  [(C) out-of-pocket advertising production 
                costs;
                  [(D) testing and evaluation of advertising;
                  [(E) evaluation of the effectiveness of the 
                media campaign;
                  [(F) the negotiated fees for the winning 
                bidder on request for proposals issued by the 
                Office of National Drug Control Policy;
                  [(G) partnerships with community, civic, and 
                professional groups, and government 
                organizations related to the media campaign; 
                and
                  [(H) entertainment industry collaborations to 
                fashion antidrug messages in motion pictures, 
                television programing, popular music, 
                interactive (Internet and 
                new) media projects and activities, public 
                information, news media outreach, and corporate 
                sponsorship and participation.
          [(2) Advertising.--In carrying out this subtitle, the 
        Director shall devote sufficient funds to the 
        advertising portion of the national media campaign to 
        meet the stated reach and frequency goals of the 
        campaign.
  [(b) Prohibitions.--None of the amounts made available under 
section 105 may be obligated or expended--
          [(1) to supplant current antidrug community based 
        coalitions;
          [(2) to supplant current pro bono public service time 
        donated by national and local broadcasting networks;
          [(3) for partisan political purposes; or
          [(4) to fund media campaigns that feature any elected 
        officials, persons seeking elected office, cabinet 
        level officials, or other Federal officials employed 
        pursuant to section 213 of Schedule C of title 5, Code 
        of Federal Regulations, unless the Director provides 
        advance notice to the Committees on Appropriations of 
        the House of Representatives and the Senate, the 
        Committee on Government Reform and Oversight of the 
        House of Representatives and the Committee on the 
        Judiciary of the Senate.
  [(c) Matching Requirement.--Amounts made available under 
section 105 should be matched by an equal amount of non-Federal 
funds for the national media campaign, or be matched with in-
kind contributions to the campaign of the same value.

[SEC. 104. REPORTS TO CONGRESS.

  [The Director shall--
          [(1) submit to Congress on an annual basis a report 
        on the activities for which amounts made available 
        under section 105 have been obligated during the 
        preceding year, including information for each quarter 
        of such year, and on the specific parameters of the 
        national media campaign; and
          [(2) not later than 1 year after the date of 
        enactment of this Act, submit to Congress a report on 
        the effectiveness of the national media campaign based 
        on measurable outcomes provided to Congress previously.

[SEC. 105. AUTHORIZATION OF APPROPRIATIONS.

  [There is authorized to be appropriated to the Office of 
National Drug Control Policy to carry out this subtitle 
$195,000,000 for each of fiscal years 1999 through 2002.]
                              ----------                              


            SECTION 878 OF THE HOMELAND SECURITY ACT OF 2002

SEC. 878. OFFICE OF COUNTERNARCOTICS ENFORCEMENT.

  (a) * * *

           *       *       *       *       *       *       *

  (c) Limitation on Concurrent Employment.--[Except as provided 
in subsection (d), the] The Director of the Office of 
Counternarcotics Enforcement shall not be employed by, assigned 
to, or serve as the head of, any other branch of the Federal 
Government, any State or local government, or any subdivision 
of the Department other than the Office of Counternarcotics 
Enforcement.
  [(d) Eligibility To Serve as the United States Interdiction 
Coordinator.--The Director of the Office of Counternarcotics 
Enforcement may be appointed as the United States Interdiction 
Coordinator by the Director of the Office of National Drug 
Control Policy, and shall be the only person at the Department 
eligible to be so appointed.]
  [(e)] (d) Responsibilities.--The Secretary shall direct the 
Director of the Office of Counternarcotics Enforcement--
          (1) * * *

           *       *       *       *       *       *       *

  [(f)] (e) Savings Clause.--Nothing in this section shall be 
construed to authorize direct control of the operations 
conducted by the Directorate of Border and Transportation 
Security, the Coast Guard, or joint terrorism task forces.
  [(g)] (f) Reports to Congress.--
          (1) * * *

           *       *       *       *       *       *       *

                              ----------                              


             SECTION 464P OF THE PUBLIC HEALTH SERVICE ACT

                     MEDICATION DEVELOPMENT PROGRAM

  Sec. 464P. (a) * * *

           *       *       *       *       *       *       *

  (c) Report.--
          (1) In general.--Not later than December 31, 1992, 
        and each December 31 thereafter, the Director of the 
        Institute shall submit to the Office of National Drug 
        Control Policy established [under section 1002 of the 
        Anti-Drug Abuse Act of 1988 (21 U.S.C. 1501)] under 
        section 703 of the Office of National Drug Control 
        Policy Reauthorization Act of 1998 (21 U.S.C. 1702) a 
        report, in accordance with paragraph (3), that 
        describes the objectives and activities of the program 
        assisted under this section.
          (2) National drug control strategy.--The Director of 
        National Drug Control Policy shall incorporate, by 
        reference or otherwise, each report submitted under 
        this subsection in the National Drug Control Strategy 
        submitted the following February 1 [under section 1005 
        of the Anti-Drug Abuse Act of 1988 (21 U.S.C. 1504)] 
        under section 706 of the Office of National Drug 
        Control Policy Reauthorization Act of 1998 (21 U.S.C. 
        1705).

           *       *       *       *       *       *       *

                              ----------                              


      SECTION 6073 OF THE ASSET FORFEITURE AMENDMENTS ACT OF 1988

[SEC. 6073. ESTABLISHMENT OF SPECIAL FORFEITURE FUND.

  [(a) In General.--There is established in the Treasury of the 
United States the Special Forfeiture Fund (hereafter referred 
to in this section as the ``Fund'') which shall be available to 
the Director of the National Drug Control Policy without fiscal 
year limitation in such amounts as may be specified in 
appropriations Acts.
  [(b) Deposits.--There shall be deposited into the Fund the 
amounts specified by section 524(c)(8) of title 28, United 
States Code, and section 9703(g) of title 31, United States 
Code, and any earnings on the investments authorized by 
subsection (d).
  [(c) Super Surplus.--(1) Any unobligated balance up to 
$20,000,000 remaining in the Fund on September 30 of a fiscal 
year shall be available to the Director, subject to paragraph 
(2), to transfer to, and for obligation and expenditure in 
connection with drug control activities of, any Federal agency 
or State or local entity with responsibilities under the 
National Drug Control Strategy.
  [(2) A transfer may be made under paragraph (1) only with the 
advance written approval of the Committees on Appropriations of 
each House of Congress.
  [(d) Investment of Fund.--Amounts in the Fund which are not 
currently needed for the purposes of this section shall be kept 
on deposit or invested in obligations of, or guaranteed by, the 
United States and all earnings on such investments shall be 
deposited in the Fund.
  [(e) President's Budget.--The President shall, in 
consultation with the Director for National Drug Control 
Policy, include, as part of the budget submitted to the 
Congress under section 1105(a) of title 31, United States Code, 
a separate and detailed request for the use of the amounts in 
the Fund. This request shall reflect the priorities of the 
National Drug Control Strategy.
  [(f) Funds Provided Supplemental.--Funds disbursed under this 
subsection shall not be used to supplant existing funds, but 
shall be used to supplement the amount of funds that would be 
otherwise available.
  [(g) Annual Report.--No later than 4 months after the end of 
each fiscal year, the President shall submit to both Houses of 
Congress a detailed report on the amounts deposited in the Fund 
and a description of expenditures made under this subsection.]

                                  
